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Nowadays, cardiovascular disease (CVD) is the leading cause of death amongst women worldwide.1, 2 
For certain cardiovascular risk factors, such as hypertension and diabetes, there is a tremendous 
global awareness. However, pregnancy related risk factors are often overseen, in particular 
hypertensive disorders of pregnancy. These include gestational hypertension and preeclampsia; 
disorders that are characterized by the occurrence of new onset hypertension in pregnancy, with 
our without proteinuria.3 Women with a hypertensive disorder of pregnancy have a higher risk 
to develop CVD compared to women with a normotensive pregnancy.4 For comparison, these 
women are 16 times more likely to die from CVD than from breast cancer.5 
Even though awareness for women’s health increased over the last decennium, the management 
of cardiovascular risk factors after a hypertensive disorder of pregnancy is still not clearly defined 
in cardiovascular prevention guidelines.6-8 The first large studies that showed a higher risk of 
CVD after preeclampsia were conducted 13 years ago.4, 9 Since then, numerous studies examined 
the relation between hypertensive disorders of pregnancy, cardiovascular risk factors and 
CVD.10-14 Results showed that these women are more likely to develop cardiovascular risk factors, 
such as hypertension, obesity, dyslipidemia and insulin resistance after pregnancy. However, it 
remains unknown whether hypertensive disorders of pregnancy are a risk factor for CVD or if 
they just share common risk factors. Also, at what age and to what extend cardiovascular risk 
factors become apparent remains unclear.  
Several scores, such as the Framingham score and the Atherosclerotic Cardiovascular Disease 
score, combine cardiovascular risk factors in to one model to predict 10-year CVD risk.15, 16 Though 
women with a previous hypertensive disorder of pregnancy have a substantially increased 
lifetime risk of CVD, their 10-year risk, depicted by these cardiovascular risk prediction models, 
is low.11 Consequently, it remains a challenge to provide optimal cardiovascular counseling to 
these women at a younger age. Moreover, guidelines addressing the cardiovascular follow-
up of women with a previous hypertensive disorder of pregnancy are not uniform in their 
recommendations.17-26 This raises concerns for the health of these women as the prevalence 
of hypertensive disorders of pregnancy increased with 25% in the last decennia and will most 
likely continue to grow with the rise of risk factors such as diabetes and obesity and the trend 
to conceive at older age.27-30 Identifying those women most at risk for future CVD can help to 
determine and treat cardiovascular risk factors at an early stage. 
In this thesis we discuss cardiovascular biomarkers and cardiovascular risk factors after pregnancy, 
both short term and long term, in women with a hypertensive disorder of pregnancy and women 
with a previous uncomplicated pregnancy. The aims of this thesis can be summarized as follows:
1. To determine biomarkers in pregnancy to predict the risk of developing a hypertensive 
disorder of pregnancy and a suboptimal cardiovascular risk profile after pregnancy.
2. To determine cardiovascular risk factors after pregnancy in women with a previous 
hypertensive disorder of pregnancy, women with a previous normotensive pregnancy as 
well as their offspring.
3. To determine cardiovascular health in and after pregnancy in women with a hypertensive 
disorder of pregnancy. 
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Outline of this thesis
The outline of this thesis is discussed in three main parts. Part I is focussed on biomarkers in 
pregnancy and cardiovascular risk factors after pregnancy (Chapter 2 and 3). In Chapter 2, we 
examine the association between PlGF in mid-pregnancy and cardiovascular risk factors after 
pregnancy. In Chapter 3 associations are being presented between the lipid profile in early 
pregnancy and the risk of a hypertensive disorder of pregnancy and blood pressure throughout 
pregnancy. Part II describes cardiovascular risk factors after a hypertensive disorder of pregnancy 
(Chapter 4-9). In Chapter 4, we examine blood pressure profile one year after pregnancy in 
women with severe preeclampsia. In Chapter 5 associations are being presented between a 
hypertensive disorder of pregnancy and the maternal lipid profile six years after pregnancy. 
In Chapter 6, we examine whether cardiovascular risk factors track from mother to child. In 
Chapter 7 associations are being presented between a hypertensive disorder of pregnancy and 
the maternal retinal microvasculature six years after pregnancy. In Chapter 8 and 9 the risk 
of coronary artery calcification in women with a previous hypertensive disorder of pregnancy 
is being examined. Part III describes cardiovascular health in and after pregnancy in women 
with a hypertensive disorder of pregnancy (Chapter 9 and 10). In Chapter 10 we examine the 
association between cardiovascular health in pregnancy and the carotid intima-media thickness 
and cardiovascular health after pregnancy. In Chapter 11, we examine cardiovascular health 
in women with previous severe preeclampsia and the association with carotid intima-media 
thickness as a measure of vascular age. Lastly, in Chapter 12 we provide a general discussion.  
General design
The research presented in this thesis was based on three study populations: the Generation R 
Study, the Follow-Up Preeclampsia (FUPEC) population and the Cardiovascular RiskprofilE: 
IMaging And Gender-specific disOrders (CREw-IMAGO) study. 
The Generation R Study is a population-based prospective cohort from early pregnancy onwards. 
Pregnant women from the city Rotterdam in the Netherlands with an expected delivery date 
between April 2002 and January 2006 were eligible. In total, 8880 women were included during 
pregnancy. Women visited the research center in early (< 18 weeks), mid- (18 – 25 weeks) and late 
(> 25 weeks) pregnancy, and six and nine years after pregnancy. Measurements and information 
in pregnancy included: anthropometrics, blood pressure, blood samples, medical files and 
questionnaires. Follow-up measurements six and nine years after pregnancy in both mother and 
child included: anthropometrics, blood pressure, blood samples, cardiac ultrasound, pulse wave 
velocity, carotid intima-media thickness, retinal vascular imaging and questionnaires. 
FUPEC is a prospective hospital based population of women with previous severe preeclampsia 
who receive multidisciplinary long-term cardiovascular follow-up after pregnancy. The 
outpatient clinic is located in Erasmus MC, Rotterdam, the Netherlands. All women throughout 
the Netherlands with previous severe preeclampsia are eligible and inclusion is still ongoing. 
Women (N = 636) attended the outpatient clinic six weeks, three months and one year after 
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pregnancy between April 2011 and September 2017. Cardiovascular follow-up included: 
anthropometrics, glucose and lipid profile, 24-hour ambulatory blood pressure monitoring, 
carotid intima-media thickness, medical files and questionnaires. 
The CREw-IMAGO study is a retrospective hospital based multicenter study (Erasmus MC, 
Rotterdam and University Medical Center Utrecht) of women with gestational hypertension and 
preeclampsia. Women with a previous hypertensive disorder of pregnancy between the age of 40 
and 55 and (a)symptomatic of cardiovascular disease were eligible. These women (N = 269) were 
recruited from three cohorts (Utrecht Cohort, Preeclampsia Risk Evaluation in FEMales cohort 
and Hypitat Risk Assessment Study cohort) and the FUPEC population. Between February 2016 
and January 2018 women underwent coronary computed tomography angiography (CCTA) and 
cardiovascular screening. 
FIGURE 1 | Overview of the cardiovascular biomarkers and risk factors studied in this thesis.
Overview of the cardiovascular biomarkers and risk factors studied in this thesis
Placental growth factor 
Placental growth factor (PlGF) is a pro-angiogenic factor, released by the syncytiotrophoblast 
of the placenta, and is enquired for proper remodeling of the maternal spiral arteries in the 
placenta. Suboptimal spiral artery remodeling, as seen in preeclampsia, can lead to abnormal 
placental perfusion and fetal growth restriction. Lower concentrations of circulating PlGF in mid-
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pregnancy are associated with subnormal cardiovascular remodeling in pregnancy. It remains 
unclear whether PlGF concentrations in pregnancy are also associated with cardiovascular risk 
factors and CVD after pregnancy. If so, PlGF in pregnancy could be used as a biomarker to 
identify those women at risk for a suboptimal cardiovascular risk profile after pregnancy. 
Blood pressure
Hypertension is a major risk factor for CVD and can explain up to 50 percent of an individual’s 
cardiovascular risk.31 After pregnancy, women with preeclampsia have on average a higher blood 
pressure and more often hypertension than women with a normotensive pregnancy.32 They also 
develop hypertension at a younger age, which gives them a longer lifetime exposure to high blood 
pressure resulting in more endothelial damage. In current practice, women with preeclampsia 
undergo a single blood pressure measurement at the physician’s office six weeks after 
pregnancy. However, some forms of hypertension, such as masked hypertension, white-coat 
hypertension, night-time hypertension, and a disadvantageous systolic night-to-day dipping 
pattern will remain undetected without 24-hour ambulatory blood pressure monitoring. All four 
are clinically relevant by serving as independent cardiovascular risk predictors. In the general 
population, one in four hypertension diagnoses are missed without a 24-hour ambulatory blood 
pressure monitoring.33 Measuring 24-hour blood pressure pattern after pregnancy will help to 
objectify the actual hypertension percentages in these women.  
Lipid profile
An atherogenic lipid profile, characterized by elevated total-cholesterol, low density lipoprotein 
(LDL)-cholesterol triglycerides, lipoprotein (a) and low high density lipoprotein (HDL)-
cholesterol, can lead to atherosclerosis in later life. Previous studies showed that women with a 
hypertensive disorder of pregnancy are more often affected by an atherogenic lipid profile after 
pregnancy than women with uncomplicated pregnancies.11, 34-36 Possibly, a hypertensive disorder 
of pregnancy leads to a more atherogenic lipid profile after pregnancy or an atherogenic lipid 
profile precedes the hypertensive disorder. Obtaining better insight in this mechanism will help 
to improve cardiovascular risk prevention strategies.  
Microvasculature
The microvasculature in the eye can be visualized through non-invasive retinal vascular 
imaging. A suboptimal microvasculature is characterized by smaller retinal arteries and 
wider retinal venules and is associated with an increased risk of future CVD. A previous study 
showed that endothelial dysfunction is associated with a suboptimal microvasculature in the 
general population.37 Women with a hypertensive disorder of pregnancy show endothelial 
dysfunction both in pregnancy and long after.38, 39 Therefore, they might be more at risk for a 
suboptimal microvasculature and consequently future CVD. Visualizing the microvasculature 
after pregnancy might help to understand which women are most at risk for future CVD and 
understand the pathophysiological mechanisms involved. 
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Cardiac measurements and arterial stiffness
Acquired cardiac abnormalities, such as a larger left ventricular mass, larger left atrial diameter 
and larger aortic root diameter, are associated with an increased risk of CVD. A larger pulse 
wave velocity or carotid intima-media thickness, measures of arterial stiffness and subclinical 
atherosclerosis which often coincide with hypertension, are also risk factors of CVD. Identifying 
early markers of these aberrations can help to detect those women most at risk for CVD and to 
start treatment for underlying risk factors. 
Coronary artery calcification
Coronary artery calcification is an important precursor of ischemic heart disease. Underlying 
risk factors, such as hypertension, diabetes, obesity and renal dysfunction, are prevalent in 
women with a previous hypertensive disorder of pregnancy. This might explain their increased 
risk of ischemic heart disease later in life.12 Coronary artery calcification progression can be 
potentially halted or even attenuated by adapting a healthy lifestyle and implementing blood 
pressure and cholesterol control.40 Early detection of coronary artery calcification could help to 
identify women at increased cardiovascular risk before they present with symptomatic CVD.  
Cardiovascular health scores
The cardiovascular health score was created by the American Heart Association to improve 
cardiovascular health of all Americans.41 The score consists of seven metrics: three health factors 
(blood pressure, and total-cholesterol and glucose concentration) and four health behaviors 
(body mass index, smoking habit, diet and physical activity). Healthier metrics result in a higher 
score, which is associated with a lower risk of CVD.42, 43 It remains unclear whether the increased 
risk associated with a hypertensive disorder of pregnancy results from the disorder itself or 
predisposing risk factors. The cardiovascular health score in early pregnancy can visualize these 
risk factors in a single score, which can be reassessed after pregnancy. The latter might be a 
better approach in cardiovascular risk assessment of premenopausal women with a previous 
hypertensive disorder of pregnancy than applying conventional cardiovascular risk prediction 
models, such as Framingham and SCORE, which classify these women into a low risk category.11
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Abstract
Background: Preeclampsia increases the long-term risk of cardiovascular disease, possibly 
through occurrence of hypertension after delivery such as masked hypertension, night-
time hypertension and an adverse systolic night-to-day blood pressure ratio. These types of 
hypertension are often unnoticed and can only be detected with ambulatory blood pressure 
monitoring. We aimed to determine hypertension prevalence and 24-hour blood pressure 
pattern with ambulatory blood pressure monitoring and office blood pressure measurements in 
women one year after severe preeclampsia. 
Methods: This is a retrospective cohort study. As part of a follow-up program after severe 
preeclampsia 200 women underwent ambulatory blood pressure monitoring and an office 
blood pressure measurement one year after delivery. We calculated hypertension prevalence 
(sustained hypertension, masked hypertension and white-coat hypertension) and systolic 
night-to-day blood pressure ratio (dipping pattern). Medical files and questionnaires provided 
information on pre-existing hypertension and antihypertensive treatment. 
Results: One year after delivery, 41.5% of women had hypertension (sustained hypertension, 
masked hypertension or white-coat hypertension) with ambulatory blood pressure monitoring. 
Masked hypertension was most common (17.5%), followed by sustained hypertension (14.5%) and 
white-coat hypertension (9.5%). With sheer office blood pressure measurement only 24.0% of 
women would have been diagnosed hypertensive. Forty-six percent of women a disadvantageous 
dipping pattern. 
Conclusions: Hypertension is common one year after experiencing severe preeclampsia. Masked 
hypertension and white-coat hypertension are risk factors of future cardiovascular disease and 
can only be diagnosed with ambulatory blood pressure monitoring. Therefore, ambulatory 
blood pressure monitoring should be offered to all these women at high risk for developing 
hypertension and possibly future cardiovascular disease.
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Introduction
Preeclampsia affects three to five percent of pregnancies in the developed world and is 
characterized by hypertension and new onset of proteinuria or organ dysfunction after 20 
weeks of gestation.1, 2 Severe preeclampsia is characterized by organ damage and/or fetal growth 
restriction.3 Preeclampsia increases not only the short-term risk of morbidity and mortality for 
mother and child but also the lifetime risk of cardiovascular disease (CVD). Women with severe 
preeclampsia can be seven times more susceptible to develop future CVD compared to women with 
a normotensive pregnancy.4 It is unclear whether this is a direct result of only preeclampsia or 
the constitutional risk factors of preeclampsia and CVD. Recent studies have shown that women 
with preeclampsia more often have hypertension after pregnancy, which contributes considerably 
to their lifetime CVD and stroke risk.5-9 Accurate and early hypertension diagnosis and treatment 
is important, as hypertension can explain up to half of an individual’s risk for developing CVD.10 
Previous studies examining blood pressure (BP) and hypertension prevalence after preeclampsia, 
usually only measured office BP. 5, 7, 9 However, 24-hour ambulatory blood pressure monitoring 
(ABPM) is the gold standard to rule out masked hypertension or white-coat hypertension (WHC) 
and to assess systolic night-to-day BP ratio, also known as dipping pattern. Dipping pattern 
carries important prognostic information for future CVD risk; a disadvantageous dipping pattern 
(insufficient fall in systolic BP during night-time compared to daytime), even in combination with 
a normotensive ABPM, carries a similar CVD risk as an elevated ABPM.11 Sustained hypertension, 
masked hypertension, WCH and a disadvantageous dipping pattern are all independent risk 
factors for future CVD and therefore clinically important.12-14, 11, 15-17 In the general population, 25% 
of hypertension diagnoses are missed when solely using office BP and when ABPM is used as the 
reference standard.18 We hypothesize that this percentage is even higher in women with previous 
severe preeclampsia. Therefore, ABPM might help to improve diagnosis and management of 
hypertension after severe preeclampsia. The aim of this study was to determine the prevalence of 
hypertension and 24-hour BP pattern in women one year after severe preeclampsia.
Methods
Design and study population
The authors declare that all supporting data are available within the article and its online 
supplementary files. This descriptive study included women referred to the Follow-Up 
Preeclampsia (FUPEC) outpatient clinic in Erasmus Medical Center (EMC), the Netherlands 
between April 2011 and September 2017. This multidisciplinary clinic provides a specifically 
designed program for long-term cardiovascular follow-up of women with previous severe 
preeclampsia, including ABPM one year after delivery. For the present study we included 
women with previous severe preeclampsia and data available on ABPM and office BP measured 
within nine to 15 months after delivery. Women were excluded when they were diagnosed with 
acute fatty liver disease or mild preeclampsia during the index pregnancy, or when they were 
pregnant during follow-up or had been pregnant between index pregnancy and follow-up. The 
final population for analysis comprised 200 women (Figure 1). This non-interventional study 
was approved by the EMC Medical Ethics Committee. 
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N = 636 
Women enrolled in FUPEC outpatient 
clinic between February 2011 and 
September 2017 and ≥ one year after 
pregnancy.  
n = 216 
Women with 24-hour ambulatory blood 
pressure monitoring between 9 to 15 
months after pregnancy. 
n = 258 
Excluded women without 24-hour 
ambulatory blood pressure monitoring 
(n=250) or less than 70% successful blood 
pressure readings during ambulatory blood 
pressure monitoring (n=8). 
 
n = 200 
Population for analysis: women with a 
history of severe pre-eclampsia, 24-hour 
ambulatory blood pressure monitoring and 
an office blood pressure measurement 
between 9 to 15 months after delivery. 
 
Included in analysis with hypertension as 
outcome measure 
n = 12 
Women without office blood pressure 
measurement (n=4). Women being 
pregnant during 24-hour ambulatory blood 
pressure monitoring or between index 
pregnancy and 24-hour ambulatory blood 
pressure monitoring (n=8). 
   
 
n = 378 
Women with 24-hour ambulatory blood 
pressure monitoring after pregnancy. 
n = 162 
Women with 24-hour ambulatory blood 
pressure monitoring outside the range of 9 
to 15 months after pregnancy.  
 
n = 4 
Women with acute fatty liver disease or 
mild pre-eclampsia. 
 
FIGURE 1 | Flowchart. 
Severe preeclampsia
We used the ACOG 2002 criteria that were in effect at the time of inclusion to define preeclampsia 
as new onset hypertension (systolic blood pressure [SBP] ≥ 140 mmHg and/or diastolic blood 
pressure [DBP] ≥ 90 mmHg) after 20 weeks of gestation, and the presence of proteinuria with no 
evidence of urinary tract infection in a random urine sample.3 Severe preeclampsia was accordingly 
classified as preeclampsia including one or more of the following criteria: SBP ≥ 160 mmHg and/
or DBP ≥ 110 mmHg on two occasions at least six hours apart, proteinuria ≥ 5 g/24-hours or ≥ 3+ on 
two urine samples collected at least 4 hours apart, oliguria (<500 mL/24 hours), cerebral or visual 
disturbances, pulmonary edema or cyanosis, epigastric or right upper-quadrant pain, impaired 
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liver function (aspartate [AST] >70 U/L), thrombocytopenia (platelets <100 x 109/L), or fetal growth 
restriction (less than the 10th percentile). Severe preeclampsia for women with pre-existing 
hypertension was defined as hypertension before 20 weeks of gestation with an acute exacerbation 
in the second half of pregnancy combined with new-onset proteinuria (≥ 0.3 g/24h), or a sudden 
increase (doubling) in prior proteinuria, and supportive features of multisystem and/or fetal 
manifestations (e.g. neurological symptoms, HELLP syndrome or fetal growth restriction).19 
Pregnancy and follow-up information
We obtained information on maternal characteristics during pregnancy and pregnancy outcomes 
from medical files and midwifery charts. Women received a questionnaire three months and one 
year after delivery which provided details on: Ethnicity, education, pre-existing hypertension (based 
on doctor diagnosis or antihypertensive medication prescription before pregnancy), previous 
diagnosis of hypertension (prior to ABPM and office BP assessment during follow-up), smoking 
(at any moment during pregnancy and during follow-up), breastfeeding (directly after delivery and 
during follow-up), intervening pregnancies (pregnancies between the index pregnancy and follow-
up) and medication prescription (during follow-up).20, 21 We cross-checked information from the 
questionnaire with the information from medical files and midwifery charts. 
HELLP syndrome (hemolysis, elevated liver enzymes and low platelet count) was defined according 
to the class I and II 2006 Mississippi criteria (platelet count ≤ 100·109/L, AST or alanine [ALT] ≥ 40 
IU/L and lactic acid dehydrogenase [LDH] ≥ 600 IU/L).22
We used the Niklasson growth curve to define a birth weight less than the 10th percentile, adjusted 
for gestational age and child’s sex, as small for gestational age.23 To calculate body mass index 
(BMI) (kg/m2) we used the formula weight/(height * height). Weight, height and BP in early 
pregnancy (<15 weeks of gestation) were obtained from medical files or midwife charts. One year 
after delivery, maternal weight and height were measured by a trained nurse or research assistant.
Kidney function was evaluated at the time of ABPM and office BP measurement through the CKD-
EPI glomerular filtration rate ([GFR] with GFR above 90 ml/min/1.73m2 defined as a normal kidney 
function and GFR 60-90 ml/min/1.73m2 as a mildly decreased kidney function) and albuminuria 
(microalbuminuria <30 mg/g as normal albuminuria, microalbuminuria 30-300 mg/g as moderately 
increased albuminuria and microalbuminuria >300 mg/g as severely increased albuminuria).24  
Blood pressure at follow-up
A trained nurse or research assistant measured office BP in the upright sitting position after at least 
five minutes of rest. The appropriate arm cuff was placed around the right upper arm in order to 
measure BP with a validated oscillometric device. Women were not allowed to speak during the BP 
measurement. 
We carried out 24-hour ABPM through portable BP devices with an embedded oscillometric 
technique (SpaceLabs Healthcare 90207-1Q and 90217-90, SpaceLabs Inc, Redmons, USA; Oscar 2, 
SunTech Medical Inc, Morrisville, USA; ABPM 6100 Monitor, Welch Allyn Inc, Skaneateles Falls, 
USA; Mobil-O-Graph NG Classic and Mobil-O-Graph 24h PWA, I.E.M. GmbH, Stolberg, Germany; 
WatchBP® O3, Microlife, Hoofddorp, the Netherlands; Reynolds Medical Tracker NIBP, Del Mar 
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Reynolds Medical, Ltd, Hertford, UK; BOSO TM2430, Bosch and Sohn GMBH U.CO.KG, Jungingen, 
Germany). Over the course of 24 hours, ABPM was carried out at 30 minute intervals during daytime 
(between 7:00 AM and 23:00 PM) and at 60 minute intervals during night-time. Beforehand, women 
received instructions to continue with their normal daily activities during ABPM. The analyses were 
restricted to women with at least 70% successful ABPM readings (both day and night-time), no more 
than 1 hour intervals of lacking ABPM data and a night-time sleep period between 6-12 hours during 
ABPM. Women received a diary to report their activities and their bedtime and awakening time.
Hypertension was defined according to the international guidelines of the ESH and ESC: Office 
hypertension (average SBP ≥140 mmHg and/or average DBP ≥ 90 mmHg), daytime hypertension 
with ABPM (average SBP ≥135 mmHg and/or average DBP ≥ 85 mmHg), nighttime hypertension 
with ABPM (average SBP ≥120 mmHg and/or average DBP ≥ 70 mmHg), sustained hypertension 
(office hypertension in combination with daytime hypertension measured with ABPM), masked 
hypertension (normotensive office BP in combination with daytime hypertension measured with 
ABPM) and WCH (office hypertension in combination with normotensive daytime ABPM).25 Overall 
SBP and DBP were defined as the average SBP and DBP over a 24 hour period measured with ABPM.
We constructed systolic night-to-day BP ratios from the ABPM readings and categorized these in 
four dipping patterns: Reverse dippers (ratio > 1.0), non-dippers (ratio > 0.9 and ≤ 1.0), dippers (ratio 
> 0.8 and ≤ 0.9) and extreme dippers (ratio ≤ 0.8).12 Thereafter, we combined the reverse dipping 
and non-dipping categories in the disadvantageous dipping pattern group, and the dipping and 
extreme dipping categories in the normal dipping pattern group.
Statistical analyses
First, a non-response analysis was carried out to compare baseline characteristics between women 
included and excluded from this study. Differences in baseline characteristics were tested using 
Students t-test and chi-square tests. Second, baseline and follow-up characteristics were examined 
(Table 1 and Table 2). Third, percentages were determined of women with sustained hypertension, 
masked hypertension and WCH (Figure 2). Fourth, the percentage of women within each dipping 
category (dippers and extreme dippers vs. non-dippers and reverse dippers) was determined 
amongst women with a normotensive or hypertensive ABPM (Figure 3). Fifth, a sensitivity analysis 
was performed in women with a normal to mildly decreased kidney function (Supplemental Table 
1 and Supplemental Figures 1 and 2) and a second sensitivity analysis in women measured with 
the ABPM SpaceLabs device (Supplemental Table 2 and Supplemental Figures 3 and 4). In a third 
sensitivity analysis we examined the overlap between pre-existing hypertension (hypertension 
before the onset of pregnancy) and postpartum hypertension (Supplemental Table 3). Sixth, prior 
to logistic regression analyses we performed multiple imputation procedures in order to reduce 
potential bias in covariates due to missing data. Logistic regression analyses were carried out to 
determine potential risk factors for postpartum hypertension. Covariates in the regression models 
were selected based on: their association with the outcome of interest, previous studies or a change 
in effect estimate of more than 10%. The basic regression model included maternal age during 
ABPM. The full regression model included: maternal age during ABPM, small for gestational age 
below the 10th percentile, education, ethnicity, first trimester diastolic blood pressure and first 
trimester BMI. All analyses were performed with Statistical Package of Social Sciences version 21.0 
for Windows (IBM Corp., Armonk, NY, USA).
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TABLE 1 | Baseline characteristics. 
Outcomes Women
N = 200
Maternal characteristics during index pregnancy
Maternal age in years, mean (SD) 31.6 (4.8)
Ethnicity, n (%)
  Caucasian 166 (83.0)
  African descent 21 (10.5)
  Asian/South-Asian 13 (6.5)
Pre-existing hypertension, n (%) 29 (14.6)
Antihypertensive medication intake before pregnancy, n (%) 14 (7.2)
Nulliparity, n (%) 140 (70.0)
Multiple pregnancy (twin or triplet pregnancy), n (%) 16 (8.0)
§Gestational age at diagnosis of preeclampsia in weeks, median (IQR) 30.5 (5.0)
Time in days between diagnosis and delivery, median (90% range) 3.0 (0.0, 22.1)
HELLP syndrome class I and II of Mississippi criteria, n (%) 27 (14.2)
Early onset preeclampsia (<34 weeks of gestation), n (%) 146 (73.0)
Recurrent preeclampsia among multiparous women, n (%) 14 (23.3)
First trimester BMI (kg/m2), median (90% range) 24.4 (19.0, 35.6)
§First trimester systolic BP (mmHg), median (IQR) 120.0 (16.0)
§First trimester diastolic BP (mmHg), median (IQR) 73.5 (10.0)
Smoking at any moment during pregnancy, n (%) 24 (12.6)
Breastfeeding directly after delivery, n (%) 120 (83.9)
Pregnancy outcomes
Gestational age at delivery, mean (SD) 31.7 (3.7)
Boys, n (%) 96 (48.0)
Neonatal death, n (%) 6 (3.0)
Birth weight gram, median (90% range) 1350 (515, 3210)
*Small for gestational age (less than the 10th percentile), n (%) 127 (69.0)
Mode of delivery, n (%)
  Spontaneous 28 (14.0)
  Assisted delivery 6 (3.0)
  Elective cesarean 5 (2.5)
  Emergency cesarean 161 (80.9)
Maternal characteristics during follow-up
Time interval in years between delivery and ABPM, median (90% range) 1.0 (0.90, 1.2)
Time interval in days between office BP measurement and ABPM, median (90% range) 16.0 (0.05, 49.0)
Education, n (%)
  None/primary 5 (3.5)
  Lower secondary 62 (43.7)
  Upper secondary 6 (4.2)
  Academic 69 (48.6)
BMI (kg/m2), median (90% range) 25.5 (19.3, 36.6)
Smoking, n (%) 23 (13.5)
Breastfeeding, n (%) 14 (7.6)
Antihypertensive medication prescription, n (%) 41 (20.5)
Previously diagnosed hypertension, n (%)† 48 (24.0)
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Outcomes Women
N = 200
Normal GFR, n (%)
Normal albuminuria 118 (66.3)
Mildly increased albuminuria 25 (14.0) 
‡Severely increased albuminuria 4 (2.2)
Mildly decreased GFR, n (%)
Normal albuminuria 26 (14.6)
Mildly increased albuminuria 3 (1.7)
Severely increased albuminuria 2 (1.1)
Abbreviations: Ambulatory blood pressure monitoring, ABPM; Body mass index, BMI; Blood pressure, BP; 
Glomerular filtration rate, GFR; Hemolysis, elevated liver enzymes and low platelet count, HELLP; Interquartile 
range, IQR. Values are valid percentages for categorical variables, means (SD) for continuous variables with a 
normal distribution, or medians with 90% range or IQR§ for continuous variables with a skewed distribution.
*Based on weight - gestational age (24-40weeks) / Sweden 2008 (Sweden) / Niklasson.
†Occurred prior to ABPM and office BP assessment during follow-up and was based on doctor diagnosis or 
antihypertensive medication prescription. ‡ Women with severely increased albuminuria had pre-existing 
hypertension (n = 3), preeclampsia or HELLP syndrome in a previous pregnancy (n = 2), gestational diabetes in the 
index pregnancy (n = 1) or no previous disease (n = 1). 
TABLE 2 | Blood pressure one year after pregnancy.
Outcomes Women
N = 200
Systolic blood pressure (mmHg), median (IQR)
   Office 120.5 (21.0)
   Daytime ABPM 124.0 (19.0)
   Night-time ABPM 111.0 (17.0)
   Overall ABPM 121.0 (19.0)
Diastolic blood pressure (mmHg), median (IQR)
   Office 78.0 (13.0)
   Daytime ABPM 79.0 (12.0)
   Night-time ABPM 66.0 (13.0)
   Overall ABPM 75.5 (13.0)
Hypertension, n (%)
Daytime hypertension with ABPM (135/85 mmHg) 64 (32.0)
Night-time hypertension with ABPM (120/70 mmHg) 85 (42.5)
Hypertension with office BPM (140/90 mmHg) 48 (24.0)
Systolic night-to-day BP ratio, n (%)
  Reverse dippers 12 (6.0)
  Non-dippers 79 (39.5)
  Dippers 99 (49.5)
  Extreme dippers 10 (5.0)
Abbreviations: Ambulatory blood pressure monitoring, ABPM; Interquartile range, IQR. Values are numbers (n) 
and valid percentages for categorical variables and medians with interquartile range for continuous variables.
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Results
Table 1 shows pregnancy outcomes, and women’s characteristics during the index pregnancy 
and follow-up. During the index pregnancy, women were on average 31.6 years old (standard 
deviation [SD] 4.8) and mostly nulliparous (70.0%). The average gestational age at diagnosis was 
30.5 weeks (SD 5.0) with the majority of women having an early onset preeclampsia (73.0%). 
Slightly more girls (52.0%) than boys were born and children were mostly small for gestational age 
(69.0%). A large percentage (48.6%) of women was academically educated. At the time of ABPM 
and office BP measurement, 20.5% of women were already receiving treatment for previous 
diagnosed hypertension. Kidney function was determined through GFR and albuminuria levels 
at the time of ABPM and office BP measurement (Table 1). A small number of women (n = 6) 
had severely increased albuminuria one year after pregnancy of which the majority (83%) had 
pre-existing comorbidity associated with impaired renal function (data not shown). Of women 
with moderately increased albuminuria (n = 28), 40% had pre-existing comorbidity associated 
with impaired renal function (data not shown). Excluding women with moderately and severely 
increased albuminuria from our analyses did not change the results substantially (Supplemental 
Table 1 and Supplemental Figures 1 and 2). 
Associations between office hypertension prevalence, hypertension prevalence with ABPM, 
previous diagnosis of hypertension and antihypertensive medication prescription is shown 
in Figure 2. In total, 41.5% of women had some form of hypertension (sustained hypertension 
[14.5%], masked hypertension [17.5%] or WCH [9.5%]). A percentage of women with sustained 
hypertension, masked hypertension or WCH had been diagnosed with hypertension prior to 
ABPM and office BP measurement (55.2%, 31.4% and 47.4%, respectively) or prior to the onset of 
pregnancy (Supplemental Table 3). Figure 2 also shows that 75.0% of women (36 out of 48) with 
a diagnosis of hypertension prior to ABPM and office BP measurement either did not receive 
optimal antihypertensive drug treatment or were non-adherent to their antihypertensive 
treatment.
Table 2 shows mean blood pressures, hypertension prevalence and dipping pattern one year 
after delivery. The hypertension prevalence was higher during night-time ABPM (42.5%) than 
during daytime ABPM (32.0%) or office BP measurement (24.0%). Systolic night-to-day BP ratio 
showed a reverse dipping pattern or non-dipping pattern in 45.5% of women.
We examined the association between all characteristics mentioned in Table 1 and the risk of 
any type of hypertension after pregnancy through multivariate logistic regression analysis (data 
not shown). Only pre-existing hypertension before pregnancy and BMI were associated with 
hypertension after pregnancy. Pre-existing hypertension was associated with an increased risk 
for: daytime hypertension with ABPM (Odds ratio [OR] 2.8; 95% Confidence Interval [CI] 1.0, 
7.7, P-value 0.048), office hypertension (OR 3.1; 95% CI 1.0, 9.3, P-value 0.042) and sustained 
hypertension (OR 7.5; 95% CI 1.7, 32.0, P-value 0.007). First trimester BMI was solely associated 
with an increased risk of office hypertension (OR 1.1; 95% CI 1.0, 1.2, P-value 0.04).
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Figure 3 shows the association between systolic night-to-day BP ratio dipping pattern and 
hypertension status defined with daytime ABPM. A disadvantageous dipping pattern was seen in 
45.6% of women with a normotensive daytime ABPM and in 45.3% of women with a hypertensive 
daytime ABPM.
Non-response analysis showed that women excluded from this study (due to missing ABPM) 
were on average slightly older at the time of follow-up (34.1 years [SD 7.7]) compared to women 
included in the study (32.7 years [SD 4.8], p-value 0.02). No differences were observed in ethnicity 
and educational level between women included and excluded from the study. Lastly, sensitivity-
analysis showed that the use of various ABPM devices (other than the SpaceLabs device) did not 
change our results substantially (Supplemental Table 2 and Supplemental Figures 3 and 4).
FIGURE 3 | The association between systolic night-to-day blood pressure ratio (dipping pattern) and hypertension 
prevalence with ambulatory blood pressure monitoring (N = 200).
Abbreviations: Ambulatory blood pressure monitoring, ABPM. Hypertension is defined as daytime hypertension 
with ambulatory blood pressure monitoring (≥135/85 mmHg). †Values are calculated as percentages of women 
with a normotensive daytime ambulatory blood pressure monitoring. *Values are calculated as percentages of 
women with hypertension during daytime ambulatory blood pressure monitoring.
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Discussion
Our study of 200 women with previous severe preeclampsia shows that 41.5% of women have some 
form of hypertension one year after delivery based on ABPM. ABPM was essential to diagnose 
masked hypertension (17.5% of the total population) and WCH (9.5% of the total population) in 
27% of women. Additionally, 45.5% of women had a disadvantageous systolic night-to-day BP 
ratio dipping pattern. This percentage was equal between women with a normotensive and 
hypertensive daytime ABPM. 
It is well known that women with previous preeclampsia have an increased risk of CVD later 
in life,1, 2, 4 especially in women with early-onset and/or severe preeclampsia 4. The exact 
pathophysiological mechanism leading to this increased CVD risk remains unknown and might 
in fact be multifactorial. A previous study showed increased sensitivity to angiotensin II during 
and after a hypertensive pregnancy.26 This increases the risk of persistence or development of 
hypertension after delivery.5-9, 26 Clinical guidelines on hypertensive disorders in pregnancy 
and guidelines on the prevention of stroke therefore recommend BP screening in women with 
previous preeclampsia.27, 28 However, specific recommendations regarding the appropriate 
method and timing to measure BP after preeclampsia is not provided, possibly because there 
are very few studies available examining 24-hour BP pattern after preeclampsia.29 With regard 
to the method of BP measurement, we show that ABPM after a severe preeclampsia provides 
important additional information aside of office BP. Various types of hypertension (e.g. masked 
hypertension, WCH and night time hypertension) can be diagnosed with ABPM which would 
otherwise remain unnoticed. These types of hypertension and systolic night-to-day BP ratio 
dipping pattern are predictors of future CVD, independent of office hypertension.17
In our study 17.5% of women had masked hypertension, which has been associated in other 
studies with an increased risk of developing sustained hypertension, cardiovascular events and 
cardiovascular mortality, independent of office BP.30-33 The prevalence of masked hypertension 
amongst women in the general population is 9.5%.34 A known risk factor for masked 
hypertension is pre-hypertension (BP 130–139/85–89 mmHg), which affected 15.0% of women 
in our study. Seventeen to 30.3% of individuals with pre-hypertension will eventually develop 
masked hypertension. A large percentage (38%) of women with previous severe preeclampsia 
will ultimately be diagnosed with hypertension (based on office BP measurement) after nine to 
16 years after delivery.5 Possibly, these women are still in a pre-hypertensive state during the 
first decade after delivery, which makes them more vulnerable to develop masked hypertension. 
The percentage of women with WCH in our study is comparable to percentages described in a 
large study of 115,708 Spanish patients with treated and untreated hypertension.35 WCH is an 
important diagnosis because these individuals have an increased risk of developing sustained 
hypertension and target organ damage (e.g. microalbuminuria and left ventricular hypertrophy) 
compared to normotensive controls.31, 35-37 Therefore, BP should be monitored after diagnosis 
of WCH for timely diagnosis of the development of sustained hypertension. However, WCH 
should not be treated with antihypertensive medication as this can lead to hypotension.12, 38
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Night-time hypertension affected 42.5% of women in our study. Even a minor rise in night-time 
BP increases the risk of cardiovascular events, stroke, and non-cardiovascular and cardiovascular 
mortality.39 Accordingly, progression towards a disadvantageous dipping pattern (from dipping, 
to non-dipping to reverse dipping pattern) also progressively increases the risk of future CVD 
by inducing subclinical target organ damage.39, 40 Several pathophysiological mechanisms have 
been suggested to explain the insufficient reduction of night-time BP, including deficient 
decrease of night-time sympathetic activity.40, 41 Sympathetic activity is inversely associated 
with the difference in day-to-night BP, suggesting that it may influence 24-hour BP pattern in 
hypertensive individuals.41 In women with preeclampsia, sympathetic over-activity is described 
both during and after pregnancy.29, 42-44 This might explain the high prevalence of night-time 
hypertension and disadvantageous dipping patterns in our study population compared to 
other study cohorts.45, 46 The prevalence of a disadvantageous dipping pattern, especially the 
percentage of women with a non-dipping pattern was higher in our study population compared 
to that of a large meta-analysis conducted in European, Japanese, Chinese and South-American 
women (39.5% vs. 24.4%).39 Interestingly, women in the aforementioned study were more than 
20 years older than women in our study (mean age 56.8 years [SD 13.9] vs 32.7 years [SD 4.8]). 
Results of our study should be interpreted within the context of some limitations. First, due 
to the descriptive design of this study differences in hypertension prevalence and dipping 
pattern between women with previous preeclampsia and women with a previous normotensive 
pregnancy or other gestational hypertensive disorder (e.g. gestational hypertension or mild 
preeclampsia) cannot be examined. Second, findings may not be generalizable to all women 
with previous severe preeclampsia because the majority of women were Caucasian and highly 
educated. Further analyses showed that women excluded from this study, due to missing 
ABPM, were on average slightly older at the time of follow-up compared to women included 
in the study. Third, 15.7% and 3.4% of women had moderately increased and severely increased 
albuminuria one year after pregnancy, which could affect BP. Nevertheless, our results did not 
change substantially when these women were excluded from our analyses (Table S1 and Figures 
S1 and S2). Fourth, we measured office BP and ABPM once, which might have reduced the 
diagnostic accuracy of true BP values. Previous studies showed that BP obtained from ABPM 
can be more accurately reproduced than BP obtained from office measurement47, 48 and that the 
diagnoses of masked hypertension and WCH are well reproducible in short-term but tend to 
shift towards sustained hypertension in the long-term.49 Limited evidence suggests that repeated 
measurements of office BP improve the diagnosis of hypertension 50. It seems therefore unlikely 
that we overestimated the percentage of women with sustained hypertension. Lastly, ABPM was 
not standardized for device type. Though the majority of women (73.6%) were examined with one 
device brand (SpaceLabs Healthcare 90207-1Q  and 90217-90, SpaceLabs Inc, Redmons, USA) 
and all devices used the oscillometric technique with identical time intervals, we should take 
intra-device BP reproducibility in to account. Sensitivity analysis in women measured with the 
SpaceLabs devices showed similar results to those of the total population (Table S2 and Figures 
S3 and S4). Therefore, the use of various ABPM devices did not seem to affect our results.
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Conclusion
We show that 41.5% of women with previous severe preeclampsia have some form of hypertension 
one year after delivery (sustained hypertension, masked hypertension or WCH) and that 45.5% of 
women have a disadvantageous systolic night-to-day BP ratio dipping pattern, which cannot be 
diagnosed without ABPM. Current clinical guidelines on the prevention of CVD and stroke after 
a hypertensive pregnancy disorder lack advice on ABPM after delivery. We believe that ABPM 
should be offered to all women who experienced severe preeclampsia for more accurate BP 
assessment. By doing so, hypertension management can be improved which eventually might 
reduce the risk of future CVD. 
Blood pressure profile one year after severe preeclampsia   |   81
4
References
1. Mol BW, Roberts CT, Thangaratinam S, Magee LA, de Groot CJ, Hofmeyr GJ. Preeclampsia. Lancet. 
2016;387:999-1011
2. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Preeclampsia. Lancet. 2010;376:631-644
3. Bulletins--Obstetrics ACoP. Acog practice bulletin. Diagnosis and management of preeclampsia and 
eclampsia. Number 33, january 2002. Obstet Gynecol. 2002;99:159-167
4. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and risk of cardiovascular disease and cancer 
in later life: Systematic review and meta-analysis. BMJ. 2007;335:974
5. Bokslag A, Teunissen PW, Franssen C, van Kesteren F, Kamp O, Ganzevoort W, Paulus WJ, de Groot CJM. 
Effect of early-onset preeclampsia on cardiovascular risk in the fifth decade of life. Am J Obstet Gynecol. 
2017;216:521-523
6. Behrens I, Basit S, Melbye M, Lykke JA, Wohlfahrt J, Bundgaard H, Thilaganathan B, Boyd HA. Risk of post-
pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: Nationwide cohort 
study. BMJ. 2017;358:j3078
7. Breetveld NM, Ghossein-Doha C, van Kuijk S, van Dijk AP, van der Vlugt MJ, Heidema WM, Scholten RR, 
Spaanderman ME. Cardiovascular disease risk is only elevated in hypertensive, formerly preeclamptic 
women. BJOG. 2015;122:1092-1100
8. Bushnell C, Chireau M. Preeclampsia and stroke: Risks during and after pregnancy. Stroke Res Treat. 
2011;2011:858134
9. Veerbeek JH, Hermes W, Breimer AY, van Rijn BB, Koenen SV, Mol BW, Franx A, de Groot CJ, Koster MP. 
Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-
induced hypertension. Hypertension. 2015;65:600-606
10. Lawes CM, Vander Hoorn S, Rodgers A, International Society of H. Global burden of blood-pressure-related 
disease, 2001. Lancet. 2008;371:1513-1518
11. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Blunted sleep-time relative blood pressure decline increases 
cardiovascular risk independent of blood pressure level--the “normotensive non-dipper” paradox. Chronobiol 
Int. 2013;30:87-98
12. O’Brien E, Parati G, Stergiou G et al. European Society of Hypertension Working Group on Blood Pressure 
Monitoring. European society of hypertension position paper on ambulatory blood pressure monitoring. J 
Hypertens. 2013;31:1731-1768
13. Verdecchia P. Prognostic value of ambulatory blood pressure: Current evidence and clinical implications. 
Hypertension. 2000;35:844-851
14. Niiranen TJ, Maki J, Puukka P, Karanko H, Jula AM. Office, home, and ambulatory blood pressures as 
predictors of cardiovascular risk. Hypertension. 2014;64:281-286
15. Satoh M, Asayama K, Kikuya M et al. Long-term stroke risk due to partial white-coat or masked hypertension 
based on home and ambulatory blood pressure measurements: The ohasama study. Hypertension. 2016;67:48-
55
16. Salles GF, Reboldi G, Fagard RH, Cardoso CR, Pierdomenico SD, Verdecchia P, Eguchi K, Kario K, Hoshide 
S, Polonia J, de la Sierra A, Hermida RC, Dolan E, O’Brien E, Roush GC, Investigators A-H. Prognostic effect 
of the nocturnal blood pressure fall in hypertensive patients: The ambulatory blood pressure collaboration in 
patients with hypertension (abc-h) meta-analysis. Hypertension. 2016;67:693-700
17. Fagard RH, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Night-day blood pressure 
ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. J Hum Hypertens. 
2009;23:645-653
18. Hodgkinson J, Mant J, Martin U, Guo B, Hobbs FD, Deeks JJ, Heneghan C, Roberts N, McManus RJ. Relative 
effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure 
monitoring in diagnosis of hypertension: Systematic review. BMJ. 2011;342:d3621
82   |   Chapter 4
4
19. Brown MA, Hague WM, Higgins J, Lowe S, McCowan L, Oats J, Peek MJ, Rowan JA, Walters BN, Austalasian 
Society of the Study of Hypertension in P. The detection, investigation and management of hypertension in 
pregnancy: Full consensus statement. Aust N Z J Obstet Gynaecol. 2000;40:139-155
20. UNESCO Institute for Statistics, the OECD and Eurostat. ISCED 2011 operational manual: Guidelines for 
classifying national education programmes and related qualifications. 2015
21. The U.S. office of management and budget. Race and ethnicity classifications. 1997
22. Martin JN, Jr., Rose CH, Briery CM. Understanding and managing hellp syndrome: The integral role of 
aggressive glucocorticoids for mother and child. Am J Obstet Gynecol. 2006;195:914-934
23. Niklasson A, Ericson A, Fryer JG, Karlberg J, Lawrence C, Karlberg P. An update of the swedish reference 
standards for weight, length and head circumference at birth for given gestational age (1977-1981). Acta 
Paediatr Scand. 1991;80:756-762
24. Group KDIGOKCW. Clinical practice guideline for the evaluation and management of chronic kidney 
disease. Kidney Int Suppl. 2013;3:1-150
25. ESH ESC Task Force for the Management of Arterial Hypertension. 2013 practice guidelines for the 
management of arterial hypertension of the european society of hypertension (ESH) and the european 
society of cardiology (ESC): ESH/ESC task force for the management of arterial hypertension. J Hypertens. 
2013;31:1925-1938
26. Saxena AR, Karumanchi SA, Brown NJ, Royle CM, McElrath TF, Seely EW. Increased sensitivity to 
angiotensin ii is present postpartum in women with a history of hypertensive pregnancy. Hypertension. 
2010;55:1239-1245
27. Piepoli MF, Hoes AW, Agewall S et al. 2016 european guidelines on cardiovascular disease prevention in 
clinical practice. The sixth joint task force of the european society of cardiology and other societies on 
cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and 
by invited experts. Developed with the special contribution of the european association for cardiovascular 
prevention & rehabilitation. G Ital Cardiol (Rome). 2017;18:547-612
28. Bushnell C, McCullough LD, Awad IA et al. Guidelines for the prevention of stroke in women: A statement 
for healthcare professionals from the american heart association/american stroke association. Stroke. 
2014;45:1545-1588
29. Collen AC, Hellgren M, Gustafsson H, Johansson MC, Manhem K. Cardiovascular and metabolic 
characteristics 40 years after hypertensive pregnancies: A long-term follow-up study of mothers. J Hypertens. 
2013;31:758-765
30. Redmond N, Booth JN, 3rd, Tanner RM, Diaz KM, Abdalla M, Sims M, Muntner P, Shimbo D. Prevalence 
of masked hypertension and its association with subclinical cardiovascular disease in african americans: 
Results from the jackson heart study. J Am Heart Assoc. 2016;5:e002284
31. Siven SS, Niiranen TJ, Kantola IM, Jula AM. White-coat and masked hypertension as risk factors for 
progression to sustained hypertension: The finn-home study. J Hypertens. 2016;34:54-60
32. Asayama K, Thijs L, Li Y et al. International Database on Ambulatory Blood Pressure in Relation to 
Cardiovascular Outcomes (IDACO) Investigators. Setting thresholds to varying blood pressure monitoring 
intervals differentially affects risk estimates associated with white-coat and masked hypertension in the 
population. Hypertension. 2014;64:935-942
33. Hanninen MR, Niiranen TJ, Puukka PJ, Johansson J, Jula AM. Prognostic significance of masked and white-
coat hypertension in the general population: The finn-home study. J Hypertens. 2012;30:705-712
34. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure monitoring 
and risk of cardiovascular disease: A population based study. Am J Hypertens. 2006;19:243-250
35. de la Sierra A, Vinyoles E, Banegas JR, Segura J, Gorostidi M, de la Cruz JJ, Ruilope LM. Prevalence and 
clinical characteristics of white-coat hypertension based on different definition criteria in untreated and 
treated patients. J Hypertens. 2017;35:2388-2394
36. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, Benjamin EJ, Vasan RS, Mitchell GF. Aortic 
stiffness, blood pressure progression, and incident hypertension. JAMA. 2012;308:875-881
Blood pressure profile one year after severe preeclampsia   |   83
4
37. Sung SH, Cheng HM, Wang KL, Yu WC, Chuang SY, Ting CT, Lakatta EG, Yin FC, Chou P, Chen CH. 
White coat hypertension is more risky than prehypertension: Important role of arterial wave reflections. 
Hypertension. 2013;61:1346-1353
38. O’Brien E, Coats A, Owens P, Petrie J, Padfield PL, Littler WA, de Swiet M, Mee F. Use and interpretation 
of ambulatory blood pressure monitoring: Recommendations of the british hypertension society. BMJ. 
2000;320:1128-1134
39. Boggia J, Li Y, Thijs L et al. International Database on Ambulatory blood pressure monitoring in relation to 
Cardiovascular Outcomes (IDACO) investigators. Prognostic accuracy of day versus night ambulatory blood 
pressure: A cohort study. Lancet. 2007;370:1219-1229
40. Cuspidi C, Sala C, Tadic M, Gherbesi E, De Giorgi A, Grassi G, Mancia G. Clinical and prognostic significance 
of a reverse dipping pattern on ambulatory monitoring: An updated review. J Clin Hypertens (Greenwich). 
2017;19:713-721
41. Grassi G, Seravalle G, Quarti-Trevano F, Dell’Oro R, Bombelli M, Cuspidi C, Facchetti R, Bolla G, Mancia G. 
Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension. 
2008;52:925-931
42. Greenwood JP, Scott EM, Walker JJ, Stoker JB, Mary DA. The magnitude of sympathetic hyperactivity in 
pregnancy-induced hypertension and preeclampsia. Am J Hypertens. 2003;16:194-199
43. Greenwood JP, Scott EM, Stoker JB, Walker JJ, Mary DA. Sympathetic neural mechanisms in normal and 
hypertensive pregnancy in humans. Circulation. 2001;104:2200-2204
44. Lampinen KH, Ronnback M, Groop PH, Nicholls MG, Yandle TG, Kaaja RJ. Increased plasma norepinephrine 
levels in previously pre-eclamptic women. J Hum Hypertens. 2014;28:269-273
45. Saeed S, Waje-Andreassen U, Lonnebakken MT, Fromm A, Oygarden H, Naess H, Gerdts E. Covariates of 
non-dipping and elevated night-time blood pressure in ischemic stroke patients: The norwegian stroke in 
the young study. Blood Press. 2016;25:212-218
46. Cuspidi C, Facchetti R, Bombelli M, Sala C, Tadic M, Grassi G, Mancia G. Is night-time hypertension 
worse than daytime hypertension? A study on cardiac damage in a general population: The pamela study. J 
Hypertens. 2017;35:506-512
47. Viera AJ, Lin FC, Tuttle LA, Olsson E, Stankevitz K, Girdler SS, Klein JL, Hinderliter AL. Reproducibility of 
masked hypertension among adults 30 years or older. Blood Press Monit. 2014;19:208-215
48. Viera AJ, Hinderliter AL, Kshirsagar AV, Fine J, Dominik R. Reproducibility of masked hypertension in 
adults with untreated borderline office blood pressure: Comparison of ambulatory and home monitoring. 
Am J Hypertens. 2010;23:1190-1197
49. De la Sierra A, Vinyoles E, Banegas JR, Parati G, de la Cruz JJ, Gorostidi M, Segura J, Ruilope LM. Short-
term and long-term reproducibility of hypertension phenotypes obtained by office and ambulatory blood 
pressure measurements. J Clin Hypertens (Greenwich). 2016;18:927-933
50. Piper MA, Evans CV, Burda BU, Margolis KL, O’Connor E, Smith N, Webber E, Perdue LA, Bigler KD, 
Whitlock EP. Screening for high blood pressure in adults: A systematic evidence review for the u.S. 
Preventive services task force. Rockville (MD): Agency for Healthcare Research and Quality (US). 2014:Report No.: 
13-05194-EF-05191
84   |   Chapter 4
4
Novelty and significance
What is new?
We examined 24-hour blood pressure profile and hypertension prevalence (sustained 
hypertension, masked hypertension or white-coat hypertension) through ambulatory blood 
pressure monitoring (ABPM) and an office blood pressure (BP) measurement in women with 
previous severe preeclampsia.
What is relevant? 
Unrecognized masked hypertension and a disadvantageous systolic night-to-day BP dipping 
pattern are associated with an increased risk of cardiovascular disease (CVD). This might at least 
partly explain the increased risk of CVD after preeclampsia.
Summary
Not only is hypertension common (41.5%) one year after a severe preeclampsia, 17.5% of women 
suffer from masked hypertension and 45.5% of women have a disadvantageous systolic night-to-
day BP dipping pattern. These are diagnoses that would remain undetected when only office BP 
measurement is performed. 
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Supplemental material 
SUPPLEMENTAL TABLE 1 | Blood pressure one year after pregnancy in women with normal to mildly increased 
albuminuria .
Outcomes Women
n = 149
Systolic blood pressure (mmHg), median (IQR)
   Office 120.0 (22.0)
   Daytime ABPM 122.5 (18.0)
   Night-time ABPM 109.5 (18.0)
   Overall ABPM 120.0 (18.00
Diastolic blood pressure (mmHg), median (IQR)
   Office 78.0 (13.0)
   Daytime ABPM 78.6 (11.0)
   Night-time ABPM 65.5 (13.0)
   Overall ABPM 75.0 (12.0)
Hypertension, n (%)
Daytime hypertension with ABPM (135/85 mmHg) 40 (26.8)
Night-time hypertension with ABPM (120/70 mmHg) 58 (38.9)
Hypertension with office BPM (140/90 mmHg) 33 (22.1)
Systolic night-to-day BP ratio, n (%)
  Reverse dippers 6 (4.0)
  Non-dippers 58 (38.9)
  Dippers 76 (51.0)
  Extreme dippers 9 (6.0)
Abbreviations: Ambulatory blood pressure monitoring, ABPM; Interquartile range, IQR. Values are numbers (n) 
and valid percentages for categorical variables and medians with interquartile range for continuous variables.
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SUPPLEMENTAL TABLE 2 | Blood pressure one year after pregnancy of the total population and women measured 
with the ABPM SpaceLabs device.
Outcomes Total 
population
N = 200
SpaceLabs 
device
n = 134
P-value
Systolic blood pressure (mmHg), median (IQR)
   Office 120.5 (21.0) 121.5 (25.0) 0.79
   Daytime ABPM 124.0 (19.0) 124.0 (17.0) 0.15
   Night-time ABPM 111.0 (17.0) 111.0 (15.0) 0.15
   Overall ABPM 121.0 (19.0) 120.0 (17.0) 0.15
Diastolic blood pressure (mmHg), median (IQR)
   Office 78.0 (13.0) 77.5 (14.0) 0.28
   Daytime ABPM 79.0 (12.0) 79.0 (12.0) 0.71
   Night-time ABPM 66.0 (13.0) 67.0 (13.0) 0.69
   Overall ABPM 75.5 (13.0) 75.5 (11.0) 0.66
Daytime hypertension with ABPM (135/85 mmHg), n (%) 64 (32.0) 42 (31.3) 0.78
Night-time hypertension with ABPM (120/70 mmHg), n (%) 85 (42.5) 57 (42.5) 0.97
Hypertension with office BPM (140/90 mmHg), n (%) 48 (24.0) 34 (25.4) 0.53
Nightly blood pressure dippers, n (%) 0.43
  Reverse dippers 12 (6.0) 6 (4.5)
  Non-dippers 79 (39.5) 58 (43.3)
  Dippers 99 (49.5) 66 (49.3)
  Extreme dippers 10 (5.0) 4 (3.0)
Abbreviations: Ambulatory blood pressure monitoring, ABPM; Interquartile range, IQR. Values are numbers (n) 
with valid percentages for categorical variables and medians with interquartile range for continuous variables. 
Statistical testing was carried out through Student’s t-test for continuous variables, and through chi-square test 
for categorical variables.
SUPPLEMENTAL TABLE 3 | Blood pressure one year after pregnancy in women with pre-existing hypertension. 
Outcomes Total 
population
N = 200
Women with 
pre-existing 
hypertension
n = 29
Masked hypertension, n (%) 35 (17.5) 7 (24.1)
White-coat hypertension, n (%) 19 (9.5) 6 (20.7)
Sustained hypertension, n (%) 29 (14.5) 11 (37.9)
Daytime hypertension with ABPM (135/85 mmHg), n (%) 64 (32.0) 18 (62.1)
Night-time hypertension with ABPM (120/70 mmHg), n (%) 85 (42.5) 19 (65.5)
Hypertension with office BPM (140/90 mmHg), n (%) 48 (24.0) 17 (58.6)
Abbreviation: Ambulatory blood pressure monitoring, ABPM. Values are numbers (n) with valid percentages. 
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SUPPLEMENTAL FIGURE 2 | The association between systolic night-to-day blood pressure ratio (dipping 
pattern) and hypertension rate with ambulatory blood pressure monitoring for women with normal to mildly 
increased albuminuria (n = 149).
Hypertension is defined as daytime hypertension with ambulatory blood pressure monitoring (≥135/85 mmHg). 
†Values are calculated as percentages of women with a normotensive daytime ambulatory blood pressure 
monitoring. *Values are calculated as percentages of women with hypertension during daytime ambulatory blood 
pressure monitoring.
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SUPPLEMENTAL FIGURE 4 | The association between systolic night-to-day blood pressure ratio (dipping 
pattern) and hypertension rate with ambulatory blood pressure monitoring for women measured with the 
SpaceLabs device (n = 134).
Hypertension is defined as daytime hypertension with ambulatory blood pressure monitoring (≥135/85 mmHg). 
†Values are calculated as percentages of women with a normotensive daytime ambulatory blood pressure 
monitoring. 
*Values are calculated as percentages of women with hypertension during daytime ambulatory blood pressure 
monitoring.
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Abstract
Background: Hypertensive disorders of pregnancy, including gestational hypertension and 
preeclampsia, are associated with an increased risk of cardiovascular disease (CVD) in later life, 
possibly through an atherogenic lipid profile. The objective of this study was to assess if women 
with a previous hypertensive disorder of pregnancy have a more atherogenic lipid profile six 
years after pregnancy compared to women with a previous normotensive pregnancy.
Methods: In a population-based prospective cohort study, we included 4933 women during 
pregnancy, including 302 women with a hypertensive disorder of pregnancy. Six years after 
pregnancy, we determined maternal lipid profile (total-cholesterol, triglycerides, HDL-c, LDL-c, 
lipoprotein[a] and apolipoprotein B) and glucose levels. 
Results: Women with a previous hypertensive disorder of pregnancy had a more atherogenic 
lipid profile six years after pregnancy compared to women with a previous normotensive 
pregnancy. These atherogenic lipid profiles were a result of higher levels of triglycerides, LDL-c 
and apolipoprotein B and lower levels of HDL-c. Differences in lipid profile between women 
with a previous hypertensive disorder of pregnancy and women with a previous normotensive 
pregnancy were attenuated after adjustment for pre-pregnancy BMI. Between women from 
both groups, no differences were observed in total-cholesterol, lipoprotein[a] and glucose levels.
Conclusions: Women with a previous hypertensive disorder of pregnancy show a more 
atherogenic lipid profile six years after pregnancy than women with a previous normotensive 
pregnancy. The increased risk of CVD after a hypertensive disorder of pregnancy might result 
from an atherogenic lipid profile after pregnancy, primarily driven by pre-pregnancy BMI.
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Introduction
An atherogenic lipid profile, consisting of high levels of total-cholesterol, triglycerides, low-
density lipoprotein cholesterol (LDL-c), lipoprotein(a) (Lp[a]) or apolipoprotein B (apoB), or low 
levels of high-density lipoprotein cholesterol (HDL-c), increases the risk of future cardiovascular 
disease (CVD), stroke and transient ischemic attack.1, 2 High levels of these individual lipids can 
stimulate lipid absorption by macrophages in the arterial vessel wall. This process will induce 
local vascular inflammation and the formation of atherosclerotic plaques.3 Women with previous 
gestational hypertensive disorders such as gestational hypertension and preeclampsia are also 
more likely to develop CVD in later life.4-7 Both conditions are characterized by hypertension in 
pregnancy but only preeclampsia is a placenta mediated syndrome with abnormal placentation 
leading to proteinuria, systemic inflammation and organ dysfunction.6, 8 Multiple factors 
may contribute to the process of CVD after gestational hypertension and preeclampsia, such 
as accelerative development of classical cardiovascular risk factors after pregnancy.9-13 Some 
of these cardiovascular risk factors, such as weight and blood pressure after pregnancy, are 
consistently higher in women with a previous gestational hypertensive disorder compared to 
women with a previous normotensive pregnancy.10, 14-16 Other cardiovascular risk factors, such 
as insulin resistance, visceral adiposity and the metabolic syndrome, are also more prevalent 
in these women.10, 15, 17, 18 As a result, women with a previous gestational hypertensive disorder 
seem to be more susceptible to exhibit an atherogenic lipid profile after pregnancy compared 
to women with a previous normotensive pregnancy. Nevertheless, studies on their lipid 
profiles after pregnancy show contradictory results10, 14-17, 19-22 and current clinical cardiovascular 
guidelines do not provide uniform recommendations on lipid profile assessment after a 
gestational hypertensive disorder.23-25
The aim of this study was to assess if women with a previous hypertensive disorder of pregnancy 
have a more atherogenic lipid profile six years after pregnancy compared to women with a 
previous normotensive pregnancy. As gestational hypertension and preeclampsia do share 
similar risk factors (e.g. obesity, advanced maternal age, nulliparity and diabetes) but differ in 
their pathophysiological pathways we also assess the individual association between gestational 
hypertension and preeclampsia, and maternal lipid profile after pregnancy. 
Materials and methods
Design and study population
This study was embedded in the Generation R Study, a multi-ethnic and population-based 
prospective cohort study from early pregnancy onwards in Rotterdam, the Netherlands.26, 27 
Approval has been obtained by the Medical Ethics Committee of the Erasmus Medical Center, 
Rotterdam, the Netherlands.28 For the present study we included women with: a live born 
singleton (exclusion of twin pregnancies), available information regarding postnatal development 
and information on the occurrence of a hypertensive disorder of pregnancy. Women were 
excluded when they had a history of chronic hypertension prior to enrollment in the Generation 
R Study, if they were pregnant during the follow-up visit or in case information on cholesterol 
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or glucose mediating medication at follow-up was missing. The final population for analysis 
comprised 4933 women (Figure 1). All women included in this study gave informed consent (MEC 
198.782/2001/31). 
 
 
 
N = 8198 
Women enrolled during pregnancy.  
n = 5439 
Women with postnatal visit at research 
center.   
n = 2759 
Excluded women without postnatal 
follow-up data. 
n = 291 
Twins (n=34), women being pregnant 
during their visit at the research center 
(n=257). 
 
n = 4933 
Population for analysis: pre-pregnancy 
normotensive women with live born 
singleton pregnancies (exclusion of twin 
pregnancies) and available information on 
gestational hypertensive disorders and 
glucose and cholesterol mediating 
medication use. 
 
Included in analysis with hypertension as 
outcome measure 
n =  200 
Excluded women without information on 
gestational hypertensive disorders (n=110) 
and with chronic hypertension before 
enrolment in the Generation R Study 
(n=90). 
n = 5239 
Pre-pregnancy normotensive women with 
postnatal visit at research center.   
n = 15 
Excluded women with missing data on 
glucose and cholesterol mediating 
medication use.  
FIGURE 1 | Flowchart.
Blood pressure, hypertensive disorders of pregnancy and chronic hypertension
Trained research assistants wearing usual clothing (i.e. no white coats) measured blood pressure 
in early pregnancy (median 13.9 weeks of gestation [90% range 10.8, 22.5]) and six years after index 
pregnancy (median 6.0 years [90% range, 5.7 to 7.3]), with the validated Omron 907 automated 
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digital oscillometric sphygmomanometer (OMRON Healthcare Europe B.V., Hoofddorp, the 
Netherlands).29 To prevent differences due to position, women sat in a standardized supine 
position with the cuff placed around the right upper arm. In case of an upper arm exceeding 33 
centimeters a larger cuff  (32 – 42 cm) was used. The mean value of two blood pressure readings 
over a five-minute interval was documented for each participant. 
Women with a hypertensive disorder of pregnancy were affected by gestational hypertension 
or preeclampsia during the index pregnancy. Information on doctor diagnosed gestational 
hypertension or preeclampsia was retrieved from hospital charts.30 The diagnosis was 
determined on the basis of the former criteria of 2001 described by the International Society 
for the Study of Hypertension in Pregnancy.31, 32 Gestational hypertension was defined by a 
systolic blood pressure ≥ 140 mmHg or a diastolic blood pressure ≥ 90 mmHg after 20 weeks of 
gestation in previously normotensive women. Preeclampsia was defined as de novo gestational 
hypertension with concurrent new onset proteinuria in a random urine sample with no evidence 
of urinary tract infection.31 We obtained information on chronic hypertension before pregnancy 
from three sources: a questionnaire during pregnancy, information from the original medical 
records and the Dutch obstetric database.30, 33
Maternal anthropometrics 
Maternal height (cm) and weight (kg) without shoes were measured in early pregnancy and body 
mass index (BMI) (kg/m2) was calculated. Identical measurements were obtained during follow-
up six years after index pregnancy. Pre-pregnancy BMI was established at study enrollment 
by questionnaire and was highly correlated with BMI measured in early pregnancy (Pearson’s 
correlation coefficient r 0.95 (P<0.001)) indicating good intra-individual agreement.34 Previous 
research has shown that self-reported BMI of women around the reproductive age is accurate.35
Maternal glucose and plasma lipid levels at follow-up six years after index pregnancy
Non-fasting blood samples were obtained six years after index pregnancy by trained research 
nurses and were temporarily stored at our research center at room temperature. Twice a day, 
these blood samples were transported to a dedicated laboratory facility of the regional laboratory 
in Rotterdam, the Netherlands (STAR-MDC) for further processing and storage at -80 °C. All 
collected EDTA plasma samples were processed within four hours after venous puncture.27 
Between 2013 and 2014 the samples were transferred from the STAR MC laboratory to the 
laboratory of Vascular Medicine of the Erasmus Medical Center Rotterdam. After thawing, the 
following lipids could be analyzed in the EDTA plasma samples: total-cholesterol (mmol/L), 
triglycerides (mmol/L), HDL-c (mmol/L), LDL-c (mmol/L), apoB (g/L) and Lp(a) (g/L). Also, 
plasma glucose (mmol/L) was determined. Samples were analyzed using the Vital Scientific 
(Merck) Selectra E Chemistry Analyzer (Vital Scientific N.V., Dieren, the Netherlands). Details 
of the mean range of the intra-assay and inter-assay precision with the coefficient of variation 
(CV) per lipid are provided in Supplemental Table 1. Remnant cholesterol was calculated as 
(total-cholesterol – LDL-c) – HDL-c and non-HDL-c level as total-cholesterol – HDL-c. 
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TABLE 1 | Subject characteristics by hypertensive disorder of pregnancy n = 4933.
Normotensive 
Pregnancy
n = 4631
Hypertensive 
disorder of 
pregnancy 
n = 302
P-value
Maternal characteristics (pregnancy)
Age at intake, mean (SD), (years) 30.1 (5.1) 30.4 (5.1) 0.74
Gestational age at intake, median (90% range), (weeks) 13.9 (10.9, 22.2) 13.6 (10.5, 22.9) 0.23
Pre-pregnancy BMI, median (90% range), kg/m2) 22.7 (18.7, 31.5) 24.9 (19.8, 38.5) <0.001
   Normal BMI (≥18.5 and < 25.0), n (%) 2790 (73.0) 133 (51.0)
   High BMI (≥25.0), n (%) 1030 (27.0) 128 (49.0)
BMI, median (90% range), (kg) 23.9 (19.6, 32.6) 26.1 (20.3, 39.0) <0.001
SBP at intake, mean (SD), (mmHg) 114.9 (11.7) 123.4 (13.2) <0.001
DBP at intake, mean (SD), (mmHg) 67.4 (8.9) 75.6 (10.3) <0.001
Primigravida, n (%) 2152 (46.7) 198 (65.6) <0.001
Non-European ethnicity, n (%) 1917 (41.4) 94 (31.1) 0.001
Lower educational level, n (%) 555 (12.0) 24 (7.9) 0.06
Smoking, n (%) 1222 (26.4) 83 (27.5) 0.77
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; N, number; SBP, systolic blood pressure. 
Values are numbers with valid percentages for categorical variables, means (SD) for continuous variables with 
a normal distribution, or medians (90% range) for continuous variables with a skewed distribution. Presented 
values are not imputed. Statistical testing was carried out through Student’s  t-test for continuous variables with a 
normal distribution and Kruskal-Wallis test for continuous variables with a skewed distribution. Chi-square tests 
were used for categorical variables.
Covariates
Information on maternal characteristics during pregnancy including maternal age, self-
reported pre-pregnancy weight, gravidity, parity, ethnicity, educational level and smoking was 
available from questionnaires repeatedly applied during pregnancy.  We obtained information 
on gestational age at birth and birth weight from midwifery and obstetric medical records.36, 37 Six 
years after index pregnancy, questionnaires were used to obtain information on cholesterol and 
glucose mediating medication, smoking as well as gravidity and parity at follow-up. The time 
interval between delivery at index pregnancy and the follow-up visit was calculated and referred 
to as time interval. The time of blood sampling during the follow-up visit after pregnancy was 
also documented and used as a covariate.
Statistical analyses
Statistical analyses were performed using the Statistical Package for the Social Sciences version 
21.0 for Windows (SPSS Inc, Chicago, IL, USA) and R version 3.0.0 (R foundation for Statistical 
Computing, Vienna, Austria, packages rmeta and metafor).38 Maternal characteristics during 
pregnancy and follow-up were compared between women with a previous hypertensive disorder 
of pregnancy and women with a previous normotensive index pregnancy. We used Student’s 
t-test to analyze continuous variables with a normal distribution (presented as means with 
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a standard deviation) and the Kruskal-Wallis test for variables with a skewed distribution 
(presented as medians with a 90% confidence interval [CI]). Categorical variables were analyzed 
with Chi-square tests. A P-value  < 0.05 was considered statistically significant. 
The association between a previous hypertensive disorder of pregnancy and lipid and glucose 
levels after pregnancy was assessed through linear and logistic regression analyses. Triglyceride 
levels were log transformed to obtain a normal distribution. Lp(a) could not obtain a normal 
distribution and was therefore analyzed with logistic regression analyses using a cut-off value 
above the 80th percentile. We also created cut-off values for lipid and glucose levels to define 
dyslipidemia and examine whether differences between women with a previous normotensive 
pregnancy and women with a previous gestational hypertensive disorder were driven by extreme 
values. Dyslipidemia was defined as exceeding the cut-off value of at least one of the lipids. The 
90th percentile was used as the cut-off value for total-cholesterol, triglycerides, LDL-c, apoB and 
glucose. For Lp(a) we applied a cut-off value above the 80th percentile and for HDL-c a cut-off 
value below the 10th percentile. Differences were tested using chi-square tests. We repeated 
all linear and logistic regression analyses to test whether results differed between women with 
previous gestational hypertension and preeclampsia (Supplemental Tables 5 and 6). To perform 
regression analyses we selected potential confounders depending on their association with 
the outcome of interest and/or based on previous studies and/or based on a change in effect 
estimate of  more than 10%. The final regression models included the following confounders; 
(1) basic model, adjusted for maternal age at intake, visit interval and time of blood sampling; 
(2) confounder model, which in addition to model (1) included ethnicity, educational level, 
smoking and gravidity at follow-up); (3) BMI model, which in addition to model (2) included pre-
pregnancy BMI. Results of linear and logistic regression analyses are presented as regression 
coefficients (β) and odds ratios (OR) with a 95% CI. A P-value < 0.05 (*) or < 0.001 (**) was 
considered statistically significant. 
For women included in our analyses, missing values of confounders that were used in the three 
regression models were imputed through multiple imputation procedures.39 This procedure 
was carried out by taking five draws for each missing value which provided five complete data 
sets. Each dataset was analyzed separately and results were integrated into one final result 
by computing the mean over the five repeated analysis, including the variance, confidence 
interval and P-value. The following confounders had missing values (for women with a previous 
normotensive pregnancy and women with a previous hypertensive disorder of pregnancy 
respectively): pre-pregnancy BMI (17.5% and 13.6%), ethnicity (2.2% and 0.7%), educational level 
(15.2% and 12.3%), smoking in pregnancy (10.8% and 6.6%), gravidity at follow-up (0.6% and 0%) 
and blood sampling (13.3% and 14.9%). A sensitivity analysis was performed to observe differences 
in observed and expected values of confounders before and after imputation (Supplemental 
Table 4). Lastly, to test for non-response bias we compared subject characteristics between 
women with and without available follow-up data six years after index pregnancy (Supplemental 
Table 2).
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Results
Tables 1 and 2 show maternal characteristics before, during and six years after index pregnancy. 
Compared to women with a previous normotensive pregnancy, women with a hypertensive 
disorder of pregnancy showed a higher BMI both before and after pregnancy and a higher 
systolic and diastolic blood pressure both at study enrollment and after pregnancy. In total, 
0.4% and 0.5% of all women used cholesterol and glucose mediating medication after pregnancy 
respectively. The use of cholesterol and glucose regulating medication was similar between 
women with a previous normotensive pregnancy and women with a previous hypertensive 
disorder of pregnancy.
TABLE 2 |  Subject characteristics by hypertensive disorder of pregnancy six years after pregnancy n = 4933.
Normotensive 
Pregnancy
n = 4631
Hypertensive 
disorder of 
pregnancy
n = 302
P-value
Maternal characteristics (follow-up)
Visit interval, median (90% range), (years) 6.0 (5.7, 7.3) 6.1 (5.7, 7.5) 0.14
Medication use, n (%) 0.19
  Cholesterol mediating medication 18 (0.4) 1 (0.4)
  Glucose mediating medication 22 (0.5) 4 (1.3)
Smoking, n (%) 958 (20.7) 57 (18.9) 0.70
BMI,  median (90% range), (kg/m2) 24.6 (19.7, 35.2) 27.6 (20.6, 43.5) <0.001
SBP, mean (SD), (mmHg) 118.5 (12.1) 128.2 (17.5) <0.001
DBP, mean (SD), (mmHg) 70.4 (9.5) 78.5 (12.2) <0.001
Lipids at follow-up
  Total-cholesterol, mean (SD), (mmol/L) 4.85 (0.89) 4.95 (0.92) 0.08
  Triglycerides, median (90% range), (mmol/L) 1.12 (0.61, 2.48) 1.21 (0.67, 2.48) <0.001
  HDL-c, mean (SD), (mmol/L) 1.37 (0.34) 1.32 (0.33) 0.02
  LDL-c, mean (SD), (mmol/L) 2.64 (0.58) 2.73 (0.61) 0.02
  Non-HDL-c, mean (SD), (mmol/L) 3.48 (0.90) 3.63 (0.95) 0.009
  Remnant cholesterol, mean (SD), (mmol/L) 0.84 (0.49) 0.90 (0.50) 0.06
  Lp(a), median (90% range), (mmol/L) 0.16 (0.0, 2.85) 0.17 (0.0, 1.26) 0.26
  ApoB, mean (SD), (g/L) 0.80 (0.19) 0.83 (0.19) 0.005
  Glucose, mean (SD), (mmol/L) 5.48 (0.98) 5.47 (0.83) 0.82
Abbreviations: ApoB, apolipoprotein B; BMI, body mass index; DBP, diastolic blood pressure; Lp(a), lipoprotein(a); 
N, number; SBP, systolic blood pressure. Values are numbers with valid percentages for categorical variables, 
means (SD) for continuous variables with a normal distribution, or medians (90% range) for continuous variables 
with a skewed distribution. Presented values are not imputed. Statistical testing was carried out through Student’s 
t-test for continuous variables with a normal distribution and Kruskal-Wallis test for continuous variables with a 
skewed distribution. Chi-square tests were used for categorical variables.
The association between a gestational hypertensive disorder, and lipid and glucose levels at 
follow-up is presented in Table 3 and Supplemental Table 3. Six years after index pregnancy, 
women with a previous hypertensive disorder of pregnancy had higher levels of triglycerides, 
LDL-c, non-HDL-c, remnant cholesterol and apoB, and lower levels of HDL-c than women 
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TABLE 3 | Association of gestational hypertensive disorders with lipid profile and glucose six years after index 
pregnancy n = 4933.
Normotensive 
Pregnancy
n = 4631
Hypertensive disorder 
of pregnancy
Beta (95% CI)
n = 302
Total-cholesterol (mmol/L)
Basic model Ref 0.09 (-0.02, 0.20)
Confounder model Ref 0.11 (-0.01, 0.23)
BMI model Ref 0.08 (-0.03, 0.20)
Triglycerides (log, mmol/L)
Basic model Ref 0.09 (0.04, 0.14)**
Confounder model Ref 0.10 (0.04, 0.15)**
BMI model Ref 0.04 (-0.01, 0.10)
HDL-c (mmol/L)
Basic model Ref -0.05 (-0.10, -0.01)*
Confounder model Ref -0.06 (-0.10, -0.02)**
BMI model Ref -0.01 (-0.05, 0.04)
LDL-c (mmol/L)
Basic model Ref 0.08 (0.01, 0.16)*
Confounder model Ref 0.09 (0.01, 0.17)*
BMI model Ref 0.06 (-0.02, 0.14)
Non-HDL-c (mmol/L)
Basic model Ref 0.14 (0.03, 0.26)*
Confounder model Ref 0.17 (0.05, 0.29)**
BMI model Ref 0.09 (-0.03, 0.21)
Remnant cholesterol (mmol/L)
Basic model Ref 0.06 (-0.01, 0.12)
Confounder model Ref 0.08 (0.01, 0.14)*
BMI model Ref 0.02 (-0.04, 0.09)
ApoB (g/L)
Basic model Ref 0.03 (0.01, 0.06)**
Confounder model Ref 0.04 (0.02, 0.07)**
BMI model Ref 0.02 (-0.00, 0.05)
Lp(a) (OR, >p80, >0.84g/L)†
Basic model Ref 1.2 (0.88, 1.6)
Confounder model Ref 1.3 (0.91, 1.7)
BMI model Ref 1.2 (0.86, 1.6)
Glucose (mmol/L)
Basic model Ref -0.02 (-0.14, 0.10)
Confounder model Ref -0.02 (-0.15, 0.11)
BMI model Ref -0.02 (-0.16, 0.11)
Abbreviations: BMI, Body Mass Index, CI; Confidence Interval; OR, Odds Ratio. Values are regression coefficients 
(β with 95% confidence interval) and are based on linear regression models except for Lp(a)† which was based on 
a logistic regression model (OR with 95% confidence interval). Estimates are from multiple imputed data. Basic 
model: Adjusted for maternal age at intake, visit interval and time of blood sampling. Confounder model: basic 
model and additionally adjusted for ethnicity, educational level, smoking and gravidity at follow-up. BMI model: 
Confounder model and additionally adjusted for pre-pregnancy BMI. *P-value < 0.05 **P-value < 0.01.
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with a previous normotensive pregnancy. After additional adjustment for pre-pregnancy 
BMI these results attenuated to non-significant levels. No differences were observed in 
total-cholesterol, Lp(a) and glucose levels. Sensitivity analyses showed that especially women 
with previous gestational hypertension had higher lipid levels after pregnancy than women 
with a previous normotensive pregnancy ([higher levels of triglycerides, LDL-c, non-HDL-c, 
remnant cholesterol and apoB, and lower levels of HDL-c] Supplemental Table 5). Women with 
previous preeclampsia had higher triglyceride levels than women with a previous normotensive 
pregnancy. Results attenuated to non-significant levels after adjustment for pre-pregnancy 
BMI. The prevalence of dyslipidemia, defined as LDL-c levels > 90th percentile, was higher 
among women with previous hypertensive disorder of pregnancy than women with a previous 
normotensive pregnancy (Supplemental Table 3). This result remained significant after adjusting 
for confounders, including pre-pregnancy BMI (OR 1.6; 95% CI 1.1, 2.4, P 0.015 [data not shown]) 
and was most profound in women with previous gestational hypertension (Supplemental Table 
6). Women with previous preeclampsia were more often affected by dyslipidemia resulting from 
triglyceride levels > 90th percentile (Supplemental Table 6).
An additional sensitivity analysis was performed to examine whether values of confounders 
used for linear and logistic regression analyses differed before and after multiple imputation 
(Supplemental Table 4). No major differences were observed. Linear and logistic regression 
analyses showed similar results when confounders were not imputed (data not shown).   
Discussion
The results of this study suggest that women with a previous hypertensive disorder of pregnancy 
have a more atherogenic lipid profile six years after pregnancy than women with a previous 
normotensive pregnancy. The association between hypertensive disorders of pregnancy and 
lipid profile after pregnancy is largely explained by pre-pregnancy BMI. 
The results of this large prospective cohort study show that women with previous hypertensive 
disorder of pregnancy have higher levels of triglycerides, LDL-c, non-HDL-c, remnant 
cholesterol and apoB and lower levels of HDL-c after pregnancy compared to women with a 
previous normotensive pregnancy. Pre-pregnancy BMI largely explained these results as most 
lipid levels attenuated after adjustment for this factor. However, when pre-pregnancy BMI 
was taken into account, women with previous hypertensive disorder of pregnancy still had a 
higher risk of having LDL-c levels above the 90th percentile compared to women with a previous 
normotensive pregnancy. A smaller study, comparing lipid levels 7.8 years after pregnancy 
between women with a previous hypertensive disorder of pregnancy (gestational hypertension 
[n = 105] or preeclampsia [n = 63]) and women with a previous normotensive pregnancy, showed 
results similar to ours without adjusting for pre-pregnancy BMI.15 Women with previous 
gestational hypertension showed higher levels of triglycerides, apoB and glucose, and lower 
levels of HDL-c. Women with previous preeclampsia showed higher levels of LDL-c and apoB 
than women with a previous normotensive pregnancy. In the study concerned, pre-pregnancy 
BMI was not taken in to consideration and might therefore have overestimated their results.15 
Other studies comparing lipid profile and glucose levels between women with only previous 
preeclampsia and women with a previous normotensive pregnancy show no differences within 
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the first 10 years after pregnancy (1.5 to 9.1 years).19, 20, 22 However, after a longer time period 
(up to 16 years after pregnancy), women with previous preeclampsia do seem to have a more 
atherogenic lipid profile, but this is largely driven by BMI.14, 21 These results are in line with our 
findings, suggesting pre-pregnancy BMI is an important factor contributing to an atherogenic 
lipid profile after a pregnancy affected by a hypertensive disorder of pregnancy. 
We observed no differences in total-cholesterol, Lp(a) and glucose levels between women with 
a previous hypertensive disorder of pregnancy and women with a previous normotensive 
pregnancy. Lp(a) is a plasma lipoprotein consisting of an LDL-like particle, apolipoprotein B100 
and apolipoprotein(a).40 The structure of apolipoprotein(a) resembles plasminogen and plasmin 
which can stimulate a prothrombotic effect. The LDL-like particle of Lp(a) contains a high 
concentration of cholesterol which can induce atherogenesis through deposition of cholesterol 
in the arterial vessel wall.41 Both characteristics increase the risk of CVD substantially.42 In our 
study, no differences were observed in Lp(a) levels between women with a previous hypertensive 
disorder of pregnancy and women with a previous normotensive pregnancy. As Lp(a) is to a 
large extent genetically determined, one could hypothesize that lipid levels after pregnancy in 
women with previous hypertensive disorder of pregnancy might be less genetically determined 
and more through environmental factors such as BMI. This hypothesis supports our findings of 
pre-pregnancy BMI attenuating most lipid levels after pregnancy to non-significant levels.
Additional analyses showed that our results were stronger in women with previous gestational 
hypertension than in women with previous preeclampsia. This might result from a greater 
constitutional cardiovascular burden at the start of pregnancy (higher pre-pregnancy BMI 
and higher blood pressure at study enrollment) in women with gestational hypertension than 
in women with preeclampsia (Table 1). These constitutional risk factors are likely to remain 
after pregnancy which increases the risk of developing an atherogenic lipid profile. Women 
with preeclampsia also exhibit a greater constitutional cardiovascular burden at the start of 
pregnancy but less than women with gestational hypertension. This might explain why women 
with previous gestational hypertension have a more atherogenic lipid profile after pregnancy 
than women with previous preeclamspia. 
There is an established association between gestational hypertensive disorders and the risk 
for CVD in later life.6, 43 Depending on the type and the severity of the hypertensive disorder 
of pregnancy, the occurrence of CVD can be seven times larger compared to women with a 
previous normotensive pregnancy.43 Currently, there are several guidelines in practice for the 
prevention of CVD after a hypertensive disorder of pregnancy.23, 24, 44 Nevertheless, it remains 
controversial whether to assess a woman’s lipid profile after a hypertensive disorder of pregnancy 
and a uniform recommendation of these clinical guidelines is not available. The guideline of 
the American Heart Association (AHA) for the prevention of stroke in women, as well as the 
NICE and ACOG guidelines on the management of hypertensive disorders during pregnancy 
advise to perform annual measurement of a lipid profile and glucose level after a hypertensive 
disorder of pregnancy.23, 24, 44 Contrarily, the guidelines of the ESC on CVD prevention and of 
the AHA on the prevention of CVD in women do not address lipid profile assessment after a 
hypertensive disorder of pregnancy, although the former does recommend periodic screening 
for hypertension and diabetes in these women.45, 46
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The association between an atherogenic lipid profile and the risk of future CVD is evident within 
the general population.47, 48 Nevertheless, results from similar studies on women with a previous 
hypertensive disorder of pregnancy remain inconsistent, possibly due to a variety in study 
methodology. The most important methodological differences are: the time interval between 
pregnancy and lipid profile assessment (varying between 0.5 to 16 years),10, 14, 15, 17, 19-21 incomplete 
lipid profile assessment,10, 14, 17, 19-21 differences in statistical models to adjust for confounding14, 20 
and differences in the definition of gestational hypertensive disorders.10, 21
Interestingly, our study shows that differences in lipid profile between women with a previous 
normotensive pregnancy and women with previous gestational hypertensive disorders are 
most likely the result of a higher pre-pregnancy BMI in the latter. BMI and blood pressure are 
important constitutional risk factors for developing a hypertensive disorder of pregnancy as well 
as developing future CVD.49
Lipid profile assessment after a hypertensive disorder of pregnancy, especially in overweight 
women,  might help to identify those women at risk for CVD. Based on our results we foremost 
suggest to encourage women to achieve a healthy weight status before pregnancy as pre-
pregnancy weight is strongly associated with an atherogenic lipid profile after pregnancy and 
with an increased risk of developing a hypertensive disorder of pregnancy.49
The main strengths of our study are the prospective data collection from early pregnancy 
onwards until six years after index pregnancy, the large sample size of 4933 participants, the 
detailed analysis of lipid profiles and the wide variety of included ethnicities, which gives a good 
representation of the general population. Given the prospective nature of this study, information 
on microalbuminuria or other markers of kidney injury might have been interesting to examine. 
Unfortunately, this data was not available within our study. An important issue that might 
have affected the generalizability of our results is the selection of a relatively healthy population 
(Supplemental Table 2). Women without postnatal follow-up information were on average younger 
and more often of non-European descent. These women tended to have a lower pre-pregnancy 
BMI and lower education, they smoked more often and suffered more often from preeclampsia. 
A second is that, due to unavailability of pre-pregnancy data on glucose and lipid levels (as is also 
the case in most other studies focusing on pregnant women and lipid profile after pregnancy), we 
cannot exclude the possibility that changes in glucose levels and lipid profile preceded the onset 
of the hypertensive disorder of pregnancy. A third issue is that we did not obtain lipid and glucose 
levels in the fasting state, which might have introduced a random measurement error. Finally, the 
observational nature of this study does not allow for inference of causality. 
Conclusion
Women with a previous hypertensive disorder of pregnancy have a more atherogenic lipid 
profile six years after pregnancy than women with a previous normotensive pregnancy. This is 
more likely resulting from a higher pre-pregnancy BMI than from the hypertensive disorder of 
pregnancy itself. Weight counseling before the onset of pregnancy might therefore be beneficial 
in reducing the risk of developing an atherogenic lipid profile after pregnancy and possibly CVD 
in later life.50 
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Supplemental material
SUPPLEMENTAL TABLE 1 | Mean range of the intra-assay precision with the coefficient of variation (CV) per 
lipid.
Mean range of the intra-assay precision Coefficient of variation
Triglycerides 55-448 < 0.80%
Apolipoprotein B 24.2-156 < 2.63%
Total-cholesterol 108-254 < 1.62%
Glucose 4.4-188 < 3.78%
HDL-c 0.204-1.25 < 0.82%
LDL-c 101-164 < 0.67%
Lipoprotein(a) 26.9-52.3 < 2%
Mean range of the inter-assay precision Coefficient of variation
Triglycerides 90-238 < 1.48%
Apolipoprotein B 25.4-158 < 2.89%
Total-cholesterol 104-245 < 1.22%
Glucose 86.6-248 < 1.88%
HDL-c 0.44 < 1.88%
LDL-c 108-135 < 1.45%
Lipoprotein(a) 26.2-52.2 < 3.06%
SUPPLEMENTAL TABLE 2 |  Subject characteristics between women with follow-up visit six years after pregnancy 
and women without follow-up visit (n = 8198).
Maternal characteristics Follow-up six years     
after index pregnancy
n = 5439
Loss to follow-up
n = 2759
P-value
Age at intake (years) 30.2 (5.1) 28.2 (5.5) <0.001
Gestational age at intake (weeks) 13.9 (10.8, 22.6) 14.5 (10.8, 23.8) <0.001
Pre-pregnancy BMI (kg/m2) 22.9 (18.9, 32.6) 22.6 (18.2, 33.1) 0.02
SBP at intake (mmHg) 115.7 (12.3) 114.7 (12.4) 0.001
DBP at intake (mmHg) 68.2 (9.5) 67.5 (9.8) 0.002
Primigravida, n (%) 2338 (43.0) 1332 (48.3) <0.001
Non-European ethnicity, n (%) 2192 (40.3) 1454 (52.7) <0.001
Lower educational level, n (%) 533 (9.8) 455 (16.5) <0.001
Smoking, n (%) 1446 (26.6) 849 (30.8) <0.001
Gestational hypertension, n (%) 239 (4.4) 85 (3.1) 0.009
Preeclampsia, n (%) 114 (2.1) 80 (2.9) 0.04
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure.
Values are numbers with valid percentages for categorical variables, means (SD) for continuous variables with a 
normal distribution, or medians (90% range) for continuous variables with a skewed distribution. Statistical testing 
was carried out through Student’s t-test for continuous variables with a normal distribution and Kruskal-Wallis 
test for continuous variables with a skewed distribution. Chi-square tests were used for categorical variables.
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SUPPLEMENTAL TABLE 3 | Maternal glucose and lipid profile six years after pregnancy (n = 4933).
Outcomes Normotensive 
Pregnancy
n = 4631
Hypertensive 
disorder of 
pregnancy
n = 302
P-value
Total-cholesterol  > 90th percentile, n (%) 397 (9.9) 29 (11.3) 0.47
Triglycerides > 90th percentile, n (%) 397 (9.9) 29 (11.3) 0.47
HDL-c  < 10th percentile, n (%) 399 (10.0) 27 (10.5) 0.76
LDL-c  > 90th percentile, n (%) 387 (9.7) 39 (15.2) 0.004
Non-HDL-c  > 90th percentile, n (%) 391 (9.8) 34 (13.3) 0.07
Remnant cholesterol  > 90th percentile, n (%) 394 (9.8) 31 (12.1) 0.24
Lp(a) > 80th percentile, n (%) 837 (21.2) 61 (24.3) 0.24
ApoB  > 90th percentile, n (%) 394 (9.8) 32 (12.5) 0.17
Glucose  > 90th percentile, n (%) 404 (10.1) 22 (8.6) 0.43
Abbreviations: ApoB, apolipoprotein B; Lp(a), lipoprotein(a). Values are numbers with percentages and are not 
imputed. Statistical testing was carried out through chi-square tests.
SUPPLEMENTAL TABLE 4 | Observed and expected values for confounders.
Normotensive 
Pregnancy
n = 4631
Hypertensive disorder 
of pregnancy
n = 302
Observed Expected Observed Expected
Maternal characteristics (pregnancy)
Age at intake, mean (SD), (years) 30.1 (5.1) 30.1 (5.1) 30.4 (5.1) 30.4 (5.1)
Pre-pregnancy BMI, median (90% range), 
(kg/m2)
22.7 
(18.8, 31.6)
22.8 
(18.8, 31.7)
24.9 
(19.8, 38.5)
24.8 
(19.8, 38.1)
   Normal BMI (≥18.5 and < 25.0), n (%) 2790 (60.2) 3331 (71.9) 133(44.0) 154 (51.0)
   High BMI (≥25.0), n (%) 1030 (22.2) 1300 (28.1) 128 (42.4) 148 (49.0)
Non-European ethnicity, n (%) 1828 (39.5) 1919 (41.4) 92 (30.5) 94 (31.1)
Lower educational level, n (%) 417 (9.0) 555 (12.0) 19 (6.3) 24 (7.9)
Smoking, n (%) 1095 (23.6) 1213 (26.2) 77 (25.5) 85 (28.1)
Primigravid, n (%) 318 (6.9) 406 (8.8) 41 (17.6) 48 (15.9)
Maternal characteristics (follow-up)
Visit interval, median (90% range), (years) 6.0 (5.7, 7.3) 6.0 (5.7, 7.3) 6.1 (5.7, 7.5) 6.1 (5.7, 7.5)
Blood sampling before 10:00 h, n (%) 1129 (24.4) 1272 (27.5) 71 (23.5) 81 (26.8)
Abbreviations: BMI, body mass index; N, number. Values are numbers with percentages for categorical variables, 
means (SD) for continuous variables with a normal distribution, or medians (90% range) for continuous variables 
with a skewed distribution. 
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SUPPLEMENTAL TABLE 5 | Association of gestational hypertensive disorders with lipid profile and glucose six 
years after index pregnancy (n = 4933).
Normotensive 
Pregnancy
n = 4631
Gestational 
hypertension
Beta (95% CI)
n = 207
Preeclampsia
Beta (95% CI)
n = 95
Total-cholesterol (mmol/L)
Basic model Ref 0.11 (-0.02, 0.24) 0.04 (-0.16, 0.24)
Confounder model Ref 0.15 (0.01, 0.28)* 0.03 (-0.18, 0.24)
BMI model Ref 0.11 (-0.03, 0.25) 0.02 (-0.20, 0.23)
Triglycerides (log, mmol/L)
Basic model Ref 0.08 (0.02, 0.14)* 0.12 (0.02, 0.21)*
Confounder model Ref 0.09 (0.02, 0.16)** 0.11 (0.01, 0.22)*
BMI model Ref 0.03 (-0.04, 0.09) 0.08 (-0.02, 0.18)
HDL-c (mmol/L)
Basic model Ref -0.05 (-0.10, -0.004)* -0.05 (-0.13, 0.03)
Confounder model Ref -0.07 (-0.12, -0.01)* -0.05 (-0.13, 0.03)
BMI model Ref -0.00 (-0.05, 0.05) -0.02 (-0.09, 0.06)
LDL-c (mmol/L)
Basic model Ref 0.11 (0.02, 0.19)* 0.04 (-0.09, 0.17)
Confounder model Ref 0.12 (0.03, 0.21)* 0.02 (-0.12, 0.16)
BMI model Ref 0.09 (-0.01. 0.18) 0.00 (-0.14, 0.14)
Non-HDL-c (mmol/L)
Basic model Ref 0.17 (0.03, 0.30)* 0.09 (-0.11, 0.29)
Confounder model Ref 0.21 (0.07, 0.35)** 0.08 (-0.14, 0.29)
BMI model Ref 0.11 (-0.03, 0.25) 0.03 (-0.18, 0.24)
Remnant cholesterol (mmol/L)
Basic model Ref 0.06 (-0.02, 0.13) 0.05 (-0.06, 0.16)
Confounder model Ref 0.08 (0.01, 0.16)* 0.06 (-0.06, 0.18)
BMI model Ref 0.02 (-0.05, 0.10) 0.03 (-0.09, 0.15)
ApoB (g/L)
Basic model Ref 0.04 (0.01, 0.07)** 0.02 (-0.02, 0.06)
Confounder model Ref 0.05 (0.02, 0.08)** 0.02 (-0.03, 0.06)
BMI model Ref 0.03 (0.00, 0.06) 0.01 (-0.04, 0.05)
Lp(a) (OR, >p80, >0.84g/L)†
Basic model Ref 1.2 (0.84, 1.7) 1.2 (0.68, 2.0)
Confounder model Ref 1.3 (0.91, 1.9) 1.1 (0.59, 2.0)
BMI model Ref 1.2 (0.86, 1.8) 1.1 (0.57, 1.9)
Glucose (mmol/L)
Basic model Ref -0.06 (-0.21, 0.08) 0.07 (-0.15, 0.29)
Confounder model Ref -0.07 (-0.23, 0.09) 0.10 (-0.15, 0.34)
BMI model Ref -0.07 (-0.23, 0.09) 0.09 (-0.15, 0.33)
Abbreviations: BMI, Body Mass Index, CI; Confidence Interval; OR, Odds Ratio. Values are regression coefficients 
(β with 95% confidence interval) and are based on linear regression models except for Lp(a)† which was based on 
a logistic regression model (OR with 95% confidence interval). Estimates are from multiple imputed data. Basic 
model: Adjusted for maternal age at intake, visit interval and time of blood sampling. Confounder model: basic 
model and additionally adjusted for ethnicity, educational level, smoking and gravidity at follow-up. BMI model: 
Confounder model and additionally adjusted for pre-pregnancy BMI. *P-value < 0.05 **P-value < 0.01.
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SUPPLEMENTAL TABLE 6 | Maternal glucose and lipid profile six years after pregnancy (n = 4933).
Normotensive 
Pregnancy
n = 4631
Gestational 
hypertension 
n = 207
Preeclampsia
 
n = 95
P-value
Total-cholesterol  > 90th percentile, n (%) 397 (9.9) 22 (12.2) 7 (9.1) 0.58
Triglycerides > 90th percentile, n (%) 397 (9.9)B 15 (8.3) 14 (18.2) 0.04
HDL-c  < 10th percentile, n (%) 399 (10.0) 18 (10.1) 9 (11.7) 0.88
LDL-c  > 90th percentile, n (%) 387 (9.7)A 29 (16.1) 10 (13.0) 0.01
Non-HDL-c  > 90th percentile, n (%) 391 (9.8) 27 (15.1) 7 (9.1) 0.07
Remnant cholesterol  > 90th percentile, n (%) 394 (9.8) 20 (11.2) 11 (14.3) 0.38
Lp(a) > 80th percentile, n (%) 837 (21.2) 43 (24.4) 18 (24.0) 0.50
ApoB  > 90th percentile, n (%) 394 (9.8) 24 (13.4) 8 (10.4) 0.30
Glucose  > 90th percentile, n (%) 404 (10.1) 14 (7.8) 8 (10.4) 0.60
Abbreviations: ApoB, apolipoprotein B; Lp(a), lipoprotein(a); N, number. Values are numbers with percentages. 
Statistical testing was carried out through one-way ANOVA and chi-square tests. A: Significant (P-value < 0.05) 
differences in distribution between women with gestational hypertension and women with a normotensive 
pregnancy. B: Significant (P-value < 0.05) differences in distribution between women with preeclampsia and 
women with a normotensive pregnancy.
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Abstract
Background: Cardiovascular risk factors can track from mother to child via several pathways: 
pregnancy complications, genetic inheritance and shared environmental risk factors after 
pregnancy. The degree of tracking and to which extend this is influenced by these pathways is 
unknown. We hypothesized that cardiovascular risk factors track from mother to child regardless 
of pregnancy complications and environmental risk factors. We determined the degree of 
tracking between maternal and offspring micro- and macrovascular cardiovascular risk factors 
after pregnancy and the extent to which this is influenced by pregnancy complications and 
shared environmental risk factors.
Methods: We included 5624 mother-offspring pairs from The Generation R Study; an 
ongoing prospective population-based birth cohort. Information on pregnancy complications 
(preeclampsia, small for gestational age and preterm birth) was obtained through hospital 
charts. Mother-offspring associations were assessed six years after pregnancy (central retinal 
arteriolar and venular calibers, body mass index, blood pressure, left atrial diameter, aortic root 
diameter, left ventricular mass, fractional shortening and pulse wave velocity) and nine years 
after pregnancy (body mass index and blood pressure). 
Results: We observed that worse cardiovascular parameters in mothers were associated 
with worse cardiovascular parameters in their offspring six and nine years after pregnancy 
(P-values <.001). Results were similar when mother-offspring pairs with a previous pregnancy 
complication were excluded.
Conclusions: Six and nine years after pregnancy, an adverse cardiovascular profile in mothers 
is strongly associated with an adverse cardiovascular profile in their offspring. Results were not 
attenuated by environmental exposures or a previous pregnancy complication. This supports 
the hypothesis that cardiovascular risk factors (micro- and macrovascular) track from mother to 
child, regardless off the course of pregnancy. 
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Introduction
Cardiovascular disease is the leading cause of morbidity and mortality worldwide.1 The 
prevalence of cardiovascular risk factors (e.g. obesity, hypertension and an atherogenic lipid 
profile) is not only rising among adults but also among children. Cardiovascular risk factors are 
most likely transmitted from parents to their offspring, which can be explained through three 
potential mechanisms; pregnancy complications, genetic inheritance and shared environmental 
risk factors after pregnancy. The degree to which cardiovascular risk factors track from mother 
to child and the extent to which this is influenced by pregnancy complications and shared 
environmental risk factors after pregnancy is still unknown. Unraveling these mechanisms may 
assist us in identifying at an early stage children at risk for cardiovascular disease later in life. 
The first mechanism involves  pregnancy complications, such as preeclampsia, which require 
adaptation in order for the fetus to survive to a stressful environment. This process can affect 
perinatal health as it is associated with a low birth weight and preterm birth, which themselves 
are risk factors for the development of cardiovascular risk factors during adolescence such 
as obesity and hypertension.2 Secondly, environmental exposures (e.g. diet, exposure to 
smoking and physical activity) may be involved. These are often similar between parents and 
their offspring until they enter adulthood. Previous studies show that parents’ diet and energy 
intake, smoking behavior and physical activity  levels are positively associated with those of 
their offspring.3-7 Thirdly, heritability studies have identified genetic factors as a determinant 
for certain cardiovascular risk factors such as body mass index (BMI) level.8, 9 Obtaining better 
insight in the degree of tracking and the most important mechanisms involved will help to 
predict and reduce future cardiovascular disease in offspring. In this study, we hypothesized 
that cardiovascular risk factors track from mother to child regardless of pregnancy complications 
and environmental risk factors. We determined the degree of tracking between maternal and 
offspring microvascular (central retinal and arteriolar calibers) and macrovascular (blood 
pressure, left atrial diameter, aortic root diameter, left ventricular mass, fractional shortening 
and pulse wave velocity) cardiovascular risk factors after pregnancy and the extent to which this 
is influenced by pregnancy complications and shared environmental risk factors. 
Materials and methods
Design and Study Population
This study was embedded in The Generation R Study, a multi-ethnic population-based 
prospective cohort study from early pregnancy onwards in Rotterdam, the Netherlands.10, 11 
Mothers (N=8976) enrolled during pregnancy between April 2002 and January 2006. The response 
rate at baseline was 61% and 85% six years after pregnancy. The study has been approved by 
the Medical Ethics Committee of Erasmus Medical Center, Rotterdam, the Netherlands (MEC 
198.782/2001/31) and the procedures followed were in accordance with institutional guidelines.12 
Written informed consent was obtained from all participants. For the present study, we included 
mother-offspring pairs with at least one measurement of interest available six or nine years after 
pregnancy (N = 5624 [Figure 1]). Supplemental Figure 1 presents an overview of our exposures, 
outcomes and covariates.
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N = 8976 
Women enrolled during pregnancy.  
n = 5743 
Population for analysis: women with singleton live born pregnancies. 
Outcomes available in children: 
 
- Central retinal arteriolar and venular calibers n = 2561 
- Systolic and diastolic blood pressure 6 years  n = 4875 
after pregnancy 
- Body mass index 6 years after pregnancy  n = 4929 
- Left atrial diameter     n = 4939 
- Aortic root diameter     n = 4958 
- Left ventricular mass     n = 4739 
- Fractional shortening     n = 4898 
- Pulse wave velocity     n = 3531 
- Systolic and diastolic blood pressure 9 years n = 4266 
after pregnancy 
- Body mass index 9 years after pregnancy  n = 4479 
n = 343 
Twins, abortions and fetal death. 
 
n = 2364 
Women loss to follow-up after pregnancy.  
 
n = 526 
Siblings. 
FIGURE 1 | Flowchart.
Pregnancy complications
The presence of a pregnancy complication (preeclampsia, a small for gestational age child or 
spontaneous preterm birth) was determined from the original hospital charts. Preeclampsia 
was defined as a systolic blood pressure ≥ 140 mmHg or a diastolic blood pressure ≥ 90 mmHg 
after 20 weeks of gestation in previously normotensive women with concurrent new onset 
proteinuria in a random urine sample and no evidence of a urinary tract infection.13, 14 Small for 
gestational age was defined as a birth weight under the 10th percentile (based on our own cohort) 
and spontaneous preterm birth as the spontaneous onset of labor before 37 weeks of gestation.15
Environmental exposures and covariates
At study enrollment maternal height (cm) and weight (kg) without shoes were measured after 
which BMI (kg/m2) was calculated. Identical measurements were obtained during follow-up six 
and nine years after pregnancy for both mother and child. Pre-pregnancy BMI was established 
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at enrollment through a questionnaire. Pre-pregnancy BMI was strongly correlated with BMI 
measured in early pregnancy (Pearson’s correlation coefficient r = 0.95 (P<0.001)).16 
Questionnaires were repeatedly applied during pregnancy to obtain information on maternal 
age, pre-pregnancy weight, gravidity, ethnicity, educational level, smoking and folic acid intake. 
Information on gestational age at birth, birth weight and child’s sex was obtained from medical 
records.15, 17 Six years after index pregnancy we obtained information on gravidity at follow-up 
and smoking through questionnaires.
Cardiovascular measurements six years after pregnancy
Central retinal arteriolar and venular calibers were assessed in mothers and offspring by 
taking digital retinal photographs six years after index pregnancy. Details of this procedure are 
described previously.18-20
Research assistants in non-medical clothing (i.e. no white coat) measured blood pressure 
during study enrollment (median 13.2 weeks of gestation [90% range 10.6, 17.0]) and six 
years after pregnancy (90% range, 5.7 to 7.4 years) with the validated Omron 907 automated 
digital oscillometric sphygmomanometer (OMRON Healthcare Europe B.V., Hoofddorp, the 
Netherlands).21 Blood pressure was measured in the right upper arm and in a standardized 
supine position to prevent differences due to position. The mean value of two systolic and 
diastolic blood pressure readings (SBP and DBP) was documented for each participant. 
Carotid-femoral pulse wave velocity (PWV) was measured with an automatic non-invasive, 
validated device (Complior®; Artech Medical, Pantin, France) to assess arterial wall stiffness. The 
device measures the distance between the recording sites at the carotid (proximal) and femoral 
(distal) artery. Echocardiographic measurements were performed in two-dimensional M-mode 
using the ATL-Philips Model HDI 5000 (Seattle, WA, USA) or the Logiq E9 (GE Medical Systems, 
Wauwatosa, WI, USA) devices. Fractional shortening , aortic root diameter and left atrial 
diameter were measured. Left ventricular mass was calculated with the Devereux equation.22 
Intraobserver and interobserver intraclass correlation coefficients were described previously 
and demonstrated good repeatability and reproducibility.23
Blood pressure nine years after pregnancy
The validated automatic sphygmomanometer Datascope Accutorr Plus (Paramus, NJ, USA) was 
used to measure blood pressure in mothers and children 9.8 years after pregnancy (90% range 
9.5, 10.3 years).24 The average of the last three (out of four) blood pressure measurements was 
used for further analyses.
Statistical analyses
Baseline characteristics are presented in Table 1. The mean ± standard deviation is presented 
for data with a normal distribution and the median with 90% confidence interval for data with 
a skewed distribution. In the total population for analysis 17.7% had missing information on 
pre-pregnancy BMI, 6.9% on education, 11.0% on smoking during pregnancy, 24.1% on folic 
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acid intake during pregnancy, 1.0% on maternal systolic blood pressure at study intake, 2.5% 
on child’s ethnicity, 13.3% and 9.0% on child’s systolic and diastolic blood pressure six years 
after pregnancy, 5.4% on child’s BMI after pregnancy. To reduce potential bias associated with 
missing data we imputed missing values in variables of interest through multiple imputation.25 
Complete case analysis showed similar results to those presented in Table 2 and Table 3 (data not 
shown). Multivariate linear regression analysis was used to examine the association between 
mother-offspring cardiovascular risk factors after pregnancy (Table 2 and 3) while adjusting for 
confounders. Regression models adjusted for confounding were: basic model (including maternal 
age at enrollment and child’s age during follow-up) and four confounder models (including pre-
pregnancy BMI, maternal age at enrollment, maternal SBP at study enrollment, educational 
level mother, smoking during pregnancy, folic acid intake during pregnancy, child’s sex, child’s 
ethnicity, child’s age [six and nine years after pregnancy], child’s weight and height [six and nine 
years after pregnancy], and mean SBP and DBP six years after pregnancy). These confounders 
were selected based on their associations with the exposures and outcomes of interest and based 
on previous studies. The effect estimates in Table 2 and 3 are unstandardized beta coefficients 
and represent an increase in the outcome measure for each unit increase in the exposure. We 
applied a Benjamin-Hochberg procedure controlling for false discovery rate at 0.05 level.26 We 
tested whether there was effect modification in all mother-offspring associations by pregnancy 
complications through inclusion of the interaction term (exposure * pregnancy complication yes) 
in each regression model. To estimate the proportion of total variance in offspring attributable 
to variation in genotypes we calculated unadjusted heritability (h2, expressed as percentage) 
through regression of offspring phenotype on the maternal phenotype.27 Estimates are presented 
in the results section. Lastly, we examined baseline characteristics between women included 
and excluded from this study (Supplemental Table 1). Statistical analyses were performed with 
SPSS version 21.0 for Windows (SPSS Inc, Chicago, IL, USA). 
Results
This study included 5624 mother-offspring pairs (Figure 1). Mothers were on average 30.3 (SD 
5.1) years of age at the start of pregnancy (Table 1). They were mostly European, highly educated 
and nulliparous. In total, 15.3% of pregnancies were affected by a pregnancy complication.
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TABLE 1 | Baseline characteristics n = 5743.
Pregnancy
Age at enrollment (years), mean (SD) 30.1 (5.1)
Non-European ethnicity (%) 42.1
No education/primary school (%) 11.7
Pre-pregnancy BMI (kg/m2), median (5th, 95th percentile) 22.7 (18.7, 32.3)
Lean and normal (%) 71.2
Overweight (%) 20.3
Obese and morbidly obese (%) 8.5
SBP at enrollment (mmHg), mean (SD) 115.6 (12.1)
DBP at enrollment (mmHg), mean (SD) 68.1 (9.5)
Smoking (%) 27.1
Nulliparous (%) 60.1
No folic acid intake, (%) 28.3
Diabetes (%) 0.4
Gestational diabetes (%) 1.1
Pregnancy outcomes
Spontaneous preterm birth, (%) 3.6
Small for gestational age (< p10), (%) 9.9
Preeclampsia (%) 2.1
Gestational hypertension (%) 4.2
Boys (%) 49.6
Non-European ethnicity child (%) 39.0
Maternal outcomes six years after pregnancy
Follow-up interval (years), median (5th, 95th percentile) 6.0 (5.7, 7.4)
BMI (kg/m2), median (5th, 95th percentile) 24.8 (19.7, 36.0)
SBP (mmHg), mean (SD) 119.3 (13.0)
DBP (mmHg), mean (SD) 71.0 (10.1)
Cardiovascular medication  (%) 2.1
Central retinal arteriolar caliber (µm), mean (SD) 145.3 (16.9)
Central retinal venular caliber (µm), mean (SD) 206.8 (22.5)
Smoking (%) 20.0
Primigravid (%)‡ 8.5
Child outcomes six years after pregnancy
BMI (kg/m2), median (5th, 95th percentile) 15.9 (13.9, 19.8)
SBP (mmHg), mean (SD) 103.0 (8.3)
DBP (mmHg), mean (SD) 62.0 (8.6)
Central retinal arteriolar caliber (µm), mean (SD) 158.8 (14.9)
Central retinal venular caliber (µm), mean (SD) 218.8 (19.9)
Outcomes nine years after pregnancy
BMI mother (kg/m2), median (5th, 95th percentile) 24.8 (20.0, 36.2)
SBP mother (mmHg), mean (SD) 114.6 (12.8)
DBP mother (mmHg), mean (SD) 68.6 (8.2)
Cardiovascular medication  (%) 2.4
SBP child (mmHg), mean (SD) 103.2 (8.0)
DBP child (mmHg), mean (SD) 58.6 (6.4)
BMI child (kg/m2), median (5th, 95th percentile) 17.0 (14.4, 23.3)
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Abbreviations: Body mass index, BMI; Central retinal arteriolar caliber, Diastolic blood pressure, DBP; Systolic 
blood pressure, SBP. Values are percentages for categorical variables, means (SD) for continuous variables with a 
normal distribution, or medians (5th, 95th percentile) for continuous variables with a skewed distribution. ‡ Up until 
follow-up visit pregnancy had occurred no more than once.
Table 2 and Table 3 show the association between mother-offspring cardiovascular risk factors 
six and nine years after pregnancy for the total population and for mother-offspring pairs 
without a pregnancy complication during the index pregnancy. Maternal microvasculature 
(central retinal arteriolar and venular calibers), BMI, blood pressure (SBP and DBP), cardiac 
measurements (left atrial diameter, aortic root diameter, left ventricular mass and fractional 
shortening ) and PWV are all positively associated with the corresponding measurements in 
offspring. Results did not change after environmental factors (confounders) were taken into 
consideration nor after excluding mother-offspring pairs affected by a pregnancy complication 
(Table 3 and Supplemental Figure 2) or when we corrected for multiple testing. Also, effect 
modification analysis showed no significant interaction in all mother-offspring associations by 
pregnancy complications (data not shown).
TABLE 2 | The association between mother-offspring cardiovascular risk factors six and nine years after pregnancy 
n = 5743.
Outcomes 
child
Exposures 
mother
Basic 
model
P-value Confounder 
model
P-value
Beta (95%CI) Beta (95%CI)
Six years after pregnancy
Microvasculature
Central retinal arteriolar 
caliber (SDS) 
Central retinal arteriolar 
caliber (n = 2561)
0.12 (0.08, 0.16) <0.001 0.11 (0.07, 0.14)* <0.001
Central retinal venular 
caliber (SDS) 
Central retinal venular
caliber (n = 2561)
0.18 (0.14, 0.22) <0.001 0.19 (0.15, 0.22)* <0.001
BMI (kg/m2) BMI (n = 4929) 0.11 (0.10, 0.12) <0.001 0.10 (0.09, 0.11) † <0.001
Blood pressure
SBP (mmHg) SBP (n = 4875) 0.11 (0.09, 0.13) <0.001 0.08 (0.06, 0.10)† <0.001
DBP (mmHg) DBP (n = 4875) 0.10 (0.08, 0.12) <0.001 0.08 (0.06, 0.10)† <0.001
Cardiac measurements
Left atrial diameter 
(mm) 
Left atrial diameter 
(n = 4939)
0.14 (0.12, 0.16) <0.001 0.13 (0.11, 0.15)‡ <0.001
Aortic root diameter 
(mm) 
Aortic root diameter 
(n = 4958) 
0.16 (0.14, 0.17) <0.001 0.13 (0.12, 0.15)‡ <0.001
Left ventricular mass 
(g) 
Left ventricular mass 
(n = 4739)
0.12 (0.11, 0.13) <0.001 0.10 (0.09, 0.11)‡ <0.001
Fractional shortening 
(%) 
Fractional shortening 
(n = 4898)
0.14 (0.12, 0.17) <0.001 0.14 (0.12, 0.17)‡ <0.001
PWV (m/s) PWV (n = 3531) 0.18 (0.15, 0.21) <0.001 0.17 (0.14, 0.20)‡ <0.001
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Outcomes 
child
Exposures 
mother
Basic 
model
P-value Confounder 
model
P-value
Beta (95%CI) Beta (95%CI)
Nine years after pregnancy
BMI (kg/m2) BMI (n = 4479) 0.19 (0.18, 0.21) <0.001 0.16 (0.14, 0.17) § <0.001
SBP (mmHg) SBP (n = 4266) 0.11 (0.09, 0.13) <0.001 0.06 (0.04, 0.08)§ <0.001
DBP (mmHg) DBP (n = 4266) 0.12 (0.10, 0.14) <0.001 0.10 (0.07, 0.12)§ <0.001
Abbreviations: Body mass index, BMI; Confidence Interval, CI; Diastolic blood pressure, DBP; Pulse wave velocity, 
PWV; Standard Deviation Score, SDS; Systolic blood pressure, SBP. Values are betas with corresponding 95% CI 
and represent the mean difference in children per unit increase in maternal parameter.
Basic model: Age mother at intake and age child during follow-up.
*Confounder model: In addition to the basic model: Educational level mother at intake, ethnicity child, smoking 
during pregnancy, mean systolic blood pressure child six years after pregnancy and maternal systolic blood 
pressure during study intake.
†Confounder model: In addition to the basic model: Educational level mother at intake, ethnicity child, maternal 
systolic blood pressure during study intake, child’s sex, child’s weight and height six years after pregnancy.
‡Confounder model: In addition to the basic model: Educational level mother at intake, ethnicity child, maternal 
smoking during pregnancy, folic acid intake during pregnancy, pre-pregnancy BMI, child’s weight and height and 
diastolic blood pressure six years after pregnancy.
§Confounder model: In addition to the basic model: Educational level mother at intake, ethnicity child, maternal 
systolic blood pressure during study intake, child’s sex, child’s weight and height nine years after pregnancy.
TABLE 3 | The association between mother-offspring cardiovascular risk factors six and nine years after pregnancy 
in women without a pregnancy complication during the index pregnancy n = 4536.
Outcomes 
child
Exposures 
mother
Basic 
model
P-value Confounder 
model
P-value
Beta (95%CI) Beta (95%CI)
Six years after pregnancy
Microvasculature
Central retinal arteriolar 
caliber (SDS) 
Central retinal arteriolar 
caliber (n = 2044)
0.12 (0.08, 0.16) <0.001 0.11 (0.07, 0.16)* <0.001
Central retinal venular 
caliber (SDS) 
Central retinal venular 
caliber (n = 2044)
0.18 (0.14, 0.23) <0.001 0.19 (0.14, 0.23)* <0.001
BMI (kg/m2) BMI (n = 3899) 0.12 (0.10, 0.13) <0.001 0.10 (0.09, 0.11) † <0.001
Blood pressure
SBP (mmHg) SBP (n = 3865) 0.12 (0.09, 0.14) <0.001 0.09 (0.07, 0.11)† <0.001
DBP (mmHg) DBP (n = 3865) 0.10 (0.08, 0.12) <0.001 0.09 (0.06, 0.11)† <0.001
Cardiac measurements
Left atrial diameter 
(mm) 
Left atrial diameter 
(n = 3898)
0.13 (0.11, 0.16) <0.001 0.12 (0.10, 0.15)‡ <0.001
Aortic root diameter 
(mm) 
Aortic root diameter 
(n = 3917) 
0.15 (0.13, 0.17) <0.001 0.13 (0.11, 0.15)‡ <0.001
Left ventricular mass 
(g) 
Left ventricular mass 
(n = 3753)
0.12 (0.10, 0.13) <0.001 0.10 (0.09, 0.11)‡ <0.001
Fractional shortening 
(%) 
Fractional shortening 
(n = 3869)
0.14 (0.12, 0.17) <0.001 0.14 (0.12, 0.17)‡ <0.001
PWV (m/s) PWV (n = 2821) 0.19 (0.16, 0.22) <0.001 0.18 (0.15, 0.22)‡ <0.001
TABLE 2 | Continued.
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Outcomes 
child
Exposures 
mother
Basic 
model
P-value Confounder 
model
P-value
Beta (95%CI) Beta (95%CI)
Nine years after pregnancy
BMI (kg/m2) BMI (n = 3549) 0.19 (0.18, 0.21) <0.001 0.16 (0.14, 0.18) <0.001
SBP (mmHg) SBP (n = 3382) 0.11 (0.09, 0.14) <0.001 0.06 (0.04, 0.08) <0.001
DBP (mmHg) DBP (n = 3382) 0.12 (0.10, 0.15) <0.001 0.10 (0.08, 0.13) <0.001
Abbreviations: Body mass index, BMI; Confidence Interval, CI; Diastolic blood pressure, DBP; Pulse wave velocity, 
PWV; Standard Deviation Score, SDS; Systolic blood pressure, SBP. Values are betas with corresponding 95% CI 
and represent the mean difference in children per unit increase in maternal parameter. *†‡§Regression models 
were identical to those presented under Table 2.
Heritability varied between 9 and 20% (central retinal arteriolar caliber [12%], central retinal 
venular caliber [19%], BMI, SBP and DBP at the age of six [12%, 11% and 9%], left atrial diameter 
[15%], aortic root diameter [15%], left ventricular mass [12%], fractional shortening [14%], PWV 
[16%] and BMI, SBP and DBP at the age of nine [20%, 11% and 11%]. 
Supplemental Table 1 shows baseline characteristics of women included and excluded from this 
study. Excluded women were on average younger during study enrollment, more often non-
European, lower educated, smoked more often in pregnancy and had more often children born 
small for gestational age.
Discussion
This large prospective study shows that adverse maternal cardiovascular risk factors (central 
retinal arteriolar and venular calibers, BMI, blood pressure, left atrial diameter, aortic root 
diameter, left ventricular mass, fractional shortening and PWV) are strongly associated with 
corresponding adverse cardiovascular risk factors in offspring at the age of six years, and for 
BMI and blood pressure also at the age of nine years, independent of pregnancy complications 
and environmental factors. This indicates that cardiovascular risk factors most likely track from 
mother to child via genetic and epigenetic pathways. Possibly, central retinal arteriolar and 
venular calibers, cardiac ultrasound measurements and PWV also track up to nine years after 
pregnancy. However, these measurements were not available nine years after pregnancy.
The association between mother-offspring retinal arteriolar and venular calibers has not been 
studied previously. Our study shows that the offspring retinal microcirculation is a representation 
of the maternal microcirculation and possibly also of the paternal microcirculation but we did 
not examine the latter. In adults, smaller retinal arteriolar calibers and larger retinal venular 
calibers are independent risk factors for cardiac heart disease and stroke death.28 
Several studies have examined traits between mother and offspring, such as BMI and blood 
pressure.29-31 Results indicate that tracking of these cardiovascular risk factors from mother to 
offspring likely continues into adult life. A large cross-sectional study in Norwegian parent-
offspring pairs showed that a higher BMI in parents was associated with a higher BMI in their 
TABLE 3 | Continued.
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adult offspring (mean age 38-41 years).30 A similar tracking pattern was also observed for blood 
pressure. Compared to our study, effect estimates were larger for BMI but similar for blood 
pressure. A smaller study in mother-offspring pairs from Ohio also showed a positive association 
between mother-offspring BMI throughout childhood and adolescence. The tracking pattern 
was stronger from mother to daughter than from mother to son, which we did not observe in 
our study.29 A similar study to ours, conducted in French school children (age 5-13 years), also 
showed a stronger association between maternal-offspring BMI than paternal-offspring BMI.32 
This might be due to pregnancy complications which the authors did not correct for. Genetic 
and epigenetic mechanisms might also be involved in the mother-offspring associations we 
examined in this study; previous studies have shown a transgenerational epigenetic inheritance 
of cardiovascular disease.33
Increased left atrial diameter is a risk factor for atrial fibrillation, thrombus formation and 
consequently stroke.34, 35 BMI and blood pressure are two major determinants of left atrial 
diameter. Adjusting for these confounders did not attenuate our results significantly, indicating 
that other factors might be more important, such as pregnancy complications, heritability 
and epigenetics. Removing those pregnancies affected by a pregnancy complication from our 
analyses did not affect our results. We observed relatively small heritability (15%), which was also 
small in previous studies examining parents and their teenagers or adult offspring (2-7%).36, 37  
Aortic root diameter increases with age and BMI and is a risk factor for aortic root dissection.38, 39 
The association between mother-offspring aortic root diameter has not been studied previously. 
Therefore, we cannot compare our results to other studies.
Previous population and twin studies that examined the association between parent-offspring 
cardiovascular risk factors have shown a strong heritability component for cardiac features, such 
as left ventricular mass.40, 41 Left ventricular mass is a predictor of cardiac and cerebrovascular 
related morbidity and mortality.42 Family-based studies showed a wide variation in left 
ventricular mass heritability estimates between different ethnicities: 12% to 41% for Caucasians, 
22% to 44% for African-Americans, 15% for Chinese and 43% to 61% for Japanese.43 Our heritability 
estimate of 12% is comparable to that found in previous studies examining Caucasians. Besides 
genetic variance, the variation in heritability estimates between studies might be due to several 
other factors including differences in study design, statistical modeling and characteristics of 
study participants. Left ventricular mass is strongly related to the efficacy of glucose and fatty 
acid oxidation by the mitochondria.44 Mitochondrial DNA is inherited through the mother, 
which might explain why previous studies presented stronger mother-offspring left ventricular 
mass associations than father-offspring associations.45 
This is the first study to examine the association between parent-offspring fractional shortening. 
Reduced fractional shortening is associated with left ventricular systolic dysfunction. 
To our knowledge, PWV in children has been examined in one previous study of 291 American 
mother-offspring pairs (child’s mean age 12 years).46 Results showed a higher heritability 
estimate for PWV compared to our study (26% vs. 16%).46 Similar to our results, findings were 
not affected by environmental factors such as age and BMI. 
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All our results were not driven by children born from pregnancies affected by a pregnancy 
complication. Therefore, the impact of intrauterine growth and development on cardiovascular 
risk factors in offspring seemed small. 
Strengths and limitations
Some limitations need to be addressed. Retinal vascular imaging six years after pregnancy 
was introduced into the Generation R Study after recruitment of study subjects had already 
started. Therefore, retinal vascular images were not available of 52.6% of mothers and children 
who attended follow-up visit six years after pregnancy. This was independent of any subject 
characteristics, which makes it unlikely that selection bias occurred. Compared to women 
included in this study, those excluded were on average younger during study enrollment, more 
often non-European, lower educated, smoked more often in pregnancy and had more often 
children born small for gestational age. This may have led to some degree of selection bias as 
the included women were relatively healthy and may have led to an underestimation of our 
associations. Nevertheless, we still observed significant associations that support tracking from 
mother to child of cardiovascular traits. Data on fathers was not available. A large population-
based study, examining cardiovascular risk factors (BMI, blood pressure, lipid profile and waist 
circumference), showed that offspring risk factors were positively associated with those in both 
parents.31 This finding argues against a strong impact of pregnancy complications and is more in 
favor of a genetic or epigenetic predisposition of cardiovascular risk factors in offspring. Reported 
heritability estimates might be confounded by pregnancy complications and environmental risk 
factors as we did not adjust for these factors. Strengths of this study are the large sample size, 
the prospective data collection, the standardized procedures that were used for data collection 
and this is the first study to examine the mother-offspring microvasculature. Future studies 
should also examine tracking of the microvasculature and cardiac ultrasound measurements 
from father to offspring.
Conclusion
Six and nine years after pregnancy, an adverse cardiovascular profile in mothers is strongly 
associated with an adverse cardiovascular profile in their offspring. Results were not attenuated 
by environmental exposures or a previous pregnancy complication. This supports the hypothesis 
that cardiovascular risk factors (micro- and macrovascular) track from mother to child, regardless 
off the course of pregnancy. Besides focusing on children born from complicated pregnancies 
we should also focus our efforts on children whose mothers have a worse cardiovascular risk 
profile. 
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SUPPLEMENTAL FIGURE 1 | Timeline of exposures, outcomes and confounders measured in mother and child.
Abbreviations: BMI, body mass index; SBP, systolic blood pressure.
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SUPPLEMENTAL FIGURE 2 | Overview of results in complicated and uncomplicated pregnancies.
Abbreviations: Body mass index, BMI; Central retinal arteriolar caliber, CRAE; Central retinal venular caliber, 
CRVE; Confidence Interval, CI; Diastolic blood pressure, DBP; Systolic blood pressure, SBP. Values are betas with 
corresponding 95% CI and represent the mean difference in children per unit increase in maternal parameter.
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SUPPLEMENTAL TABLE 1 | Baseline characteristics of women included and excluded in this study n = 8107.
Included
n = 5743
Excluded
n = 2364
P-value
Pregnancy
Age at enrollment (years), mean (SD) 30.1 (5.1) 27.9 (5.5) <0.001
Non-European ethnicity (%) 42.1 60.6 <0.001
No education/primary school (%) 11.7 21.2 <0.001
Pre-pregnancy weight, median (5th, 95th percentile) 64.0 (50.0, 90.0) 63.0 (49.0, 92.0) 0.06
SBP at enrollment (mmHg), mean (SD) 115.6 (12.1) 114.8 (12.6) 0.01
DBP at enrollment (mmHg), mean (SD) 68.1 (9.5) 67.6 (9.9) 0.02
Smoking (%) 27.1 35.7 <0.001
Nulliparous (%) 60.1 54.9 <0.001
No folic acid intake, (%) 28.3 45.3 <0.001
Pregnancy outcomes
Spontaneous preterm birth, (%) 3.6 4.3 0.12
Small for gestational age (< p10), (%) 9.9 11.6 0.03
Preeclampsia (%) 2.1 2.6 0.24
Gestational hypertension (%) 4.2 3.3 0.06
Boys (%) 49.6 52.6 0.01
Non-European ethnicity child (%) 39.0 55.6 <0.001
Abbreviations: Body mass index, BMI; Diastolic blood pressure, DBP; Systolic blood pressure, SBP. Values are 
percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medians 
(5th, 95th percentile) for continuous variables with a skewed distribution.
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Abstract 
Background: Changes in the microvasculature associated with preeclampsia and gestational 
hypertension have been proposed as a potential pathway in the development of cardiovascular 
disease. We examined whether hypertensive disorders of pregnancy, such as preeclampsia 
and gestational hypertension, are related to the maternal retinal microvasculature status after 
pregnancy.
Methods: This study is part of an ongoing population-based prospective cohort study. During 
pregnancy and 6.2 years after index pregnancy (90% range 5.7, 7.4 years) we examined 3391 
women with available information on preeclampsia, gestational hypertension and retinal 
vascular calibers. Retinal arteriolar and venular calibers were measured in the left eye from 
digitized retinal photographs.
Results: Women with preeclampsia had smaller retinal arteriolar calibers six years after 
pregnancy than women with a normotensive pregnancy (adjusted difference: -0.40 SDS; 95% 
confidence interval (CI): -0.62, -0.19). For women with previous gestational hypertension 
similar trends were observed (-0.20 SDS; 95% CI: -0.34, -0.05). With respect to retinal venular 
calibers, we did not observe consistent trends for women with previous preeclampsia. However, 
in women with previous gestational hypertension we observed larger venular calibers (0.22 SDS; 
95% CI: 0.07, 0.36) than in women with a previous normotensive pregnancy. The association of 
hypertensive disorders of pregnancy with retinal vessel calibers was mediated through mean 
arterial pressure at the time of retinal imaging.
Conclusions: Compared to women with a previous normotensive pregnancy women with 
preeclampsia and gestational hypertension show an altered status of the microvasculature 
six years after index pregnancy. This is reflected by smaller retinal arteriolar calibers and 
wider retinal venular calibers. These microvascular changes may possibly contribute to the 
development of cardiovascular disease in later life.
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Introduction
Hypertensive disorders of pregnancy (e.g. preeclampsia and gestational hypertension) 
affect seven percent of pregnancies today.1, 2 Both disorders are characterized by new onset 
of hypertension after 20 weeks of gestation and, in the case of preeclampsia, proteinuria. All 
features of hypertensive disorders of pregnancy were previously believed to resolve after delivery. 
However, results from a large meta-analysis show that women with a history of a hypertensive 
disorders of pregnancy have a two to seven-fold increased risk of developing cardiovascular 
disease (CVD) in later life.3 The exact pathophysiologic mechanism underlying this increased 
CVD risk remains unclear. Nevertheless, it has been shown that microvascular endothelial 
dysfunction as reflected by a reduced brachial artery flow-mediated dilatation persists in former 
preeclamptic women for many years after their index pregnancy.4 These data suggest that the 
microvasculature may have been affected by a hypertensive disorder of pregnancy and therefore 
form an important link between hypertensive disorders of pregnancy and the development of 
CVD in later life. 
In recent years, retinal vascular imaging has emerged as a non-invasive technique to visualize 
the microvasculature.5-7 Using this technique in individuals over 50 years of age, several studies 
have shown that microvascular pathology is an independent contributor to the development of 
CVD in later life, especially in women.8 Furthermore, a recent study examining the vasodilatory 
response of retinal vessels to flicker light showed that women with preeclampsia had reduced 
arteriolar vasodilatation during and after pregnancy compared to women with a normotensive 
pregnancy, indicating that microvascular dysfunction may already start early in life.9 Examining 
the retinal microvasculature may provide further inside into why women with a previous 
hypertensive disorder of pregnancy have an increased risk for developing CVD later in life. 
In the current study we investigated the association between a history of a hypertensive disorder 
of pregnancy and the status of the microvasculature six years after index pregnancy, as reflected 
by retinal vascular calibers, in women between the age of 24 to 36 years.
Materials and methods
Design and Study Population
This study was embedded in the Generation R Study, a population-based prospective cohort 
study from early pregnancy onwards in Rotterdam, the Netherlands.10, 11 The study has been 
approved by the Medical Ethics Committee of the Erasmus Medical Center, University Medical 
Centre, Rotterdam, the Netherlands and the procedures followed were in accordance with 
institutional guidelines.12 Written informed consent was obtained from all participants. For 
the present study we included women with a live born singleton with available information on 
hypertensive disorders of pregnancy and on postnatal follow-up data. Women were excluded 
from the main analyses when they had a history of chronic hypertension prior to enrollment 
in the Generation R Study. We also excluded women who were pregnant during follow-up and 
women without information on retinal vascular calibers during follow-up visit six years after 
index pregnancy. The final population for analysis comprised 3391 women (Figure 1). 
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FIGURE 1 | Flowchart. 
Hypertensive disorders of pregnancy
The presence of doctor diagnosed preeclampsia or gestational hypertension was retrieved 
from hospital charts and was determined on the basis of the former criteria described by the 
International Society for the Study of Hypertension in Pregnancy of 2001.13, 14 Gestational 
hypertension was defined by a systolic blood pressure ≥ 140 mmHg or a diastolic blood pressure 
≥ 90 mmHg after 20 weeks of gestation in previously normotensive women. Preeclampsia was 
defined as de novo gestational hypertension with concurrent new onset proteinuria in a random 
urine sample with no evidence of urinary tract infection.13 
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Maternal blood pressure and anthropometrics 
Blood pressure was measured at study enrollment (median 13.2 weeks of gestation [90% range 
10.6, 17.0]) and six years after index pregnancy (90% range, 5.7 to 7.4 years) as the average of 
two systolic and diastolic blood pressure readings, with the validated Omron 907 automated 
digital oscillometric sphygmomanometer (OMRON Healthcare Europe B.V., Hoofddorp, the 
Netherlands).15 All participants were in a standardized supine position to prevent differences 
due to position. A cuff was placed around the right upper arm. In case of an upper arm exceeding 
33 centimeters a larger cuff (32 – 42 cm) was used. The mean value of two blood pressure readings 
over a five minute interval was documented for each participant. Blood pressure was measured 
by trained research assistants wearing normal clothing (i.e. no white coat). Mean arterial 
pressure (MAP) six years after pregnancy was calculated as the average systolic blood pressure 
plus two times the average diastolic blood pressure, divided by 3. Hypertension six years after 
index pregnancy was defined by the average of two consecutive blood pressure readings, with 
systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or the use of 
antihypertensive medication 16. Using an alternative cut-off, with systolic blood pressure ≥130 
mmHg and/or diastolic blood pressure ≥80 mmHg, did not change the direction of our results 
but attenuated our results to non-significant levels.
At study enrollment maternal height (cm) and weight (kg) without shoes were measured after 
which body mass index (BMI) (kg/m2) was calculated. Identical measurements were obtained 
during follow-up six years after pregnancy. Pre-pregnancy BMI was established at enrollment 
through a questionnaire. Pre-pregnancy weight was highly correlated with the measured early 
pregnancy weight (Pearson’s correlation coefficient r 0.95 (P<0.001)).17 
Retinal vascular caliber assessment
Retinal vascular calibers were assessed by taking digital retinal photographs six years after index 
pregnancy. Unilateral and unfractionated photographs were taken of the left eye by a Topcon 
digital retinal camera (model TRC, NW300) while centered on the optic disc. The resolution of 
the images was set to 4096 and 3072 pixels. Additionally, a semi‐automatic computer‐imaging 
program was used to measure the six largest retinal arteriolar and venular calibers of the photos. 
These calibers were located one half to one disc diameter from the optic disc margin.18 The 
average of the six largest retinal arteriolar and retinal venular calibers were then summarized 
as central retinal arteriolar and central retinal venular equivalents.19 The semi‐automatic 
computer‐imaging program that was used for computation of the central retinal arteriolar and 
central retinal venular equivalents was operated by two graders who were blinded to participants’ 
characteristics. Grader specific standard deviation scores were used for both central retinal 
arteriolar and central retinal venular equivalents. Intraclass correlation coefficients between 
both graders were excellent for both retinal arteriolar calibers (0.77; 95% CI: 0.69, 0.84) and 
retinal venular calibers (0.87; 95% CI: 0.81, 0.91). This suggests adequate reproducibility.
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Covariates
Information on maternal characteristics during pregnancy including maternal age, self-
reported pre-pregnancy weight, gravidity, parity, ethnicity, educational level, smoking and 
chronic hypertension was available from questionnaires repeatedly applied during pregnancy. 
Information on gestational age at birth, birth weight and child sex was obtained from medical 
records.20, 21 Six years after index pregnancy we obtained information on gravidity and parity at 
follow-up, medication intake and smoking through questionnaires.
Statistical analyses
We performed four types of analyses. First, a non-response analysis was performed by comparing 
subject characteristics between mothers with and mothers without available follow-up data six 
years after index pregnancy (Additional file 1). Women with available follow-up data, but without 
information on retinal vascular calibers, were left out of the non-response analysis. Second, to 
reduce the possibility of potential bias associated with missing data, missing values in covariates 
were imputed using multiple imputation procedures. Five draws for each missing value were 
performed providing five substituted data points, which in turn created five completed data 
sets. Analyses were performed separately on each completed dataset and thereafter combined 
into one global result.22 In the total population for analysis 19.4% had missing information on 
pre-pregnancy BMI, 2.3% on ethnicity, 6.7% on education, 11.3% on smoking during pregnancy, 
29.5% on gravidity at follow-up, 29.9% on smoking during follow-up, 2.3% on blood pressure 
during follow-up and 0.2% on medication intake during follow-up. Third, differences in 
maternal characteristics during pregnancy and follow-up were compared between women with 
a hypertensive disorder of pregnancy and women with normotensive pregnancies using one-
way ANOVA for continuous variables and chi-square tests for categorical variables. Fourth, 
associations between hypertensive disorders of pregnancy, normotensive pregnancies and 
retinal vascular calibers were assessed through linear regression. The linear regression model 
included covariates selected based on their associations with the outcome of interest based on 
previous studies or a change in effect estimate of >10% (maternal age at enrollment, ethnicity, 
educational level at enrollment, smoking during pregnancy, pre-pregnancy BMI and lastly when 
assessing retinal arteriolar caliber we additionally adjusted for retinal venular caliber and vice 
versa. Hypertensive disorders of pregnancy are known to increase blood pressure and blood 
pressure is known to be associated with smaller retinal arteriolar calibers.23 To examine the 
mediating role of mean arterial blood pressure at the time of retinal imaging in the association 
of hypertensive disorders of pregnancy with retinal vascular calibers, we analyzed the direct 
and indirect causal mediation effects through mediation analyses.24 We used the full model, 
as was used for linear regression analysis, to adjust for confounding. Statistical analyses were 
performed using the Statistical Package for the Social Sciences version 21.0 for Windows (SPSS 
Inc, Chicago, IL, USA) and R version 3.3.2 (R foundation for Statistical Computing, Vienna, 
Austria [packages ‘foreign’, ‘rms’ and ‘mediation’]).25
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Results
Table 1 and Table 2 show maternal characteristics during pregnancy and six years after index 
pregnancy. Women with hypertensive disorders of pregnancy had higher systolic and diastolic 
blood pressures at the start of pregnancy and six years later compared to women with a normotensive 
pregnancy. Additionally, women with a history of a hypertensive disorder of pregnancy had more 
often hypertension and were more likely to take cardiovascular or antihypertensive medication six 
years after pregnancy compared to women with a normotensive pregnancy.  
TABLE 1 | Subject characteristics by hypertensive disorder of pregnancy n = 3391.
Normotensive
Pregnancy
n = 3183
Gestational      
hypertension
n = 145
Preeclampsia
n = 63
P-value
Maternal characteristics (pregnancy)
Age at enrollment (years) 30.1 (5.1) 30.4 (5.1) 29.4 (5.5) 0.44
Gestational age at enrollment (weeks) 13.9 (10.9, 22.2) 13.4 (10.1, 22.9) 13.8 (10.3, 22.5) 0.15
Height (cm) 166.6 (7.4) 168.0 (7.3) 165.3 (6.8) 0.03
Pre-pregnancy weight (kg) 64.0 (50.0, 87.0) 70.0 (54.0, 114.4) 68.0 (53.2, 105.0) <0.001
Pre-pregnancy BMI (kg/m2) 22.7 (18.7, 31.5) 25.2 (20.0, 40.2) 24.4 (19.2, 37.2) <0.001
Weight at enrollment (kg) 67.0 (52.8, 91.1) 75.0 (56.3, 112.0) 70.0 (52.0, 110.4) <0.001
SBP at enrollment (mmHg) 114.8 (11.7) 126.0 (13.1) 120.4 (12.9) <0.001
DBP at enrollment (mmHg) 67.3 (9.0) 76.7 (11.3) 74.3 (9.9) <0.001
Primiparous, n (%) 1894 (60.0) 110 (75.9) 51 (81.0) <0.001
Non-European ethnicity, n (%) 1267 (40.8) 42 (29.0)  30 (47.6) 0.005
Lower educational level, n (%) 272 (9.2) 11 (7.9) 6 (10.0) 0.02
Smoking, n (%) 749 (26.6) 43 (32.1) 13 (21.3) 0.29
Pregnancy outcomes
Gestational age at birth (weeks) 40.1 (37.1, 42.1) 40.1 (37.2, 42.1) 38.6 (30.9, 41.5) <0.001
Birth weight (g) 3442.1 (539.8) 3432.8 (578.6) 2889.3 (877.4) <0.001
Small for gestational age < p10, n (%) 296 (9.3) 20 (13.8) 17 (27.0) <0.001
Male sex, n (%) 1624 (51.0) 76 (52.4) 25 (39.7) 0.19
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; N, number; SBP, systolic blood pressure. 
Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, 
or medians (90% range) for continuous variables with a skewed distribution. Differences in baseline characteristics 
were tested using Students t-test, ANOVA, Kruskal-Wallis and chi-square tests. Presented values are not imputed.
Table 3 and Supplemental Figures 1A and 1B show that women with preeclampsia had smaller 
retinal arteriolar calibers six years after pregnancy than women with a previous normotensive 
pregnancy (age-adjusted difference: -0.49 SDS; 95% confidence interval [CI] -0.74, -0.25). 
Additional adjustment for ethnicity, educational level, smoking, pre-pregnancy BMI and retinal 
venular caliber did not alter these results. Women with gestational hypertension also had smaller 
retinal arteriolar calibers than women with a previous normotensive pregnancy (fully adjusted 
difference: -0.20 SDS; 95% CI -0.34, -0.05). Women with previous preeclampsia did not show 
any difference in retinal venular calibers six years after pregnancy compared to those with a 
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normotensive pregnancy. However, retinal venular calibers were larger in women with gestational 
hypertension than in those with a previous normotensive pregnancy (0.22 SDS; 95% CI 0.07, 0.36). 
TABLE 2 | Subject characteristics six years after index pregnancy by hypertensive disorder of pregnancy n = 3391.
Normotensive
Pregnancy
n = 3183
Gestational      
hypertension
n = 145
Preeclampsia
n = 63
P-value
Age (years) 36.7 (5.1) 37.1 (4.9) 26.0 (5.5) 0.38
Visit interval (years) 6.2 (5.7, 7.4) 6.1 (5.7, 7.6) 6.0 (5.7, 7.5) 0.30
SBP (mmHg) 118.1 (12.0) 128.4 (17.6) 126.5 (15.8) <0.001
DBP (mmHg) 70.0 (9.3) 78.2 (12.0) 78.5 (12.4) <0.001
Mean arterial pressure (mmHg) 86.0 (9.6) 95.0 (13.2) 94.5 (12.9) <0.001
Hypertension, n (%) 203 (6.4) 39 26.9) 15 (23.8) <0.001
Primigravid, n (%) 225 (10.1) 19 (17.0) 9 (22.0) 0.003
Medication, n (%)
Cholesterol lowering medication 8 (0.3) 1 (0.7) 0 (0.0) 0.55
Glucose lowering medication 13 (0.4) 2 (1.4) 1 (1.6) 0.11
Anti-hypertensives 36 (1.1) 10 (6.9) 4 (6.3) <0.001
Cardiovascular medication 43 (1.4) 10 (6.9) 4 (6.3) <0.001
Combined 54 (1.7) 11 (7.6) 5 (7.9) <0.001
Smoking, n (%) 420 (18.9) 21 (18.9) 3 (7.3) 0.17
Retinal arteriolar caliber (μm) 145.8 (16.9) 141.9 (17.8) 137.8 (14.4) <0.001
Retinal venular caliber (μm) 207.1 (22.5) 208.6 (22.5) 203.8 (19.0) 0.36
Retinal arteriolar venular ratio 0.71 (0.07) 0.68 (0.07) 0.68 (0.06) <0.001
Weight (kg) 68.6 (53.6, 97.8) 77.0 (58.8, 121.1) 73.5 (53.3, 120.7) <0.001
BMI (kg/m2) 24.5 (19.7, 34.5) 27.7 (21.3, 45.5) 27.6 (19.6, 43.9) <0.001
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; N, number; SBP, systolic blood pressure. 
Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, 
or medians (90% range) for continuous variables with a skewed distribution. Differences in baseline characteristics 
were tested using Students t-test, ANOVA, Kruskal-Wallis and chi-square tests. Values are not imputed.
TABLE 3 |  Associations of hypertensive disorders of pregnancy with retinal vascular calibers six years after index 
pregnancy n = 3391.
Normotensive
pregnancy
n = 3183
Gestational 
hypertension
n = 145
Beta (95% CI)
P-value Preeclampsia
n = 63
Beta (95% CI)
P-value
Retinal arteriolar caliber (SDS)
Full model Ref -0.20 (-0.34, -0.05) 0.007 -0.40 (-0.62, -0.19) 0.0002
Retinal venular caliber (SDS)
Full model Ref 0.22 (0.07, 0.36) 0.003 0.08 (-0.13, 0.30) 0.45
Abbreviations: Confidence Interval, CI; standard deviation scores, SDS. Values are regression coefficients (95% 
confidence interval) and are based on linear regression. Estimates are from multiple imputed data. Full model: 
adjusted for maternal age at enrollment, ethnicity, educational level at intake, smoking at intake and pre-
pregnancy BMI. Additionally, we adjusted for retinal venular caliber when assessing the outcome retinal arteriolar 
caliber and vice versa. 
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TABLE 4 | The mediation role of mean arterial pressure at the time of retinal imaging in the association of 
hypertensive disorders of pregnancy with retinal vascular calibers six years after index pregnancy n = 3391.
Normotensive 
pregnancy
n = 3183
Gestational 
hypertension
n = 145
Beta (95% CI)
P-value Preeclampsia
n = 63
Beta (95% CI)
P-value
Retinal arteriolar caliber (SDS)
Total effect Ref -0.20 (-0.35, -0.05) 0.01 -0.41 (-0.62, -0.21) <0.001
Direct effect Ref -0.01 (-0.14, 0.13) 0.94 -0.21 (-0.41, -0.02) 0.03
Mediated effect Ref -0.20 (-0.26, -0.13) <0.001 -0.20 (-0.29, -0.11) <0.001
Retinal venular caliber (SDS)
Total effect Ref 0.22 (0.08, 0.36) <0.001 0.08 (-0.09, 0.27) 0.39
Direct effect Ref 0.16 (0.02, 0.30) 0.02 0.03 (-0.14, 0.22) 0.76
Mediated effect Ref 0.06 (0.03, 0.09) <0.001 0.05 (0.02, 0.09) <0.001
Abbreviations: Confidence Interval, CI; body mass index, SDS. Values are regression coefficients (95% confidence 
interval) and are based on mediation analysis. Values are adjusted for maternal age at enrollment, ethnicity, 
educational level at intake, smoking at intake and pre-pregnancy BMI. Additionally, we adjusted for retinal 
venular caliber when assessing the outcome retinal arteriolar caliber and vice versa.
The results of mediation analyses for the mediating role of  mean arterial pressure at the time 
of retinal imaging in the association of hypertensive disorders of pregnancy with retinal vessel 
calibers is presented in Table 4. There was mediation by mean arterial pressure in the association of 
both preeclampsia and gestational hypertension with retinal arteriolar and retinal venular calibers. 
Finally, we tested whether the amount of previous pregnancies affected our results. No 
differences were observed in retinal vascular calibers in association to gravidity or parity. 
Discussion
Our study shows that women with hypertensive disorders of pregnancy have an altered status 
of the retinal microvasculature six years after index pregnancy compared to women with a 
normotensive index pregnancy. In particular women with preeclampsia have smaller retinal 
arteriolar calibers than women with previous normotensive pregnancies. Additionally, women 
with gestational hypertension have wider retinal venular calibers than women with previous 
normotensive pregnancies. These associations may partly be related to concurrent blood 
pressure, since adjustment for mean arterial pressure attenuated most relationships. 
During a normotensive pregnancy the maternal cardiovascular system undergoes imperative 
adaptations by increasing intravascular volume, heart rate and cardiac output.26 Concomitantly 
with these cardiovascular adaptations there is a decrease in blood pressure accompanied by 
physiologic vasodilatation of the microvasculature.27 Cross-sectional results from the GUSTO 
study support these adaptations showing that each 10 mmHg increase in MAP during pregnancy 
was associated with a significant reduction in retinal arteriolar caliber, especially when MAP 
≥ 90mmHg.28 Another study, using retinal images obtained throughout pregnancy and six 
months after pregnancy of 53 normotensive women, also demonstrated changes in the retinal 
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microvasculature over the course of a normotensive pregnancy in conjunction with blood 
pressure adaptations.29 During mid-pregnancy, when blood pressure shows a physiologic 
decrease, retinal arteriolar and retinal venular calibers increased significantly. Nevertheless, 
retinal arteriolar and venular calibers returned to normal (early pregnancy) values in late 
pregnancy and six months after pregnancy. These results imply that changes in the retinal 
microvasculature during pregnancy are transient and mainly the consequence of concurrent 
physiologic blood pressure fluctuations. However, other studies in non-pregnant populations 
demonstrated that not only concurrent but also past elevated blood pressures are associated 
with retinal arteriolar narrowing.30-32 Therefore, retinal arteriolar narrowing may not only be 
considered a transient response to an increased blood pressure, but also the result of cumulative 
exposure to hypertension over the life course. The underlying pathophysiology might be 
explained by accumulating endothelial damage, due to hypertension, eventually leading to 
endothelial dysfunction and microvascular impairment.33, 34 
This might also explain the larger retinal venular calibers in women with previous gestational 
hypertension in our study and not in women with previous preeclampsia. Gestational 
hypertension women had a higher weight and blood pressure at the start of pregnancy than 
preeclampsia women. These factors have been associated with larger retinal venular calibers, 
possibly through local vascular inflammation and endothelial damage.35, 36 Though we did not 
reach statistical significance, retinal venular calibers also tended to be larger in women with 
previous preeclampsia than in women with a previous normotensive pregnancy. Nevertheless, 
we need to be causative with interpreting this finding due to the small sample size of women 
with previous preeclampsia.
Even though previous studies did not examine retinal microvascular calibers both before and 
after a hypertensive disorder of pregnancy, it seems likely that damage to the endothelium as 
a result of the hypertensive disorder of pregnancy is not completely reversible and therefore 
enhances retinal microvascular changes after pregnancy. Previous studies showed through 
flickering response and laser Doppler perfusion imaging technique in women with preeclampsia 
that retinal microvascular function is impaired both during pregnancy up to 25 years after.9, 37 
Microvascular dysfunction therefore does not merely seem to be a disorder of pregnancy. For 
this reason, future research should aim to visualize the retinal microvasculature, before and 
at multiple time points after a hypertensive disorder of pregnancy, in order to detect if retinal 
microvascular abnormalities precede the onset of a hypertensive disorder of pregnancy and 
whether they progress after pregnancy.
Numerous studies have shown a relationship between retinal vascular changes (e.g. retinal 
arteriolar narrowing and retinal venular widening) and future CVD.5, 32, 38-40 For instance, a large 
meta-analysis showed an increased risk of coronary heart disease (CHD) in women with wider 
retinal venular or narrower retinal arteriolar calibers.41 The Atherosclerosis Risk in Communities 
Study (ARIC) assessed retinal microvascular calibers among men and women aged 49-73 showing 
that retinal arteriolar narrowing was associated with an increased risk of CHD, myocardial 
infarction, congestive heart failure and incident hypertension.32, 38, 39 Additionally, the Beaver 
Dam Eye Study demonstrated that retinal arteriolar narrowing is associated with an increased 
Gestational hypertensive disorders and the retinal microvasculature   |   139
7
10-year risk of hypertension.42 Our study provides evidence to support the concept that women 
with hypertensive disorders of pregnancy show more unfavorable retinal microvascular calibers 
six years after pregnancy than women with previous normotensive pregnancies. As a result, it 
is reasonable to speculate that women with hypertensive disorders of pregnancy might have an 
increased risk for future CVD.
Strengths and limitations
Several limitations of the present studies need to be discussed: First, we did not obtain retinal 
vascular imaging from 33.6% of all women who came for follow-up visit six years after pregnancy, 
because retinal vascular imaging was introduced into the Generation R Study after recruitment 
of study subjects had already started. As this was independent of any subject characteristics, 
we do not expect any additional selection bias. However, there may be some loss of power due 
to a smaller sample size available for our analysis and hence larger confidence intervals of the 
reported associations. Second, compared to non-responders (43%) study participants were on 
average older at study enrollment, more often primiparous and of European descent, higher 
educated, more often non-smokers, and had more often gestational hypertension. This may have 
led to some degree of selection bias as the included women were relatively healthy and may have 
led to an underestimation of the association between hypertensive disorders of pregnancy and 
retinal microvasculature. Third, due to unavailability of pre-pregnancy data on blood pressure 
(as is also the case in most other studies focusing on pregnant women and cardiovascular 
outcomes after pregnancy) we cannot exclude the possibility that microvascular changes and 
hypertension preceded the onset of hypertensive disorders of pregnancy. However, we coped 
with this by excluding women with chronic hypertension. Information on chronic hypertension 
before pregnancy was obtained through a questionnaire during pregnancy which was cross-
checked with information from the original medical records and the Dutch obstetric database.43 
Our results did not change significantly after performing a sensitivity analyses excluding women 
with hypertension in early pregnancy (13.2 weeks of gestation, 95% CI; 11.1, 17.0) or women with 
hypertension at the time of retinal imaging. Hypertension in early pregnancy was defined 
as a systolic blood pressure of ≥ 140 mmHg and/or a diastolic blood pressure ≥ 90 mmHg. 
Hypertension at the time of retinal imaging was defined as the intake of antihypertensive 
medication and a systolic blood pressure of ≥ 140 mmHg and/or a diastolic blood pressure ≥ 
90 mmHg. Lowering the cut-off for hypertension at the time of retinal imaging (systolic blood 
pressure of ≥ 130 mmHg and/or a diastolic blood pressure ≥ 80 mmHg) did not change the 
direction of our results, but did attenuate our results to non-significant levels. Fourth, retinal 
vascular calibers were not assessed before pregnancy. Therefore, microvascular changes might 
be due to hypertensive disorders of pregnancy or might have predated pregnancy. Fifth, the 
observational nature of this study does not allow for inference of causality and does not preclude 
the existence of residual confounding. Sixth, information on pregnancies and hypertensive 
disorders of pregnancy occurring after the index pregnancy was incomplete. The absence of 
these data might have affected our results. Finally, our study also has several strengths. First, 
this is a prospective cohort study from early pregnancy onwards with a large sample size of 3391 
participants. Second, retinal images were taken and graded following standardized protocols. 
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Conclusion
Our study shows that in women with a hypertensive disorder of pregnancy the microvasculature 
is already affected early in life. Six years after index pregnancy women with a hypertensive 
disorder of pregnancy show smaller retinal arteriolar and wider retinal venular calibers than 
women with a normotensive pregnancy, suggesting that the changes in the microvasculature 
possibly represent the pathophysiological substrate linking hypertensive disorders of pregnancy 
to CVD in later life. Future research should therefore aim to investigate associations between 
the microvasculature and cardiovascular risk factors before and after the onset of hypertensive 
disorders of pregnancy and the long-term cardiovascular outcomes in these women.  
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Supplemental material
A
B
SUPPLEMENTAL FIGURE 1 | The association of gestational hypertensive disorders with retinal arteriolar (A) and 
venular (B) calibers six years after index pregnancy.
Values are regression coefficients (95% confidence interval) and are based on linear regression models. Estimates 
are from multiple imputed data. We adjusted for maternal age at enrollment, ethnicity, educational level at 
enrollment, smoking during pregnancy, pre-pregnancy BMI and lastly when assessing retinal arteriolar caliber we 
additionally adjusted for retinal venular caliber and vice versa.
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SUPPLEMENTAL TABLE 1 | Maternal and fetal characteristics stratified for loss to follow-up  n=5966.
Included in analyses
n = 3391
Not included
n = 2575
P-value
Maternal characteristics (prenatal)
Age at enrollment (years) 30.1 (5.1) 28.2 (5.5) <0.001
Gestational age at enrollment (weeks) 13.8 (10.8, 22.3) 14.4 (10.8, 23.8) <0.001
Height (cm) 166.7 (7.4) 168.6 (7.4) 0.09
Pre-pregnancy weight (kg) 64.0 (50.0, 90.0) 63.0 (49.0, 92.0) 0.07
Pre-pregnancy BMI(kg/m2) 22.7 (18.8, 31.9) 23.3 (19.2, 30.9) 0.52
Weight at enrollment (kg) 67.0 (53.0, 93.0) 67.0 (51.0, 95.0) 0.92
SBP at intake (mmHg) 115.3 (12.0) 114.7 (12.3) 0.06
DBP at intake (mmHg) 67.8 (9.3) 67.5 (9.8) 0.25
Primiparous (%) 61.0 55.8 <0.001
Non-European ethnicity (%) 40.4 53.1 <0.001
Lower educational level (%) 9.1 16.9 <0.001
Smoking (%) 26.8 30.5 0.004
Birth and childhood characteristics
Gestational age at birth (weeks) 40.1 (37.1, 42.1) 40.0 (36.5, 42.1) <0.001
Birth weight (g) 3450.0 (2540.0, 4300.0) 3380.0 (2450.0, 4300.0) <0.001
Small for gestational age (<p10), (%) 9.8 11.3 0.07
Male sex (%) 50.9 51.7 0.51
Pregnancy complications
Gestational hypertension (%) 4.4 3.1 0.02
Preeclampsia (%) 1.9 2.7 0.07
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure. Values are 
percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medians 
(90% range) for continuous variables with a skewed distribution. Differences in baseline characteristics were 
tested using Students t-test, ANOVA, Kruskal-Wallis and chi-square tests. Presented values are not imputed.
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Introduction
Preeclampsia is associated with an increased risk of coronary artery disease (CAD), although 
evidence on premature CAD development after preeclampsia is limited.1 A cross-sectional study 
among 491 postmenopausal women with a mean age of 67 years showed an increased prevalence of 
coronary artery calcification (CAC) in participants with self-reported high blood pressure during 
any previous pregnancy compared with women without such history.2 However, the association 
between hypertensive pregnancy, CAC and coronary plaque formation has not been reconfirmed 
in prospective studies, and there are no data on the timeline by which atherosclerosis develops 
in women with previous preeclampsia. The aim of this study is to compare the prevalence of 
coronary artery atherosclerosis of asymptomatic women aged 45 to 55 years with a history of 
preeclampsia to a population-based reference cohort.
Methods
The rationale and design of the Cardiovascular RiskprofilE: IMaging And Gender-specific 
disOrders (CREw-IMAGO) have been published previously.3 Asymptomatic women, aged 45 to 
55 years, with a history of preeclampsia 10 to 20 years earlier were included in this multicenter, 
prospective cohort study. Medical records, including pregnancy characteristics and hospital 
admission, were available for all women. Outcomes were compared with women of similar 
age and ethnicity who participated in the Multi-Ethnic Study of Atherosclerosis (MESA).4 
MESA is a prospective cohort study measuring CAC and traditional cardiovascular risk factors 
in 6814 multiethnic participants without a history of physician-diagnosed cardiovascular or 
neurovascular disease. For our analyses, MESA data were restricted to all participating women 
from Caucasian descent aged 45 to 55 years, resulting in a reference group of 387 women.
 Routine cardiovascular risk assessment included medical and pregnancy history, age, body-
mass index, waist circumference, blood pressure, and a venous blood sample assessed lipid 
profile, fasting plasma glucose, glycated hemoglobin and high-sensitivity C-reactive protein. 
CAC score (CACS) and contrast-enhanced coronary computed tomography angiography (CCTA) 
were performed in women with previous preeclampsia. In the MESA cohort only CACS was 
performed. CACS were converted to MESA percentiles adjusted for age, gender and ethnicity. 
The primary outcome was the prevalence of CACS >0 Agatston Units (AU) and/or any coronary 
atherosclerotic plaques on CCTA. Secondary outcomes included CACS ≥100AU, CACS ≥95th 
MESA percentile, and presence of a significant (≥50%) luminal stenosis on CCTA. The study 
was approved by the medical ethics committee of the University Medical Center Utrecht and 
all participants provided written informed consent. Analyses were performed with Statistical 
Package for Social Sciences (SPSS) version 22.0 (SPSS Inc).
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Results
We included 164 asymptomatic women with a history of preeclampsia (mean age 48.4 ± 2.9 years 
at inclusion). Overall, 31% presented with a CACS >0 and 17% had CACS ≥95th MESA percentile. 
Compared with the MESA reference group, women with a history of preeclampsia showed a 
higher risk of CACS >0AU (RR 1.7, 95% CI 1.2-2.3), CACS >100AU (RR 2.8, 95% CI (0.4-19.3) and 
CACS ≥95th MESA percentile (RR 3.5; 95% CI 2.0-6.1). In addition, 47% of women with previous 
preeclampsia had coronary atherosclerotic plaques on CCTA and 4.3% showed significant 
stenosis. Compared to the MESA cohort, women with a history of preeclampsia had higher 
prevalence of hypertension and metabolic syndrome (Table 1).
Discussion
Our data are the first to demonstrate that preeclampsia is associated with accelerated 
atherosclerosis. CAC and plaques are detectable as early as the fifth decade of life, which may 
explain the higher rate of ischemic coronary events in these women as observed by Smith and 
colleagues in 2001.1 We present new evidence for signs of subclinical atherosclerosis on CCTA 
in middle-aged women with a history of preeclampsia in a well-phenotyped prospective cohort 
study. CCTA reference data on coronary plaques in the general population with similar ethnicity 
are not available yet. However, prevalence of subclinical plaques on CCTA has been reported 
in a retrospective cohort study from South Korea.5 The presence of plaques on CCTA in 1282 
asymptomatic middle-aged women (50.0 ± 8.4 years) was substantially lower than the plaque 
burden detected in our cohort of women with previous preeclampsia (6.7% versus 47.2%). 
Limitations of our study include uncertainty whether a positive CACS and CCTA result will progress 
to symptomatic CAD and/or ischemic coronary events, and the lack of data on women younger 
than 45 years or of nonwhite ethnicity. Future research should address these knowledge gaps.
Conclusion
In conclusion, 30% of women with a history of preeclampsia show signs of coronary 
atherosclerosis on vascular CT imaging compared with 18% of women from the reference group. 
Therefore, women with previous preeclampsia have an increased risk of subclinical coronary 
artery atherosclerosis at age 45 to 55 years. These findings demonstrate that early coronary 
atherosclerosis precedes the development of subclinical ischemic heart disease in women with 
previous preeclampsia. Early identification of these women at high risk may facilitate timely 
prevention to reduce future CAD events. 
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TABLE 1 | Baseline characteristics of the preeclampsia group and the reference group.
  Preeclampsia MESA P-value Relative Risk
n = 164 n = 161 n = 387 (95% CI)
Patient characteristics
Age, y 48.4 (2.9) 50.0 (3.0) <0.01
White ethnicity, n (%) 162 (99%) 187 (100%) 0.09
History of pregnancy, n (%) 164 (100%) 288 (75%) <0.01
Premenopausal, n (%) 78 (57%) 179 (46%) <0.01
Clinical measurements
Systolic blood pressure, mmHg 130 (15) 110 (16) <0.01
Diastolic blood pressure, mmHg 81 (10) 66 (9) <0.01
BMI, kg/m2 28.1 (6.2) 27.6 (6.7) 0.40
Waist circumference, cm 89.4 (13.3) 92.8 (18.1) 0.01
Total cholesterol, mmol/L 5.4 (1.0) 5.1 (1.0) <0.02
Triglycerides, mmol/L 1.2 (0.5) 1.4 (1.1) 0.02
HDL-cholesterol, mmol/L 1.52 (0.34) 1.49 (0.41) 0.28
LDL-cholesterol, mmol/L 3.4 (0.9) 3.0 (0.8) <0.01
Glucose, mmol/L 5.5 (1.1) 4.7 (1.0) <0.01
Cardiovascular disease risk factors
Family history of premature CVD, n (%) 31 (19%) 114 (32%) 0.02
Hypertension,* n (%) 89 (54%) 88 (23%) <0.01
Diabetes, n (%) 5 (3%) 10 (3%) 0.78
Current smoking, n (%) 12 (8%) 69 (18%) <0.01
Obesity, n (%) 49 (30%) 114 (29%) 0.92
Metabolic syndrome,† n (%) 54 (33%) 75 (20%) <0.01
Cardiovascular disease risk score
≥2 risk factors,† n (%) 29 (18%) 68 (19%) 0.79
Intermediate–high risk, FRS ≥10%, n (%) 15 (9%) 20 (5%) 0.07
Coronary artery calcium score, AU, n (%)
>0 50 (31%) 70 (18%) 1.7 (1.2-2.3)
0.1 – 9 14 (9%) 33 (9%) 1.2 (0.6-2.1)
10 – 99 26 (16%) 30 (8%) 2.2 (1.3-3.5)
 ≥100 10 (6%) 7 (2%) 2.8 (0.4-19.3)
MESA ≥95th percentile, n (%) 28 (17%) 19 (5%) 3.5 (2.0-6.1)
Coronary CT angiography
Any plaque, n (%) 76 (47%)
Significant stenosis,‡ n (%) 7 (4%)
Abbreviations: AU, Agatston units; BMI, body mass index; CACS, coronary artery calcium score; HDL-cholesterol, 
high-density lipoprotein cholesterol; LDL-cholesterol, low-density lipoprotein cholesterol; FRS, Framingham 
Risk Score; MESA, multi-ethnic study of atherosclerosis; CI, confidence interval. Data are presented as mean ± 
standard deviation, unless otherwise stated. Unadjusted relative risk and 95% CI’s presented. 
*Blood pressure ≥140/90 mmHg or current antihypertensive treatment.
†According to National Cholesterol Education Program Adult Treatment Panel III criteria.
‡Luminal stenosis ≥50%.
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One in two women die due to cardiovascular disease (CVD), making it the largest contributor 
to global mortality.1, 2 Traditional cardiovascular risk factors, such as hypertension, obesity, 
dyslipidemia and smoking explain up to 90% of CVD risk.3 For this reason, the main focus 
of cardiovascular prevention guidelines lies in reducing these risk factors through the 
implementation of cost-effective population wide strategies. Recently, there has been more 
awareness for CVD in women and women’s health.4 More attention is however needed for 
a specific category within the female population. This includes women with a pregnancy 
complicated by a hypertensive disorder such as gestational hypertension and preeclampsia. 
Compared to women with a previous normotensive pregnancy, they are two to eight times more 
likely to develop CVD in later life and if so, at a younger age, depending on the severity of the 
hypertensive disorder of pregnancy.5 Traditional cardiovascular risk factors are more frequently 
present in these women after pregnancy. These cardiovascular risk factors might be preexisting 
to pregnancy or they might be a direct consequence of the hypertensive disorder of pregnancy, 
resulting in a greater cardiovascular stress level after pregnancy than there would have been 
without the disease.6 
The general aim of this thesis was to determine cardiovascular health and to identify early 
cardiovascular risk factors and cardiovascular risk biomarkers in women with a previous 
hypertensive disorder of pregnancy and compare these results to women with a previous 
normotensive pregnancy. This chapter reflects on our main findings, clinical practice and future 
implications.
Pre-pregnancy Pregnancy First 10 years after pregnancy Middle-age Advanced age 
BMI 
CVH 
Disadventageous  
lipid profile 
Blood pressure 
CVH 
  Triglycerides 
  Vascular age 
Disadventageous 
microvasculature 
Coronary artery 
calcification and plaque 
Cardiovascular 
disease 
FIGURE 1 | Cardiovascular and metabolic outcomes over the life course in women with a hypertensive disorder of 
pregnancy.
Abbreviations: BMI, body mass index; CVH, cardiovascular health.
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Biomarkers
In Part I of this thesis we aimed to determine biomarkers in pregnancy to predict the risk of 
developing a hypertensive disorder of pregnancy and a suboptimal cardiovascular risk profile 
after pregnancy. The World Health Organization (WHO) defines a biomarker as “any substance, 
structure, or process that can be measured in the body or its products and influence or predict the 
incidence of outcome or disease”.7 This definition provides a wide range of potential biomarkers 
in relation to hypertensive disorders of pregnancy, including biochemical tests (e.g. placental 
growth factor [PlGF], lipids and glucose), physical tests (e.g. blood pressure and body mass 
index [BMI]) or imaging tests (coronary artery calcification by coronary computed tomography 
angiography and carotid intima-media thickness by ultrasound).
Biomarkers are only relevant when they can be related to clinical endpoints.8 All too often, 
clinical endpoints are considered to be the only relevant outcomes in research. However, they 
can be scarce in certain populations (e.g. death in a young population), resulting in a long and 
costly follow-up time. Biomarkers can then be used as surrogate endpoints to provide interim 
information on the risk of developing a clinical endpoint. This provides the opportunity to 
implement interventions and reduce the risk of a clinical endpoint such as cardiovascular events 
or death. In the context of hypertensive disorders of pregnancy, the ideal biomarker could be 
measured before pregnancy or in an early stage of pregnancy, predicts the risk of developing 
the pregnancy disorder while also predicting the risk of future CVD. Circulating PlGF is such 
a biomarker to predict the risk of preeclampsia.9, 10 PlGF is a proangiogenic factor produced by 
the syncytiotrophoblast of the placenta.11, 12 In complicated pregnancies affected by a placental 
disorder, such as preeclampsia or fetal growth restriction, the syncytiotrophoblast is stressed, 
produces lower concentrations of PlGF, leading to a suboptimal hemodynamic adaptation to 
pregnancy.13-15 It is well known that these women more often have cardiovascular risk factors 
after pregnancy than women with an uncomplicated pregnancy. However, also women with 
an uncomplicated pregnancy might have had low PlGF concentrations in mid-pregnancy, as a 
sign of suboptimal hemodynamic adaptation to pregnancy, without clinically apparent disease. 
Consequently, they might also be more at risk for developing cardiovascular risk factors after 
pregnancy. We examined whether low PlGF concentrations in mid-pregnancy were associated 
with cardiovascular risk factors after pregnancy in women with and without a complicated 
pregnancy (Chapter 2). Results showed that low PlGF was independently associated with a 
larger left atrial diameter and left ventricular mass six years after pregnancy, regardless of the 
pregnancy course. In animal knockout studies, the absence of PlGF in pregnancy has also been 
linked to a larger left ventricular mass.16 Low concentrations of mid-pregnancy PlGF therefore 
seem to be a biomarker of not only suboptimal hemodynamic adaptation to pregnancy but also 
of a suboptimal cardiovascular risk profile after pregnancy. 
An atherogenic lipid profile is a common biomarker of atherosclerotic risk.17, 18 We showed 
(Chapter 3) that an atherogenic lipid profile in early pregnancy is associated with an increased 
risk of developing a hypertensive disorder of pregnancy. This might be due to a higher degree of 
atherosis in the spiral arteries of the placental bed.19, 20 Atherosis is histologically comparable to 
the early stage of atherosclerosis.21 In theory, this could lead to a suboptimal functioning of the 
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placenta and consequently to a complicated pregnancy. In addition, women with a hypertensive 
disorder of pregnancy have an increased risk of coronary atherosclerosis later in life (Chapter 
8). As such, an atherogenic lipid profile in early pregnancy might be a precursor of not only a 
hypertensive disorder of pregnancy but also coronary atherosclerosis later in life.
Cardiovascular follow-up
Health care providers should not merely focus on cardiovascular health in pregnancy but also be 
aware of the importance of cardiovascular follow-up afterwards. Table 12.1 provides an overview 
of the recommendations regarding cardiovascular follow-up of women after a hypertensive 
disorder of pregnancy, by the largest national and international guidelines on cardiovascular 
risk prevention.22-30, 79 Evidently, there is no uniform recommendation for cardiovascular risk 
management in women with a previous hypertensive disorder of pregnancy. Current guidelines 
are largely developed by gynecologists and cardiologists. Gynecology guidelines mainly cover the 
diagnosis and treatment of hypertensive disorders of pregnancy and occasionally recommend 
postpartum cardiovascular follow-up. Because cardiovascular risk prevention is in general not 
the expertise of a gynecologist, most of the guidelines do not address who should be responsible 
for the organization of postpartum cardiovascular follow-up. In general, cardiovascular 
risk prevention is coordinated by cardiologists, general practitioners (GPs) and internists. 
Their guidelines mostly have a population based approach but do highlight certain specific 
populations. Some cardiovascular prevention guidelines acknowledge the cardiovascular 
follow-up of women with a previous hypertensive disorder of pregnancy.22, 23, 79 However, they 
often focus only on women with preeclampsia and to a lesser extend or not at all on women 
with gestational hypertension. Though the risk of developing CVD is higher for women with 
preeclampsia than women with gestational hypertension, absolute risks are high amongst both 
groups.31-33 Based on previous studies and the results discussed below, we like to emphasize that 
cardiovascular follow-up should be provided to all women with preeclampsia as well as those 
with gestational hypertension. 
As providers of long-term care, general practitioners seem to be the most suitable group to 
provide cardiovascular follow-up to women with a previous hypertensive disorder of pregnancy. 
GPs generally have more insight in their patient’s well-being, social network and living 
conditions than other medical specialists. Another possibility would be a ‘shared care’ model, 
as commonly used for the follow-up of oncology patients, where follow-up strategies are shared 
between specialists (e.g. gynecologist, internist and GP).34, 35 The gynecologist could provide 
an initial cardiovascular follow-up plan, intended for the GP, on discharge of the patient. This 
plan should include an overview of the medical history and a timeline with the cardiovascular 
measurements that need to be performed. 
We showed that cardiovascular risk factors after a hypertensive disorder of pregnancy were 
already apparent in the first year after pregnancy. Nearly half (41.5%) of the women with 
previous severe onset preeclampsia had some form of hypertension (sustained hypertension, 
masked hypertension, or white-coat hypertension) and a disadvantageous systolic night-to-day 
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dipping profile one year after pregnancy (Chapter 4). Their vascular age, measured by carotid 
intima-media thickness, was also more advanced than their chronological age (Chapter 11). 
Six years after pregnancy, women with any previous hypertensive disorder of pregnancy had a 
higher blood pressure and BMI and a more atherogenic lipid profile than women with a previous 
normotensive pregnancy (Chapter 5). Simultaneously, the retinal microvasculature of these 
women was more disadvantageous, reflected by smaller retinal arteriolar calibers and wider 
retinal venular calibers (Chapter 7). These microvascular changes may possibly contribute to the 
development of CVD in later life. From the age of 45 years onwards, asymptomatic CVD became 
apparent in women with a previous hypertensive disorder of pregnancy (Chapter 8 and 9). Forty-
seven percent of these women had coronary plaque formation and their risk of having coronary 
artery calcification was twice as high compared to women with no previous hypertensive 
disorder of pregnancy. Therefore, initiating cardiovascular risk assessment around the age 
of 50, as suggested by the Dutch Obstetrical guideline (NVOG Richtlijn), is too late as a large 
percentage of women will already have established subclinical CVD.30 
Based on our results and those of previous studies we suggest to start cardiovascular screening 
(blood pressure, BMI, lipid profile, glucose and lifestyle factors [smoking habit, dietary intake 
and physical activity]) one year after any hypertensive disorder of pregnancy.36-38 Cardiovascular 
screening should include annual monitoring of blood pressure and BMI. Blood pressure should 
be measured at the office and by 24 hours ambulatory blood pressure monitoring (ABPM). 
The lipid profile could be monitored one year after pregnancy and, if normal, consecutively 
in larger time intervals such as every two to five years. Glucose should be monitored one year 
postpartum.39, 40 Thereafter larger time intervals (every three years) should be sufficient. Glucose 
monitoring should be intensified if women have an increased risk for developing diabetes (e.g. 
women with gestational diabetes, obesity, a family history of early onset type 2 diabetes mellitus 
or a glucose intolerance).
To initiate treatment, it is important to understand which cut-offs of each cardiovascular risk 
factor are considered abnormal and whether treatment is appropriate. We will discuss the cut-
offs and treatment of cardiovascular risk factors examined in this thesis (hypertension and 
dyslipidemia) and those of other cardiovascular risk factors that were not examined into detail 
in this thesis but were included in the cardiovascular health score (obesity, diabetes, smoking, 
unhealthy diet and sedentary lifestyle).
Hypertension and obesity 
The presence of masked hypertension should be evaluated in women with an elevated office 
blood pressure (120-129/80 mm Hg). Lifestyle changes, including weight control, regular 
physical activity, smoking cessation and the Dietary Approaches to Stop Hypertension (DASH) 
diet, should be recommended to all these women.41 The DASH diet is rich in vegetables, fruit and 
whole grains, while limiting highly saturated foods and sweets. Previous studies showed that 
the DASH diet, in combination with reduced sodium intake, reduces blood pressure in women 
with pre(hypertension).41, 42 Regarding antihypertensive treatment, the European and American 
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guidelines on CVD prevention recommend to consider treating women with hypertension stage 
1 (130-139/or 80-89 mm Hg).22 For women with hypertension stage 2 (≥140/ ≥90 mm Hg [office] or 
≥135/ ≥85 mm Hg [daytime ABPM]) antihypertensive treatment should be started and evaluated 
after one to three months.23 These recommendations are not in line with the Dutch cardiovascular 
risk management guideline (NHG Standaard) for GPs, which recommends antihypertensive 
treatment if 10-year CVD risk is ≥20% and systolic blood pressure is ≥140 mm Hg.43 This guideline 
aims on treating individuals with a substantial 10-year CVD risk and considers this risk low in 
young women with a previous hypertensive disorder of pregnancy. Despite their high risk of 
having cardiovascular risk factors shortly after pregnancy, their absolute 10-year CVD risk is 
indeed low. This is mostly due to their relatively young age after delivery. Consequently, these 
women do not receive any or no appropriate cardiovascular follow-up after pregnancy. 
In this thesis, we suggest to focus on cardiovascular health rather than cardiovascular risk for 
the follow-up of these women (Chapter 10 and 11). Cardiovascular health (CVH), captured in the 
CVH score, does not include age and is therefore also applicable to younger women. The CVH 
score gives a clear overview of an individual’s current CVH status and the cardiovascular risk 
factors that can be improved. Moreover, a better cardiovascular health score has previously been 
associated with a reduced risk of subclinical atherosclerosis (carotid intima-media thickening), 
CVD and all-cause mortality. We showed that the cardiovascular health score after pregnancy is 
lower in women with a previous hypertensive disorder of pregnancy compared to women with a 
previous normotensive pregnancy. Especially an unhealthy blood pressure and BMI attenuated 
their score. We suggest to use the CVH score for the cardiovascular follow-up of these women in 
a way to project their current CVH, to clearly communicate which cardiovascular risk factors can 
be improved and to follow their CVH status over time. 
A blood pressure that scores on average ‘poor’ or ‘intermediate’ with the CVH score should 
be treated as advised by the aforementioned European and American guidelines on CVD 
prevention. Women with a ‘poor’ or ‘intermediate’ BMI have a higher risk of developing CVD than 
normal weight women.44 For this reason it is important to promote a healthy weight (BMI 18.5-
24.9). Overweight women should be encouraged to lose weight, e.g. through a high-intensity 
lifestyle intervention program.45 These programs combine diet, increased physical activity and 
recommendations to adhere to the program.
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Dyslipidemia 
As previously described, women with a hypertensive disorder of pregnancy have a more 
atherogenic lipid profile after pregnancy than women with a normotensive pregnancy. This is 
largely explained by BMI. Therefore, achieving a healthy weight should be the first treatment 
goal for these women with a more atherogenic lipid profile. Some women might also have to 
start with medical (statin) treatment, although this might have to be stopped in a subsequent 
pregnancy. Overall, we cannot provide a clear advise on when to initiate statin treatment as it 
remains unclear which cut-off for LDL-c should be applied due to incoherent recommendations 
of current dyslipidemia guidelines.46 Five out of six guidelines recommend statin treatment no 
sooner than after the age of 40 or 45, providing no therapy for these young women during the 
first 10 to 20 years after pregnancy.47-50 The NHG Standaard advises lifestyle changes and statin 
treatment when 10 year CVD risk is >10% and LDL-c > 2.5 mmol/L.43 The American College of 
Cardiology and American Heart Association advise statin treatment in women over the age of 
21 with a LDL-c concentration of 4.9 mmol/L.51 In addition to age, statin treatment relies on 
10-year atherosclerotic CVD risk, which has to be at least 5% and in some guidelines even 20%. 
As previously mentioned, these guidelines are therefore not suitable for young women with a 
hypertensive disorder of pregnancy because their 10-year CVD risk is still low (Chapter 11).52-54 
Glucose
The CVH score considers a fasting glucose between 5.55 and 7.0 mmol/L ‘intermediate’ and 
a glucose over 7.0 mmol/L as ‘poor’. This is in line with the recommendations of the WHO.55 
In non-diabetics, an intermediate or poor glucose should be measured again on another day. 
When results remain the same, lifestyle changes should be promoted, including a healthy diet, 
achieving a healthy weight and increased physical activity.55 Women with (newly diagnosed) 
diabetes mellitus should receive standard appropriate diabetic care.56
Smoking, unhealthy diet and sedentary lifestyle 
Smoking cessation, a healthy diet and regular physical activity should be encouraged to all 
women. Healthcare providers should explain the benefits of these healthier lifestyle choices. 
Adapting a healthy lifestyle can be encouraged through shared decision making, motivational 
interviewing, eHealth (e.g. Smarter Pregnant), support in self-management or referral to a 
dietician or behavioral therapist.43, 57-59
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TABLE 1 | Cardiovascular follow-up after a hypertensive disorder of pregnancy.
Guideline Year Follow-up blood pressure Follow-up CVD risk
WHO24 2011 In case of antihypertensive intake before 
pregnancy.
In case of severe hypertension after 
pregnancy.
None
ACOG25, 26 2013 and 2018 Evaluation within 10 days after pregnancy.
Treatment of persistent hypertension 
(BP ≥150/100 mm Hg) after pregnancy.
ASCVD risk assessment, no time period 
mentioned.
Women with preterm delivery (<37 
weeks) or recurrent preeclampsia: 
annual blood pressure, lipids, fasting 
glucose and BMI. No recommendation 
on starting time and which health care 
provider.
NICE27 2017 Antihypertensive management by GP. Discuss future CVD risk 6-8 weeks after 
pregnancy with health care provider.
ISSHP - None None
RCOG28 2006 Check proteinuria and blood pressure 6-8 
weeks after pregnancy.
Inform about increased CVD risk in the 
future.
SOGC29 2014 Blood pressure monitoring 3-6 days after 
pregnancy.
Maintain blood pressure < 160/110 mm Hg.
Consider antihypertensive medication.
In case of persistent hypertension after 
pregnancy or proteinuria/renal disease: 
referral to internal medicine.
In case of pre-pregnancy hypertension or 
persistent hypertension after pregnancy: 
urinanalysis, lipid profile, fasting glucose 
and ECG 6 weeks after pregnancy.
Assessment of traditional 
cardiovascular risk markers may be 
beneficial.
Encourage a healthy diet and lifestyle. 
Especially, for overweight women.
SOMANZ60 2014 Annual blood pressure monitoring Cardiovascular risk assessment every 
5 years.
AHA23 2017 None None
ESC22, 79 2016 and 2018 Periodic screening for hypertension and 
diabetes mellitus
Annual check of blood pressure and 
metabolic factors by primary care 
physician.
NVOG30 2014 Follow-up after pregnancy till normotensive. Cardiovascular risk assessment at the 
age of 50.
Abbreviations: ACOG, American College of Obstetricians and Gynecologists; AHA, American Heart Association; 
ASCVD, atherosclerotic cardiovascular disease; SOGC, Society of Obstetricians and Gynecologists of Canada; 
ESC, European Society of Cardiology; ISSHP, International Society for the study of Hypertension in Pregnancy; 
NICE, National Institute for Health and Care Excellence; NVOG, Nederlandse Vereniging voor Obstetrie en 
Gynaecologie; RCOG Royal College of Obstetricians and Gynaecologists; SOMANZ, Society of Obstetric Medicine 
Australia and New Zealand; WHO, World Health Organization.
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Future research
The best prevention of CVD in women with a previous hypertensive disorder of pregnancy 
might be preventing the hypertensive disorder to occur in the first place. Though a large 
number of studies aimed to disentangle the mechanisms behind gestational hypertension 
and preeclampsia, the exact pathophysiology remains largely unknown. Also, it is still unclear 
whether hypertensive disorders of pregnancy are a risk factor for CVD, whether they share 
common risk factors or both. Gestational hypertensive disorders might merely be a sign of 
failed hemodynamic adaptation to pregnancy in women with an underlying predisposition to 
CVD, already present before pregnancy. As we show in this thesis, women with a gestational 
hypertensive disorder have a higher BMI before pregnancy and a higher blood pressure in early 
pregnancy compared to women with a normotensive pregnancy. In general, some women 
might have an underlying predisposition to CVD but never develop a hypertensive disorder of 
pregnancy, whereas they do show signs of suboptimal hemodynamic remodeling in pregnancy. 
This theory is supported by our findings in Chapter 2 which show that low PlGF concentrations 
in mid-pregnancy were associated with suboptimal hemodynamic remodeling in pregnancy and 
cardiovascular risk factors after pregnancy, regardless of pregnancy complications.
A well-known cause of CVD and mortality is biological ageing. As we showed in Chapter 11, 
biological age (presented through vascular age) can accelerate and consequently be more 
advanced than chronological age. Besides the important role of genetic inheritance, some risk 
factors for accelerated biological ageing include low educational level, obesity, smoking and 
physical inactivity.61 Alongside, pregnancy also plays an important role in the ageing process 
of both mother and child.62, 63 A recent study amongst 1954 American women showed that those 
with a history of life birth had accelerated biological ageing compared to women who never gave 
birth.64 Moreover, the impact of pregnancy on the biological ageing process was greater than 
that of smoking or obesity, suggesting an independent role for pregnancy. As such, pregnancy 
might increase the risk of premature mortality and chronic disease.65 
While pregnancy itself seems to influence the biological ageing process, chronological ageing 
also influences pregnancy. Advanced chronological age is associated with infertility and adverse 
pregnancy complications such as preeclampsia.66, 67 The age-dependent decline in reproductive 
function seems to be the result of oocyte senescence as oocyte donation of younger to older 
women has shown to improve fertility.68 The reproductive ageing phenotype is passed on via the 
nucleus after which multiple factors, including abnormal meiotic spindles and DNA damage, 
can mediate the reproductive ageing process and induce embryo arrest.69  
What exactly influences the reproductive ageing process? Previous studies showed that age-
dependent changes in the bovine reproductive tract (oviduct) are partly mediated by inflammatory 
pathways and markers of inflammation (cytokines). Pro-inflammatory cytokines, including 
interleukin (IL)-1β, are more active in older bovine oviducts. Interestingly, IL-1β is also involved 
in pregnancy complications, such as infertility, early pregnancy loss and preeclampsia.70-72 In 
addition to the age-dependent increase in IL-1β, this cytokine induces cellular senescence by 
increasing the levels of senescence-associated proteins.73 These findings suggest that, at least in 
animals, ageing stimulates an inflammatory response, which further accelerates cell senescence.
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Signs of inflammation and increased oxidative stress are also typically found in women with 
preeclampsia.74 The disease is characterized by local inflammation in the placenta and a generalized 
systemic inflammation response. The concentration of pro-inflammatory markers, including 
IL-1β, is also higher in preeclamptic pregnancies compared to uncomplicated pregnancies.75, 76 
To clarify whether preeclampsia is a risk factor of CVD or whether they both share common risk 
factors, we might have to explore the association between biological ageing and preeclampsia. 
It might well be that preeclampsia induces accelerated biological ageing, thereby increasing 
the risk of CVD, or that preeclampsia is induced through accelerated biological ageing. Future 
studies should evaluate these hypotheses to improve understanding of the pathophysiology and 
consequences of preeclampsia. Such a study could include various markers of biological ageing, 
including telomere length and DNA methylation patterns (epigenetic age).77, 78
If results of these studies will confirm the first hypothesis, where preeclampsia induces 
accelerated biological ageing, then this might form the missing link between preeclampsia 
and the increased risk of CVD in these women. Future research should aim to develop new 
cardiovascular risk prediction models, including preeclampsia as a determinant of advanced 
biological age. This might lead to better risk stratification of women with previous preeclampsia 
and ultimately improve cardiovascular healthcare in these young women. 
Conclusion
Results of this thesis suggest that women with a hypertensive disorder of pregnancy have more 
cardiovascular risk factors and worse cardiovascular health after pregnancy than women with 
a normotensive pregnancy. The lipid profile in early pregnancy and PlGF concentration in 
mid-pregnancy might be useful biomarkers of cardiovascular health after pregnancy. We also 
recommend to initiate cardiovascular screening in women with a history of preeclampsia before 
the age of 45, preferably already one year after pregnancy. Additionally, we should not merely 
focus on cardiovascular screening after pregnancy in women with a history of preeclampsia but 
also in women with a history of gestational hypertension. 
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Summary
In Chapter 1 we explain the background and hypotheses of the studies presented in this thesis. 
Women with a hypertensive disorder of pregnancy have a higher risk to develop cardiovascular 
disease (CVD) later in life compared to women with a normotensive pregnancy. Cardiovascular 
risk factors after pregnancy, such as hypertension, obesity, dyslipidemia and insulin resistance, 
are more prevalent amongst women with a previous hypertensive disorder compared to women 
with a previous normotensive pregnancy. Nevertheless, it remains unclear at what age and to 
what extend cardiovascular risk factors become apparent. Consequently, cardiovascular risk 
management after pregnancy is still not clearly defined in current cardiovascular prevention 
guidelines. 
In Part I we examine biomarkers in pregnancy for cardiovascular risk factors after pregnancy 
and the risk of a hypertensive disorder of pregnancy. In Chapter 2 we examine placental growth 
factor (PlGF) in mid-pregnancy as a marker of cardiac morphology and blood pressure six and 
nine years after pregnancy. Lower PlGF levels are associated with a worse cardiovascular risk 
profile six and nine years after pregnancy. Lower PlGF concentrations in mid-pregnancy might 
help identify women who are more likely to manifest cardiovascular risk factors after pregnancy. 
In Chapter 3 we show that an atherogenic lipid profile in early pregnancy is associated with a 
higher risk of preeclampsia and a higher blood pressure throughout pregnancy and years after 
pregnancy. As such, lipid levels in early pregnancy may help to identify women at risk for future 
hypertension. 
In Part II we examine short-term and long-term cardiovascular risk factors after pregnancy. 
We show in Chapter 4 that in women with previous severe preeclampsia, hypertension is 
common one year after pregnancy. Masked hypertension, white-coat hypertension, sustained 
hypertension, night-time hypertension and a disadvantageous dipping profile were prevalent 
amongst these women. These are all individual cardiovascular risk factors and can only be 
diagnosed with ambulatory blood pressure monitoring. Ambulatory blood pressure monitoring 
one year after pregnancy should therefore be offered to all these women at high risk for developing 
hypertension and possibly future cardiovascular disease. In Chapter 5 we show that women with 
a previous hypertensive disorder of pregnancy have a more atherogenic lipid profile six years 
after pregnancy than women with a previous normotensive pregnancy. This might explain their 
higher CVD risk after pregnancy. In Chapter 6 we examined the degree of tracking between 
maternal and offspring micro- and macrovascular cardiovascular risk factors after pregnancy 
and the extent to which this is influenced by pregnancy complications and shared environmental 
risk factors. An adverse cardiovascular profile in mothers is strongly associated with an adverse 
cardiovascular profile in their offspring. This was independent of environmental exposures 
or a previous pregnancy complication, which supports the hypothesis that cardiovascular 
risk factors (micro- and macrovascular) track from mother to child. Possibly, certain mothers 
(including women with a hypertensive disorder of pregnancy) also have a genetic predisposition 
to cardiovascular risk factors. In Chapter 7 we show that women with a previous preeclampsia 
and gestational hypertension have an altered status of the microvasculature six years after index 
pregnancy compared to women with a previous normotensive pregnancy. These microvascular 
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changes may possibly contribute to the development of CVD in later life. In Chapter 8 we examine 
the risk of coronary artery calcification (CAC) and coronary plaque formation in middle-aged 
women with a previous preeclampsia. Compared to women with a previous uncomplicated 
pregnancy, these women were two times more likely to have CAC and more than 40 percent had 
plaque formation. In Chapter 9 we show that women with previous preeclampsia develop CAC 
approximately 5 years earlier than women without a history of preeclampsia. They also have more 
modifiable cardiovascular risk factors between the age of 40 to 63. These findings might explain 
why these women have a higher risk to develop CVD, but also at a younger age, compared to 
women with an uncomplicated pregnancy. Women with a previous preeclampsia might therefore 
benefit from regular cardiovascular screening and follow-up before the age of 45.
In Part III we examine cardiovascular health (CVH) in and after pregnancy in women with a 
hypertensive disorder of pregnancy and women with a normotensive pregnancy. In Chapter 
10 we show that better CVH in pregnancy is associated with less subclinical atherosclerosis, 
measured by carotid intima-media thickness, after pregnancy and better postpartum CVH in 
all women, but especially in those with a hypertensive disorder of pregnancy. As pregnancy is 
an incentive for women to improve lifestyle, future studies should evaluate whether the CVH 
score in pregnancy is useful for early cardiovascular counseling to optimize CVH. In Chapter 11 
we suggest that the CVH score is more suitable than the Framingham risk score for determining 
cardiovascular risk factors after severe preeclampsia. Additionally, the CVH score seems useful 
to assess postpartum vascular age in these women. 
In Chapter 12 we discuss the general conclusions, clinical practice and future implications. 
We conclude that women with a hypertensive disorder of pregnancy have more cardiovascular 
risk factors and worse cardiovascular health after pregnancy than women with a normotensive 
pregnancy. The lipid profile in early pregnancy and PlGF concentration in mid-pregnancy might 
be useful biomarkers of cardiovascular risk factors after pregnancy. The cardiovascular follow-
up of women with a previous hypertensive disorder of pregnancy should be clearly and uniformly 
implemented in cardiovascular prevention guidelines. Additionally, it should be clearly stated 
who should provide this follow-up.
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Samenvatting
Dit proefschrift beschrijft de relatie tussen aandoeningen in de zwangerschap waarbij de 
bloeddruk verhoogd is en risicofactoren voor hart- en vaatziekten later in het leven. Aandoeningen 
waarbij de bloeddruk in de zwangerschap verhoogd is zijn zwangerschapshypertensie en pre-
eclampsie. Samen worden zij ook wel hypertensieve zwangerschapsaandoeningen genoemd. 
In vergelijking tot vrouwen met een normale bloeddruk in de zwangerschap hebben vrouwen 
met een hypertensieve zwangerschapsaandoening een verhoogd risico op het ontwikkelen 
van hart- en vaatziekten naarmate zij ouder worden. Na de zwangerschap komen bepaalde 
risicofactoren voor hart- en vaatziekten vaker voor bij vrouwen die een hypertensieve 
zwangerschapsaandoening hebben doorgemaakt. Voorbeelden van deze risicofactoren zijn: een 
hoge bloeddruk, zwaarlijvigheid (obesitas), een slecht gehalte aan vetten (lipiden) in het bloed en 
een verminderde gevoeligheid voor het hormoon insuline waardoor men vatbaarder wordt voor 
het ontwikkelen van diabetes. Ondanks deze kennis, blijft het onduidelijk rond welke leeftijd 
en in welke mate risicofactoren voor hart- en vaatziekten zichtbaar worden bij vrouwen die een 
hypertensieve zwangerschapsaandoening hebben doorgemaakt. Dit was de aanleiding voor het 
starten van dit onderzoek en wordt verder beschreven in Hoofdstuk 1.
In Deel I van dit proefschrift onderzoeken we biologische markers in de zwangerschap om 
daarmee het risico op het ontwikkelen van hypertensieve zwangerschapsaandoeningen te 
kunnen voorspellen. Daarnaast wilden we onderzoeken of we met deze biologische markers 
risicofactoren voor hart- en vaatziekten na de zwangerschap kunnen voorspellen. We hebben 
hiervoor de markers placental growth factor (PlGF) en enkele lipiden gemeten. PlGF wordt 
onder andere door de moederkoek (placenta) aangemaakt en is belangrijk voor het goed 
functioneren van de placenta. Dit is weer belangrijk bij de ontwikkeling van hypertensieve 
zwangerschapsaandoeningen. Vrouwen met een pre-eclampsie hebben een lagere PlGF 
concentratie in het bloed dan vrouwen met een normale bloeddruk in de zwangerschap. 
We hebben in Hoofdstuk 2 onderzocht of een lage PlGF concentratie in de zwangerschap 
kan voorspellen welke vrouwen zes en negen jaar na de zwangerschap risicofactoren voor 
hart- en vaatziekten hebben. Het blijkt dat vrouwen met een lage PlGF concentratie vaker 
risicofactoren voor hart- en vaatziekten hadden, ongeacht of hun zwangerschap wel of niet in 
een hypertensieve zwangerschapsaandoening resulteerde. In Hoofdstuk 3 hebben we de lipiden 
in de vroege zwangerschap als biomarker onderzocht. Vrouwen met een lipidenprofiel wat 
aderverkalking kan veroorzaken (een atherogeen lipiden profiel), hadden een verhoogd risico op 
het ontwikkelen van pre-eclampsie en een hoge bloeddruk, zowel tijdens als na de zwangerschap. 
Het lipidenprofiel in de vroege zwangerschap zou daarom kunnen helpen om vrouwen, die een 
verhoogd risico hebben op het ontwikkelen van pre-eclampsie en een hoge bloeddruk, al in een 
vroeg stadium op te sporen. 
In Deel II van dit proefschrift onderzochten we korte en lange termijn risicofactoren voor hart- 
en vaatziekten. We tonen in Hoofdstuk 4 aan dat vrouwen die één jaar geleden een pre-eclampsie 
hebben doorgemaakt vaak een hoge bloeddruk hebben. Er bestaan verschillende vormen van een 
hoge bloeddruk die allen een individueel risico met zich meedragen voor hart- en vaatziekten. 
Wanneer de bloeddruk op het spreekuur normaal is, maar thuis verhoogd dan spreken we van 
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een gemaskeerde hoge bloeddruk. Wanneer de bloeddruk op het spreekuur verhoogd is en 
thuis normaal dan is er sprake van een witte-jassen hoge bloeddruk. Wanneer beide metingen 
verhoogd zijn dan noemt men dit een aanhoudende hoge bloeddruk. Deze drie diagnoses, maar 
ook een verhoogde bloeddruk tijdens de nacht en een onvoldoende daling van de bloeddruk in de 
nacht ten opzichte van de dag, kwamen één jaar na de zwangerschap vaak voor bij vrouwen die 
een pre-eclampsie hadden doorgemaakt. Deze diagnoses kunnen enkel opgemerkt worden door 
de bloeddruk gedurende 24 uur te meten met een draagbare bloeddrukmeter. Op basis van de 
resultaten in dit proefschrift adviseren we om deze 24 uurs meting één jaar na de zwangerschap 
uit te voeren bij vrouwen die een pre-eclampsie hebben doorgemaakt. In Hoofdstuk 5 laten we 
zien dat vrouwen die een hypertensieve zwangerschapsaandoening doormaken, zes jaar na 
de zwangerschap een ongunstiger profiel van de vetten in het bloed hebben dan vrouwen die 
een normale bloeddruk in de zwangerschap hebben. Dit zou een oorzaak kunnen zijn voor hun 
verhoogd risico op hart- en vaatziekten later in het leven. Risicofactoren voor hart- en vaatziekten 
kunnen zichtbaar zijn in de kleinste bloedvaten van het lichaam (de microvasculatuur). Een 
voorbeeld hiervan zijn de bloedvaten die door het netvlies lopen en welke gemakkelijk bekeken 
kunnen worden via het oog. In Hoofdstuk 6 hebben we onderzocht of moeder haar risicofactoren 
voor hart- en vaatziekten, op zowel het niveau van de kleinste als dat van de grote bloedvaten, 
doorgeeft aan haar kind. Hier blijkt inderdaad sprake van te zijn ongeacht de omgevingsfactoren 
die moeder met haar kind deelde. Mogelijk is er sprake van een genetische overerving van 
deze risicofactoren tussen moeder en kind. In Hoofdstuk 7 tonen we aan dat vrouwen die 
een pre-eclampsie of een zwangerschapshypertensie doormaken zes jaar na de zwangerschap 
een slechtere microvasculatuur hebben dan vrouwen die een normale bloeddruk hebben in de 
zwangerschap. Eerdere studies hebben aangetoond dat een slechtere microvasculatuur een 
risicofactor is voor het ontwikkelen van hart- en vaatziekten. De microvasculatuur zou daarom 
ook een rol kunnen spelen in het ontwikkelen van hart- en vaatziekten bij vrouwen die een 
hypertensieve zwangerschapsaandoening hebben doorgemaakt. In de kransslagaderen van het 
hart kan men een duidelijk beeld vormen van het risico op het ontwikkelen van een hartinfarct 
of een beroerte. Middels een speciale CT-scan van het hart vergeleken we kalk en vernauwingen 
in de kransslagaderen bij vrouwen die een pre-eclampsie hadden doorgemaakt met die van 
vrouwen die een normale zwangerschap doormaakten. Bijna de helft van de vrouwen met een 
doorgemaakte pre-eclampsie (namelijk 40%) bleek vaatvernauwing van de kransslagaderen te 
hebben. Na een pre-eclampsie hadden vrouwen ook een tweemaal verhoogd risico op kalk in 
de kransslagaderen ten opzichte van vrouwen met een normale zwangerschap. In Hoofdstuk 
9 laten we zien dat vrouwen met een doorgemaakte pre-eclampsie al vanaf het 45e levensjaar 
kalk vertonen in de kransslagaderen. Dit is vijf jaar eerder dan vrouwen die geen pre-eclampsie 
hebben doorgemaakt. Daarnaast hadden vrouwen na een pre-eclampsie ook meer risicofactoren 
voor hart- en vaatziekten tussen de leeftijd van 40 en 63 jaar. Deze resultaten zouden kunnen 
verklaren waarom deze vrouwen een hoger risico hebben op het ontwikkelen van hart- en 
vaatziekten en waarom ze deze risicofactoren eerder ontwikkelen dan vrouwen met een normale 
zwangerschap. Vrouwen die een pre-eclampsie hebben doorgemaakt zouden kunnen profiteren 
van reguliere screening op hart- en vaatziekten vooraf aan het 45ste levensjaar.
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In Deel III onderzoeken we een score voor het meten van de gezondheid van het hart en de 
bloedvaten: de cardiovasculaire gezondheidsscore. We bestudeerden deze score tijdens en 
na de zwangerschap in vrouwen met een hypertensieve zwangerschapsaandoening en in 
vrouwen die een normale bloeddruk hadden tijdens de zwangerschap. In Hoofdstuk 10 tonen 
we aan dat vrouwen met een slechtere cardiovasculaire gezondheidsscore in de zwangerschap 
tien jaar na de zwangerschap een dikkere vaatwand van de halsslagader hadden. Een dikkere 
vaatwand is een risicofactor voor aderverkalking en het ontwikkelen van een beroerte. Vrouwen 
met een betere gezondheidsscore in de zwangerschap hadden ook een betere cardiovasculaire 
gezondheidsscore na de zwangerschap. Deze verbanden waren het sterkst in vrouwen die een 
hypertensieve zwangerschapsaandoening hadden doorgemaakt. Toekomstige studies moeten 
evalueren of de cardiovasculaire gezondheidsscore in de zwangerschap gebruikt kan worden 
voor vroege counseling van risicofactoren voor hart- en vaatziekten en het optimaliseren van 
de score. Dit laatste zou onder andere kunnen door het optimaliseren van de bloeddruk, het 
gewicht, het cholesterolgehalte, de bloedsuiker, het dieet, de hoeveelheid dagelijkse lichamelijke 
beweging en door te stoppen met roken. De zwangerschap zou hier een goed moment voor 
kunnen zijn omdat vrouwen dan veelal gemotiveerd zijn om hun leefstijl te verbeteren ten 
behoeve van de zwangerschap. In de gezondheidszorg richt men zich veelal op het communiceren 
van risico’s, zoals het risico op hart- en vaatziekten. Dit wordt bijvoorbeeld gedaan door middel 
van een 10-jaars risicoberekening op hart- en vaatziekten met de Framingham risico score. In 
Hoofdstuk 11 tonen we aan dat de cardiovasculaire gezondheidsscore beter toepasbaar is dan 
de Framingham risico score in het bepalen van risicofactoren voor hart- en vaatziekten na een 
ernstige pre-eclampsie. Daarnaast lijkt de cardiovasculaire gezondheidsscore ook toepasbaar bij 
het bepalen van de vaatleeftijd na de zwangerschap in deze vrouwen.
In Hoofdstuk 12 bespreken we de algemene conclusies van dit proefschrift en de klinische 
en toekomstige implicaties. We concluderen dat vrouwen met een hypertensieve 
zwangerschapsaandoening na de zwangerschap meer risicofactoren voor hart- en vaatziekten 
hebben en tevens een slechtere cardiovasculaire gezondheidsscore in vergelijking tot vrouwen 
met een normale bloeddruk tijdens de zwangerschap. Het lipiden profiel en de PlGF concentratie 
in de zwangerschap zouden gebruikt kunnen worden als biomarkers van risicofactoren voor 
hart- en vaatziekten na de zwangerschap. De follow-up van deze risicofactoren voor vrouwen die 
een hypertensieve zwangerschapsaandoening hebben doorgemaakt, moet duidelijk en uniform 
geïmplementeerd worden in richtlijnen voor de preventie van hart- en vaatziekten. Daarnaast 
moet duidelijk beschreven worden wie deze follow-up moet gaan verzorgen.
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HDL-c  High density lipoprotein cholesterol
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SGA Small for gestational age
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